View:
Download DOC
Download PDF
Download XLS
Download XBRL
thrm-10k_20211231.htm
false FY 0000903129 --12-31 true 0 0 P3Y P3Y P3Y http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember P4Y3M10D P3Y6M3D P3Y2M12D P2Y7M6D P2Y7M6D P3Y6M25D P2Y10M2D P2Y5M8D P1Y3M10D P1Y3M10D 2022 2041 http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember 0000903129 2021-01-01 2021-12-31 xbrli:shares 0000903129 2022-02-14 iso4217:USD 0000903129 2021-06-30 0000903129 2021-12-31 0000903129 2020-12-31 iso4217:USD xbrli:shares 0000903129 2020-01-01 2020-12-31 0000903129 2019-01-01 2019-12-31 0000903129 us-gaap:CommonStockMember 2018-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000903129 us-gaap:RetainedEarningsMember 2018-12-31 0000903129 2018-12-31 0000903129 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000903129 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000903129 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000903129 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000903129 us-gaap:CommonStockMember 2019-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000903129 us-gaap:RetainedEarningsMember 2019-12-31 0000903129 2019-12-31 0000903129 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000903129 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000903129 us-gaap:CommonStockMember 2020-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000903129 us-gaap:RetainedEarningsMember 2020-12-31 0000903129 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000903129 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000903129 us-gaap:CommonStockMember 2021-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000903129 us-gaap:RetainedEarningsMember 2021-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 xbrli:pure 0000903129 srt:MaximumMember 2021-12-31 thrm:Segment 0000903129 srt:MinimumMember 2021-01-01 2021-12-31 0000903129 srt:MaximumMember 2021-01-01 2021-12-31 0000903129 us-gaap:ForeignCountryMember 2021-12-31 0000903129 us-gaap:ForeignCountryMember 2020-12-31 0000903129 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember thrm:LearCorporationMember 2021-01-01 2021-12-31 0000903129 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember thrm:LearCorporationMember 2020-01-01 2020-12-31 0000903129 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember thrm:AdientMember 2021-01-01 2021-12-31 0000903129 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember thrm:AdientMember 2020-01-01 2020-12-31 0000903129 us-gaap:BuildingAndBuildingImprovementsMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 us-gaap:BuildingAndBuildingImprovementsMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 thrm:PlantAndEquipmentMember 2021-01-01 2021-12-31 0000903129 thrm:ToolingMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 thrm:ToolingMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0000903129 us-gaap:TechnologyEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 us-gaap:TechnologyEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 thrm:ToolingMember 2021-12-31 0000903129 thrm:ToolingMember 2020-12-31 0000903129 us-gaap:CustomerRelationshipsMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 us-gaap:CustomerRelationshipsMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 us-gaap:InProcessResearchAndDevelopmentMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 us-gaap:InProcessResearchAndDevelopmentMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 thrm:ForciotOyMember thrm:GenthermAutomotiveSegmentMember 2021-12-31 0000903129 thrm:AutotechFundIIILPMember 2021-12-31 0000903129 thrm:AutotechFundIIILPMember 2021-01-01 2021-12-31 0000903129 srt:MinimumMember 2021-12-31 0000903129 us-gaap:LandMember srt:MinimumMember 2021-12-31 0000903129 us-gaap:LandMember srt:MaximumMember 2021-12-31 0000903129 thrm:BeckmannAndEgleIndustrieelektronikGmbHMember 2021-07-01 2021-07-01 0000903129 thrm:GlobalPowerTechnologiesMember 2019-01-01 2019-12-31 0000903129 thrm:GPTMember 2019-01-01 2019-12-31 0000903129 thrm:StihlerElectronicGmbHMember 2019-04-01 2019-04-01 0000903129 thrm:StihlerElectronicGmbHMember 2019-04-01 0000903129 thrm:CincinnatiSubZeroProductsLLCMember 2019-01-31 2019-02-01 0000903129 thrm:CincinnatiSubZeroProductsLLCMember 2019-01-01 2019-12-31 thrm:Facility 0000903129 thrm:EmployeeSeparationCostsMember thrm:ManufacturingFootprintRationalizationMember 2020-01-01 2020-12-31 0000903129 thrm:EmployeeSeparationCostsMember thrm:ManufacturingFootprintRationalizationMember 2021-01-01 2021-12-31 0000903129 thrm:ManufacturingFootprintRationalizationMember 2020-01-01 2020-12-31 0000903129 thrm:ManufacturingFootprintRationalizationMember 2021-01-01 2021-12-31 0000903129 thrm:EmployeeSeparationCostsMember thrm:ManufacturingFootprintRationalizationMember 2019-01-01 2019-12-31 0000903129 thrm:ManufacturingFootprintRationalizationMember 2019-01-01 2019-12-31 0000903129 thrm:ManufacturingFootprintRationalizationMember 2021-12-31 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2021-01-01 2021-12-31 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2020-01-01 2020-12-31 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2019-01-01 2019-12-31 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2021-01-01 2021-12-31 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2020-01-01 2020-12-31 0000903129 us-gaap:OtherRestructuringMember thrm:OtherRestructuringActivitiesMember 2019-01-01 2019-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2021-01-01 2021-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2020-01-01 2020-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2019-01-01 2019-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:MedicalSegmentsMember 2020-01-01 2020-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:MedicalSegmentsMember 2019-01-01 2019-12-31 0000903129 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2021-01-01 2021-12-31 0000903129 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2020-01-01 2020-12-31 0000903129 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2019-01-01 2019-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2019-12-31 0000903129 us-gaap:OtherRestructuringMember 2019-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2020-01-01 2020-12-31 0000903129 us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2020-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2021-01-01 2021-12-31 0000903129 us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2021-12-31 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2019-12-31 0000903129 thrm:MedicalMember us-gaap:OperatingSegmentsMember 2019-12-31 0000903129 us-gaap:OperatingSegmentsMember 2019-12-31 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000903129 thrm:MedicalMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000903129 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2020-12-31 0000903129 thrm:MedicalMember us-gaap:OperatingSegmentsMember 2020-12-31 0000903129 us-gaap:OperatingSegmentsMember 2020-12-31 0000903129 thrm:MedicalMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000903129 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentMember us-gaap:OperatingSegmentsMember 2021-12-31 0000903129 thrm:MedicalMember us-gaap:OperatingSegmentsMember 2021-12-31 0000903129 us-gaap:OperatingSegmentsMember 2021-12-31 0000903129 us-gaap:CustomerRelationshipsMember 2021-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0000903129 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000903129 us-gaap:SoftwareDevelopmentMember 2021-12-31 0000903129 us-gaap:CustomerRelationshipsMember 2020-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0000903129 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0000903129 us-gaap:TradeNamesMember 2021-12-31 0000903129 us-gaap:TradeNamesMember 2020-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember thrm:BeckmannAndEgleIndustrieelektronikGmbHMember 2021-12-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember thrm:BeckmannAndEgleIndustrieelektronikGmbHMember 2021-01-01 2021-12-31 0000903129 thrm:DevelopmentStageTechnologyCompanyMember 2020-02-28 2020-02-28 0000903129 thrm:PatentsAndIntellectualPropertyMember 2020-06-19 2020-06-19 0000903129 thrm:PatentsAndIntellectualPropertyMember us-gaap:OtherIncomeMember 2020-06-19 2020-06-19 0000903129 thrm:UnitedStateRevolvingNoteMember 2021-12-31 0000903129 thrm:UnitedStateRevolvingNoteMember 2020-12-31 0000903129 thrm:UnitedStatesRevolvingNoteEuroDenominationsMember 2020-12-31 0000903129 thrm:DEGVietnamLoanMember 2021-12-31 0000903129 thrm:DEGVietnamLoanMember 2020-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-06-27 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember thrm:LettersOfCreditMember 2021-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember thrm:SwingLineLoansMember 2021-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember thrm:LettersOfCreditMember 2020-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2019-06-27 2019-06-27 0000903129 srt:MinimumMember us-gaap:FederalFundsEffectiveSwapRateMember 2021-01-01 2021-12-31 0000903129 srt:MaximumMember us-gaap:FederalFundsEffectiveSwapRateMember 2021-01-01 2021-12-31 0000903129 thrm:UnitedStateBankOfAmericaCreditFacilityMember 2021-01-01 2021-12-31 0000903129 thrm:EuroCurrencyRateLoansMember 2021-01-01 2021-12-31 0000903129 us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-12-31 0000903129 srt:MinimumMember thrm:EuroCurrencyRateLoansMember thrm:CreditAgreementMember 2021-01-01 2021-12-31 0000903129 srt:MaximumMember thrm:EuroCurrencyRateLoansMember thrm:CreditAgreementMember 2021-01-01 2021-12-31 0000903129 srt:MinimumMember thrm:BaseRateLoansMember thrm:CreditAgreementMember 2021-01-01 2021-12-31 0000903129 srt:MaximumMember thrm:BaseRateLoansMember thrm:CreditAgreementMember 2021-01-01 2021-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2020-03-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:UnitedStateRevolvingNoteMember 2021-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-03-31 0000903129 thrm:DEGVietnamLoanMember 2021-01-01 2021-12-31 0000903129 thrm:UnitedStateAndEuroDenominatedRevolvingNoteMember 2021-12-31 0000903129 country:US 2021-01-01 2021-12-31 0000903129 country:US 2020-01-01 2020-12-31 0000903129 country:US 2019-01-01 2019-12-31 0000903129 us-gaap:ForeignPlanMember 2021-01-01 2021-12-31 0000903129 us-gaap:ForeignPlanMember 2020-01-01 2020-12-31 0000903129 us-gaap:ForeignPlanMember 2019-01-01 2019-12-31 0000903129 country:US 2021-12-31 0000903129 country:US 2020-12-31 0000903129 country:US 2019-12-31 0000903129 us-gaap:ForeignPlanMember 2021-12-31 0000903129 us-gaap:ForeignPlanMember 2020-12-31 0000903129 us-gaap:ForeignPlanMember 2019-12-31 0000903129 country:US srt:ScenarioForecastMember 2022-01-01 2022-12-31 0000903129 us-gaap:ForeignPlanMember srt:ScenarioForecastMember 2022-01-01 2022-12-31 0000903129 thrm:GenthermGmbHMember country:US 2021-12-31 0000903129 thrm:GenthermGmbHMember us-gaap:ForeignPlanMember 2021-12-31 0000903129 thrm:FourZeroOneKPlanMember 2021-01-01 2021-12-31 0000903129 thrm:FourZeroOneKPlanMember 2020-01-01 2020-12-31 0000903129 thrm:FourZeroOneKPlanMember 2019-01-01 2019-12-31 0000903129 us-gaap:CapitalAdditionsMember 2021-01-01 2021-12-31 0000903129 thrm:SemiconductorChipsMember 2021-01-01 2021-12-31 0000903129 thrm:LaborAgreementsMember 2021-01-01 2021-12-31 thrm:Agreement 0000903129 thrm:ForeignCurrencyDerivativesMember 2021-12-31 0000903129 thrm:ForeignCurrencyDerivativesMember 2020-12-31 0000903129 thrm:CopperCommoditySwapContractsMember 2021-12-31 0000903129 thrm:CopperCommoditySwapContractsMember 2020-12-31 0000903129 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:OtherCurrentAssetsMember 2021-12-31 0000903129 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember 2021-12-31 0000903129 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2021-12-31 0000903129 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2021-12-31 0000903129 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:OtherCurrentAssetsMember 2020-12-31 0000903129 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2020-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:OtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000903129 us-gaap:ForeignExchangeContractMember 2021-01-01 2021-12-31 0000903129 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000903129 us-gaap:CommodityContractMember us-gaap:OtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000903129 us-gaap:CommodityContractMember 2021-01-01 2021-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:OtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-12-31 0000903129 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:OtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000903129 us-gaap:ForeignExchangeContractMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000903129 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-12-31 0000903129 us-gaap:InterestRateSwapMember 2021-01-01 2021-12-31 0000903129 us-gaap:InterestRateSwapMember 2020-01-01 2020-12-31 0000903129 srt:MaximumMember 2021-06-01 2021-06-30 0000903129 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000903129 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000903129 us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0000903129 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000903129 thrm:TwoThousandTwentyStockRepurchaseProgramMember srt:MaximumMember 2020-12-31 0000903129 thrm:TwoThousandTwentyStockRepurchaseProgramMember 2020-01-01 2020-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2020-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000903129 thrm:AccumulatedCommodityHedgeDerivativesAdjustmentMember 2021-01-01 2021-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2021-01-01 2021-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000903129 thrm:AccumulatedCommodityHedgeDerivativesAdjustmentMember 2021-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2021-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2020-01-01 2020-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2018-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2019-01-01 2019-12-31 0000903129 thrm:EquityIncentivePlanTwoThousandThirteenMember 2021-12-31 0000903129 thrm:EquityIncentivePlanTwoThousandThirteenMember 2013-05-16 0000903129 thrm:EquityIncentivePlanTwoThousandThirteenMember 2017-05-18 2017-05-19 0000903129 thrm:EquityIncentivePlanTwoThousandThirteenMember 2020-05-21 2020-05-21 0000903129 thrm:EmployeeAndConsultantsMember srt:MinimumMember 2021-01-01 2021-12-31 0000903129 thrm:EmployeeAndConsultantsMember srt:MaximumMember 2021-01-01 2021-12-31 0000903129 srt:DirectorMember 2021-01-01 2021-12-31 0000903129 us-gaap:PerformanceSharesMember 2021-12-31 0000903129 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000903129 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000903129 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2021-01-01 2021-12-31 0000903129 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000903129 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000903129 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2020-01-01 2020-12-31 0000903129 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000903129 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000903129 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2019-01-01 2019-12-31 0000903129 us-gaap:RestrictedStockMember 2021-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000903129 2018-01-01 2018-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2018-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2019-01-01 2019-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2019-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2020-01-01 2020-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2020-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2021-01-01 2021-12-31 0000903129 us-gaap:RestrictedStockUnitsRSUMember thrm:TimeVestingSharesMember 2021-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2018-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2018-12-31 0000903129 us-gaap:PerformanceSharesMember 2018-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2019-01-01 2019-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2019-01-01 2019-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2019-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2019-12-31 0000903129 us-gaap:PerformanceSharesMember 2019-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2020-01-01 2020-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2020-01-01 2020-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2020-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2020-12-31 0000903129 us-gaap:PerformanceSharesMember 2020-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2021-01-01 2021-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2021-01-01 2021-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:AdjustedEBITDATargetSharesMember 2021-01-01 2021-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:RelativeTSRTargetSharesMember 2021-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:ROICTargetSharesMember 2021-12-31 0000903129 us-gaap:PerformanceSharesMember thrm:AdjustedEBITDATargetSharesMember 2021-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2018-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2019-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2020-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2021-12-31 0000903129 us-gaap:StockAppreciationRightsSARSMember 2018-01-01 2018-12-31 0000903129 us-gaap:DomesticCountryMember 2021-12-31 0000903129 thrm:ForeignCountryIndefiniteMember 2021-12-31 0000903129 srt:MinimumMember us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0000903129 srt:MaximumMember us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0000903129 thrm:ForeignCountryIndefiniteMember 2021-01-01 2021-12-31 0000903129 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-12-31 0000903129 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2021-01-01 2021-12-31 0000903129 thrm:ForeignCountryAndForeignCountryIndefiniteMember 2021-12-31 0000903129 thrm:ForeignCountryAndForeignCountryIndefiniteMember 2021-01-01 2021-12-31 0000903129 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember 2021-01-01 2021-12-31 0000903129 thrm:MedicalSegmentsMember 2021-01-01 2021-12-31 0000903129 us-gaap:CorporateMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember 2020-01-01 2020-12-31 0000903129 thrm:MedicalSegmentsMember 2020-01-01 2020-12-31 0000903129 us-gaap:CorporateMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember 2019-01-01 2019-12-31 0000903129 thrm:MedicalSegmentsMember 2019-01-01 2019-12-31 0000903129 us-gaap:CorporateMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:BatteryPerformanceSolutionsBPSMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:BatteryPerformanceSolutionsBPSMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:BatteryPerformanceSolutionsBPSMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2019-01-01 2019-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:OtherAutomotiveMember 2021-01-01 2021-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:OtherAutomotiveMember 2020-01-01 2020-12-31 0000903129 thrm:AutomotiveSegmentsMember thrm:OtherAutomotiveMember 2019-01-01 2019-12-31 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2021-01-01 2021-12-31 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2020-01-01 2020-12-31 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2019-01-01 2019-12-31 0000903129 thrm:IndustrialSegmentsMember thrm:GenthermGlobalPowerTechnologiesMember 2019-01-01 2019-12-31 0000903129 thrm:IndustrialSegmentsMember thrm:CincinnatiSubZeroIndustrialChamberBusinessMember 2019-01-01 2019-12-31 0000903129 thrm:IndustrialSegmentsMember 2021-01-01 2021-12-31 0000903129 thrm:IndustrialSegmentsMember 2020-01-01 2020-12-31 0000903129 thrm:IndustrialSegmentsMember 2019-01-01 2019-12-31 0000903129 country:US 2021-01-01 2021-12-31 0000903129 country:US 2020-01-01 2020-12-31 0000903129 country:US 2019-01-01 2019-12-31 0000903129 country:CN 2021-01-01 2021-12-31 0000903129 country:CN 2020-01-01 2020-12-31 0000903129 country:CN 2019-01-01 2019-12-31 0000903129 country:KR 2021-01-01 2021-12-31 0000903129 country:KR 2020-01-01 2020-12-31 0000903129 country:KR 2019-01-01 2019-12-31 0000903129 country:DE 2021-01-01 2021-12-31 0000903129 country:DE 2020-01-01 2020-12-31 0000903129 country:DE 2019-01-01 2019-12-31 0000903129 country:JP 2021-01-01 2021-12-31 0000903129 country:JP 2020-01-01 2020-12-31 0000903129 country:JP 2019-01-01 2019-12-31 0000903129 country:RO 2021-01-01 2021-12-31 0000903129 country:RO 2020-01-01 2020-12-31 0000903129 country:RO 2019-01-01 2019-12-31 0000903129 thrm:OtherCountriesMember 2021-01-01 2021-12-31 0000903129 thrm:OtherCountriesMember 2020-01-01 2020-12-31 0000903129 thrm:OtherCountriesMember 2019-01-01 2019-12-31 0000903129 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000903129 us-gaap:NonUsMember 2020-01-01 2020-12-31 0000903129 us-gaap:NonUsMember 2019-01-01 2019-12-31 0000903129 thrm:LearCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000903129 thrm:LearCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000903129 thrm:LearCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000903129 thrm:AdientMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000903129 thrm:AdientMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000903129 thrm:AdientMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000903129 country:MK 2021-12-31 0000903129 country:MK 2020-12-31 0000903129 country:CN 2021-12-31 0000903129 country:CN 2020-12-31 0000903129 country:MX 2021-12-31 0000903129 country:MX 2020-12-31 0000903129 country:VN 2021-12-31 0000903129 country:VN 2020-12-31 0000903129 country:US 2021-12-31 0000903129 country:US 2020-12-31 0000903129 country:DE 2021-12-31 0000903129 country:DE 2020-12-31 0000903129 country:UA 2021-12-31 0000903129 country:UA 2020-12-31 0000903129 country:HU 2021-12-31 0000903129 country:HU 2020-12-31 0000903129 thrm:OtherCountriesMember 2021-12-31 0000903129 thrm:OtherCountriesMember 2020-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2020-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2018-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2019-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2020-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-01-01 2021-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2019-01-01 2019-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2020-01-01 2020-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2021-01-01 2021-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-01-01 2020-12-31 0000903129 us-gaap:AllowanceForCreditLossMember 2021-12-31 0000903129 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0000903129 us-gaap:InventoryValuationReserveMember 2021-12-31

fixss

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

for the fiscal year ended December 31, 2021

or

☐

Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from                       to                      .

Commission file number 0-21810

 

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)

 

 

Michigan

 

95-4318554

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

21680 Haggerty Road, Northville, MI

 

48167

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (248) 504-0500

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, no par value

THRM

Nasdaq

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒    No  ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☒

  

Accelerated filer

 

☐

 

 

 

 

 

 

 

Non-accelerated filer

 

☐  

  

Smaller reporting company

 

☐

 

 

 

 

 

 

 

 

 

 

  

Emerging growth company

 

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☒ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒

The aggregate market value of the registrant’s Common Stock held by non-affiliates of the registrant, computed by reference to the closing price of such Common Stock on The Nasdaq Global Select Market as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2021, was $2,342,097,813. For purposes of this computation, the registrant has excluded the market value of all shares of its Common Stock reported as being beneficially owned by executive officers and directors; such exclusion shall not, however, be deemed to constitute an admission that any such person is an “affiliate” of the registrant.

As of February 14, 2022, there were 33,021,536 issued and outstanding shares of Common Stock of the registrant.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the proxy statement for the 2022 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report to the extent described herein.

 

 

 

TABLE OF CONTENTS

 

Part I

 

 

 

Item 1:

 

Business

4

 

 

Item 1A:

 

Risk Factors

17

 

 

Item 1B:

 

Unresolved Staff Comments

29

 

 

Item 2:

 

Properties

29

 

 

Item 3:

 

Legal Proceedings

29

 

 

Item 4:

 

Mine Safety Disclosures

29

 

 

Part II

30

 

 

Item 5:

 

Market for the Registrant’s Common Stock, Related Stockholder Matters and Issuer Purchases of Equity Securities

30

 

 

Item 6:

 

Reserved

30

 

 

Item 7:

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

31

 

 

Item 7A:

 

Quantitative and Qualitative Disclosures About Market Risk

44

 

 

Item 8:

 

Financial Statements and Supplementary Data

46

 

 

Item 9:

 

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

46

 

 

Item 9A:

 

Controls and Procedures

46

 

 

Item 9B:

 

Other Information

46

 

 

Item 9C:

 

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

47

 

 

Part III

48

 

 

Item 10:

 

Directors, Executive Officers and Corporate Governance

48

 

 

Item 11:

 

Executive Compensation

48

 

 

Item 12:

 

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

48

 

 

Item 13:

 

Certain Relationships and Related Transactions and Director Independence

48

 

 

Item 14:

 

Principal Accounting Fees and Services

48

 

 

Part IV

49

 

 

Item 15:

 

Exhibits and Financial Statement Schedules

49

 

 

Item 16:

 

Form 10-K Summary

52

 

 

 

 

 

GENTHERM INCORPORATED

PART I

 

Forward-Looking Statements

This Annual Report on Form 10-K for the year ended December 31, 2021 (this “Annual Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as the impact of the COVID-19 pandemic and other current macroeconomic conditions, including supply chain disruptions, labor shortages and inflationary pressures, on our financial statements, liquidity, and business as well as the global economy, our ability to maintain and grow current production levels, the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs, our ability to finance sufficient working capital, and our ability to execute our strategic plan.  Reference is made in particular to forward-looking statements included in “Item 1. Business,” “Item 1A. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms.

The forward-looking statements included in this Annual Report are made as of the date hereof or as of the date specified and are based on management’s reasonable expectations and beliefs.  Such forward-looking statements are subject to a number of important assumptions, significant risks and uncertainties (some of which are beyond our control) and other factors that may cause the Company’s actual results or performance to differ materially from that described in or indicated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to those summarized below:

 

▪

the COVID-19 pandemic and its direct and indirect adverse impacts on the automobile and medical industries and global economy, which had, and are likely to continue to have, an adverse effect on, among other things, the Company’s results of operations, financial condition, cash flows, liquidity, business operations and stock price;

 

▪

the current supply-constrained environment we are facing involving component shortages, manufacturing disruptions, logistics challenges and inflationary pressures, and any future material delays in the supply chain of the Company or the automotive original equipment manufacturers (“OEMs”) or first tier suppliers (“Tier 1s”) supplied by the Company;  

 

▪

the period of sustained price increases for various material components and shipping costs currently experienced in the automotive industry, which may continue for longer than we expect;

 

▪

the impact of industry or consumer behaviors on future automotive vehicle production, including the development and use of autonomous and electric vehicles and increasing use of car- and ride-sharing and on-demand transportation as a service, as well as related regulations;

 

▪

borrowing availability under the Company’s revolving credit facility;

 

▪

the Company’s failure to be in compliance with covenants under its debt agreements, which could result in the amounts outstanding thereunder being accelerated and becoming immediately due and payable;

 

▪

the Company’s ability to obtain additional financing by accessing the capital markets, which may not be available on acceptable terms or at all;

 

▪

the macroeconomic environment, including its impact on the automotive industry, which is cyclical;

 

▪

any significant declines in automobile production;

 

▪

market acceptance of the Company’s existing or new products, and new or improved competing products developed by competitors with greater resources;

 

▪

shifting customer preferences, including shifts due to the evolving use of automobiles and technology;

 

▪

the Company’s ability to project future sales volumes, based on which the Company manages its business;

 

▪

reductions in new business awards due to the macroeconomic environment, COVID-19 and related uncertainties;

 

▪

the Company’s ability to convert new business awards into product revenues;

3

 

 

▪

the loss or insolvency of any of the Company’s key customers, including due to M&A or other market consolidation of OEMs and Tier 1s;

 

▪

the loss of any key suppliers;

 

▪

the impact of price downs in the ordinary course, or additional increased pricing pressures from the Company’s customers;

 

▪

the feasibility of Company’s development of new products on a timely, cost effective basis, or at all;

 

▪

security breaches and other disruptions to the Company’s IT systems;

 

▪

labor shortages, wage inflation and work stoppages impacting the Company, its suppliers or customers;

 

▪

changes in free trade agreements or the implementation of additional tariffs, and the Company’s ability to pass-through tariff costs;

 

▪

unfavorable changes to currency exchange rates;

 

▪

the Company’s ability to protect its intellectual property in certain jurisdictions;

 

▪

the Company’s ability to effectively implement ongoing restructuring and other cost-savings measures or realize the full amount of estimated savings;

 

▪

compliance with, and increased costs related to, domestic and international regulations, including potential climate change regulations;

 

▪

changes in government leadership and laws, political instability and economic tensions between governments;

 

▪

severe weather conditions and natural disasters and any resultant disruptions on the supply or production of goods or services or customer demands; and

 

▪

other risks, uncertainties, and other factors set forth in “Item 1A. Risk Factors” and elsewhere in this Annual Report, and subsequent reports filed with or furnished to the Securities and Exchange Commission.  

In addition, with reasonable frequency, we have entered into business combinations, acquisitions, divestitures, strategic investments and other significant transactions. Such forward-looking statements do not include the potential impact of any such transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results.  Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

ITEM 1.

BUSINESS

Unless otherwise indicated, references to “Gentherm”, “the Company”, “we”, “our” and “us” in this Annual Report refer to Gentherm Incorporated and its consolidated subsidiaries.

Except to the extent expressly noted herein, the content of our website or the websites of other third parties noted herein are not incorporated by reference in this Annual Report.

Overview

Gentherm Incorporated is a global developer, manufacturer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications in the automotive and medical industries. Within the automotive industry, our products provide solutions for passenger climate comfort and convenience, battery thermal management and cell connecting systems. Within the medical industry our products provide patient temperature management solutions. Our automotive products can be found on vehicles manufactured by nearly all the major OEMs operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that are expected to enable improvements to existing products and to create new product applications for existing and new markets.

4

We are incorporated under the laws of the State of Michigan. Our website is www.gentherm.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are made available free of charge through our website, www.gentherm.com, as soon as reasonably practicable after we electronically file them with or furnish them to the Securities and Exchange Commission (“SEC”). These reports are also available on the SEC’s website, www.sec.gov.

Impact of COVID-19, Supply Chain Disruptions and Other Matters

The macroeconomic effects of the COVID-19 pandemic continue to cause significant volatility in the global economy, including within the automotive market and our business. Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. According to the forecasting firm IHS Markit (February 2022 release), global light vehicle production in 2021 in the Company’s key markets of North America, Europe, China, Japan and Korea, was up 0.3%, as compared to 2020. The lack of significant growth in 2021 was primarily due to the impacts of global supply chain disruptions, including the worldwide semiconductor supply shortage, and follows the significant decrease in vehicle production in 2020 which was driven by the adverse impacts of the COVID-19 pandemic. Light vehicle production remains well below recent historic levels and consumer demand.

In 2021, the Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, were unable to fully meet the vehicle production demands of the OEMs largely due to events outside the control of the Company and its suppliers and customers, as well as the automotive industry generally. Supply shortages of semiconductor chips and other components not only resulted in decreased global automotive vehicle production but also caused significant volatility in customer vehicle production schedules. Sudden changes in the production schedules of OEMs and Tier 1s resulted in operating inefficiencies which adversely affect our profitability and results of operations. In addition, we experienced inflationary cost increases in certain component parts, raw materials, labor and transportation as a result of the supply-constrained environment and general economic conditions. These broad-based operational and inflationary impacts negatively impacted the Company’s financial condition, results of operations and cash flows for the fiscal year ended December 31, 2021.

In response to the global supply chain instability and inflationary cost increases the Company has taken several actions to minimize any potential and actual adverse impacts by working closely with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. We expect global supply chain instability will continue to have an adverse impact on our business and financial performance for the foreseeable future, and such adverse impact may be material. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy continue to evolve. Accordingly, the significance of the future adverse impact on our business and financial statements remains subject to significant uncertainty.

See further discussion of the COVID-19 pandemic and related risks in Item 1A, “Risk Factors” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report.

Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Medical.

Automotive

The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems.

Climate comfort systems include seat heaters, blowers and thermoelectric devices for variable temperature Climate Control Seats® (“CCS”) and steering wheel heaters designed to provide individualized thermal comfort to automobile passengers, and integrated electronic components, such as electronic control units that utilize our proprietary electronics technology and software. Other climate comfort systems include neck and shoulder conditioners and climate control system products for door panels, armrests, cupholders and storage bins.

5

Battery performance solutions consist of cell connecting devices and battery cable technologies used for various types of automotive batteries and thermal management products for heating and cooling 12 volts, 48 volts and high voltage batteries and battery modules.

Automotive electronic and software systems include electronic control units for climate comfort systems, electronic control units for memory seat modules and other devices.

Medical

The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry.

Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health.

Business Strategy

Globally, we develop, manufacture, and deliver extraordinary thermal solutions for automotive and patient thermal management markets that make meaningful differences in everyday life by improving health, wellness, comfort and energy efficiency.

To achieve our goals and capitalize on opportunities within the automotive and patient thermal management markets, in mid-2018, we launched and continue to implement four primary strategies:

Focus Growth

The focused growth strategy includes four key goals:

 

▪

Accelerate growth in our core automotive climate and comfort businesses by leveraging human thermophysiology and smart control algorithms to increase personalized passenger comfort and improve energy efficiency;

 

▪

Introduce an innovative microclimate solution, ClimateSenseTM, which offers personalized thermal comfort in one intelligent and integrated system;

 

▪

Drive battery performance solutions with increased focus on active battery heating and cooling, passive battery cooling, battery heaters, and cell connecting board solutions; and

 

▪

Expand patient thermal management solutions that leverage our expertise in thermophysiology and drive synergies from our automotive climate and comfort businesses.

These areas of the focused growth strategy are underpinned and enabled by our electronic and software systems business.

Extend Technology Leadership

We continue to expand our technology leadership with focused investments in key core technologies and competencies, including thermophysiology, software and electronics, simulation, thermal engines and integration.  

Expand Gross Margin and Return on Invested Capital

We continue to build a culture of performance that includes a focus on high-return growth opportunities. During 2018 and 2019, we exited several non-core product categories. Additionally, we undertook restructuring actions to reduce global overhead costs to improve Selling, general and administrative expenses. We are continuing to strengthen our operational discipline and execution to expand gross margin and return on invested capital.

Optimize Capital Allocation

We are optimizing our capital allocation to drive shareholder returns, focusing on reinvesting in our business to drive continued growth through capital expenditure projects, and focused research and development investments, while opportunistically utilizing our authorized stock repurchase program. Further, we continuously evaluate acquisition and investment opportunities that will enhance other business strategies.

6

Research, Development and Partnerships

Our research, development and partnerships activities are an essential part of our efforts to develop new or improved innovative products.  Through both internal and external programs, we are working to develop a comprehensive knowledge of thermal management systems that demonstrates functionality and performance.  These activities are critical to optimize energy utilization and production efficiencies, improve effectiveness in our products and minimize the cost to integrate our products with those of our customers.

We perform advanced research and development on thermal management systems, including those that utilize new proprietary comfort software algorithms, to enhance the efficiency and functionality of our automotive heating and cooling products. We believe there are substantial opportunities to integrate innovative thermal management systems into current and future product applications.

To offer our customers cutting-edge products and technologies, our strategy includes partnering with key technology leaders in our industry.  Our advanced partnership with global automakers and manufactures address and work to solve industry preferences of today and tomorrow by leveraging our expertise in human thermophysiology.

Research and development is conducted globally and predominantly at our world headquarters in Northville, Michigan, our Technology Center in Farmington Hills, Michigan, our European research facility in Odelzhausen, Germany and our Asian research facility in Shanghai, China.

Product design and development is also performed at all of our manufacturing facilities to support our geographically diverse customers.  We believe the localized development model employed at our manufacturing facilities improves our ability to effectively serve our customers and increases our innovative capacity.

Core Technologies

Gentherm’s expertise in thermal management is focused on two general areas: managing the thermal conditions of people and objects.  

ClimateSenseTM

ClimateSenseTM is an integrated comfort system we are designing to create a personalized microclimate for passengers using localized convective, conductive and radiative heating and cooling products.  Using automatic regulation technology in combination with our unique occupant-centric control algorithm, ClimateSenseTM offers the ability to personalize and improve overall occupant thermal comfort, improve time to comfort with (all-electric) pre-conditioning, provide comfort with less energy consumption thereby lowering carbon dioxide emissions by conventional internal combustion and hybrid powertrains, and extend range for electrified powertrains through a reduction in central heating, ventilation and air conditioning (“HVAC”) system usage.  In July 2021, we received first production vehicle award for our ClimateSenseTM technology on an all-new 2024 model year electric vehicle with a global automaker.

Electronics

The electronics in our core climate comfort solution products is manufactured by us.  We also supply value-added electronic products to third parties for adjacent areas within the automotive interior.  In addition, Gentherm manufacturers and supplies electronic control units for memory seat modules that include electric motor position sensing technology. This technology further applies to other automotive products requiring fine motor controls.

Air Moving Devices

Our highly durable and quiet air moving devices, some of which include our proprietary blower and fan designs, are essential to all of our products that require air movement. We have a strong portfolio of these products, tailored to various automotive application, including seat ventilation and electric vehicle battery cooling.

7

 

Thermoelectric Technologies

Many of our thermal products manage the thermal conditions of people and objects using our internally developed advanced thermoelectric device technology (“TED”). A TED is a solid-state circuit that has the capability to produce both hot and cold thermal conditions by use of the Peltier effect. The advantages of advanced TED over conventional compressed gas systems are that they are environmentally friendly and less complex as they have no moving parts and are compact and light weight.  Our work on this technology has yielded improvements in areas of functionality, efficiency, durability and performance.

Resistive Heaters

Resistive heater technologies are comprised of wire, carbon fiber or positive thermal coefficient (“PTC”) heating elements that quickly and effectively deliver heat to people and objects.  Wire heating elements are designed from stainless steel, copper, our proprietary carbon fiber woven lattice technology called Carbotex® or printed circuit PTC heaters based on the specifications for a particular product application.  Resistive heaters have multiple automotive applications, including seat heating, steering wheel heating, interior panel heating, and battery heating.

Products

Climate Comfort Solutions – Seat Comfort

CCS

Gentherm offers a range of CCS products utilizing proprietary technologies for regulating temperature and enhancing the comfort of vehicle passengers. Our ventilated CCS products move air through the seat to provide conditioning. Our active CCS products utilize TEDs to heat and cool air used to condition the seat. The conditioning air circulates by one of our specially designed air moving devices through an air distribution system installed in the seat cushion and seat back, so that the seat surface can be heated, ventilated or cooled. Each seat has individual electronic controls to adjust the level of heating, ventilating or cooling. Our CCS products improve comfort compared with conventional vehicle cabin air conditioners by focusing heating and cooling directly on the passenger through the seat. Our CCS products can be combined with our resistive heating elements to increase heating capacity and reduce time to comfort.

By offering different models of the CCS product, our customers have the opportunity to purchase a wider range of climate control products at different price points. Sales of CCS products, primarily ventilated CCS products, contributed 38%, 38% and 37% to our total product revenues for the years ended December 31, 2021, 2020 and 2019, respectively.

Heated Seat

Heated seats, based on our resistive heater core technology, are seamlessly integrated into automotive seat designs, and are constructed using materials that offer the best capacity, installation characteristics and durability.  Our design and manufacturing capabilities allow customers to choose among a variety of resistive heater materials based on their individual vehicle specifications. Sales of heated seat products contributed 26%, 27% and 29% to our total product revenues for the years ended December 31, 2021, 2020 and 2019, respectively.  

Neck Climate Control Systems

Neck climate control systems ventilate warm or temperature-controlled air directly onto the passenger’s neck and shoulder area. The system combines electronics, air moving device technologies and a heating element into a compact, integrated headrest design that can be adjusted to suit the body size of the passenger.  

Climate Comfort Solutions – Surface Climate Control Systems

Heated Steering Wheel

Heated steering wheels deliver heating comfort to automobile drivers through resistive elements. This product can be applied to both leather and wood steering wheels.  A solution for drivers in cold and mild weather climates, the heated steering wheel is designed for the global automotive market.  

8

Heated Surfaces

Gentherm’s thermally conductive or radiative surfaces, such as door panel armrest and center console armrest products, are powered by our core technologies. The system is thermally managed by a heating control system which can be discretely located in the door panel or seat of the vehicle.  Heated door panels and armrests complement our climate-controlled seat and steering wheel products and provide a superior level of thermal comfort to the driving experience.  

Electronics Solutions

Memory Seat Modules

Gentherm has developed a unique way to control certain electrical motors in a vehicle.  Our Intelligent Positioning System, IPS® product suite utilizes proprietary software to determine the position of a power seat and control the memory seat module.

Hands-On Detection

All vehicles manufactured with autonomous driving level 2 or higher capabilities are required to ensure that the driver stays in control of the vehicle during operation.  In order to accomplish this task, Gentherm developed PilotSenseTM – a sensor integrated into the steering wheel that monitors whether the driver’s hands are maintaining contact with the steering wheel.  This product is available for both heated and non-heated steering wheels.

Battery Performance Solutions

Cell Connecting Systems

Cell connecting systems provide secure connections between advanced automotive batteries to transmit a continuous flow of information about battery temperature and cell voltage during the charging and discharging process to monitor battery system performance. Gentherm has developed a range of cell connecting system products, including flexible foil cell connecting boards that offer improved packaging, weight and functionality. We offer these products in a variety of materials to cover customers’ requirements.

Thermoelectric Battery Thermal Management

Thermal management is critically important for the long-term operation of advanced automotive batteries.  The expansion of electrified vehicle applications, such as electric vehicles, plug-in hybrids and mild hybrids, have increased the demand for battery thermal management (“BTM”) systems that enable wider operating temperature ranges, enhanced driving range and prolonged life of the battery.  Gentherm’s BTM system can provide precision battery cooling of 48-volt mild hybrid systems on pack or cell-level using patented TED technology.  The BTM system maintains the temperature of the lithium-ion battery or other advanced chemistry battery within an acceptable temperature range without the use of chilled liquids or refrigerant loops, making it a light weight, highly scalable, compact solution ideal for automotive applications. Gentherm’s proprietary BTM system is compact and energy efficient, resulting in a minimal energy usage, which is important for an electrified vehicle.

Aside from battery cooling, Gentherm’s BTM portfolio includes battery heating applications.  Based on our proprietary technology, we offer solutions to our customers that enable efficient heating of lithium-ion batteries for most electrified vehicles.

Climate Comfort Solutions – Thermal Convenience

TrueThermTM Cup Holder

The TrueThermTM Cup Holder applies Gentherm’s patented TED technologies to keep beverages of automobile drivers and passengers either warm or cool.  We have developed a range of cup holder models with varying degrees of functionality, designed to be manufactured in multiple configurations to accommodate different console environments.  Our dual independent design provides separate temperature settings in each holder allowing the driver and passenger to individually maintain a heated or cooled beverage.  

9

TrueThermTM Storage Unit

Gentherm’s TrueThermTM Storage Unit provide for food or beverage cooling for the global automotive market.  Using patented TED or refrigeration technologies, the TrueThermTM Storage Unit provides temperature control independently from a vehicle’s heating and air conditioning system.  It can be custom designed to accommodate tight interior spaces, such as the front floor console of a sport utility vehicle and provide additional cooling capacity to those who have long work commutes or transport multiple passengers.  

Automotive Cable Systems

Gentherm manufactures automotive cable systems used to connect automotive components to power sources. The automotive cable systems are an important element in the production of many of our products and form a significant component in how we generate value to our customers by being an efficient, low-cost and high-quality manufacturer. We offer cable systems as integrated parts of our products and also as stand-alone components for other automotive applications, such as oxygen sensors.  Our cable systems business includes both ready-made individual cables and ready-to-install cable networks.

Patient Temperature Management Systems

Gentherm provides a full line of patient temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health.  Our broad array of products for patient warming provides an improved patient experience and satisfaction. Our core brands include Blanketrol® hyper-hypothermia system, WarmAir®/FilteredFlo® convective warming system, Electri-Cool®/Micro-Temp® localized cooling/warming systems, the ASTOPAD® patient warming system that utilizes resistive warming technology which is also used in our automotive products, ASTOTHERM®/ASTOFLO® IV fluid and blood warming systems, ASTODIA® diaphanoscope for transillumination, Hemotherm® cardiovascular cooling/warming system and our recent launch of our next generation cardiovascular cooling/warming system utilized to deliver precise blood temperature control during cardiopulmonary by-pass and other related cardiovascular procedures. We aspire to have innovative patient temperature management product offerings coupled with clinical education enabling our customers to have enhanced patient outcomes and improved efficiencies of care.

Customers

Our Automotive segment customers include primarily light vehicle OEMs and Tier 1s, including automotive seat manufacturers.  We also directly supply CCS products to aftermarket seat distributors and installers.

The Company’s automotive marketing is directed primarily at the OEMs and their Tier 1s and focuses on the enhanced value consumers attribute to vehicles with climate comfort products. In many cases, the OEMs direct us to work with their suppliers, primarily their Tier 1s, to integrate our products into the vehicle’s seat or interior design.

Once the integration work is complete, prototypes are sent to the OEMs for evaluation and testing. If an OEM accepts our product, a program can then be launched for a particular model on a production basis, but it normally takes one to three years from the time an OEM decides to include any of our products in a vehicle model to actual production for that vehicle. During this process, we derive funding from prototype sales but obtain no significant revenue until mass production begins. Upon commencement of mass production, our products are sold by Tier 1s to the OEMs as a component of an entire seat or seating system. Inherent to the automotive supplier market are costs and commitments that are incurred well in advance of the receipt of orders and resulting revenues from customers.

The volume of products we sell is significantly affected by global and regional automotive production levels and the general business conditions in the automotive industry. Our product revenues are generally based upon purchase orders issued by our customers, with updated production schedules for volume adjustments. As such, we typically do not have a backlog of firm orders at any point in time. Once we are selected to supply products for a particular platform, we typically supply those products for the platform life, which is normally five to seven years, although there is no guarantee that this will occur. In addition, when we are the incumbent supplier to a given platform, we believe we have a competitive advantage in winning the redesign or replacement platform, although there is no guarantee that this will occur.

10

For 2021, our revenues from sales to our two largest customers, Adient plc (“Adient”) and Lear Corporation (“Lear”) were $156 million and $153 million, respectively, each representing 15% of our product revenues that is consistent with prior years. Revenues from Lear and Adient represent sales of our climate comfort products.   On October 28, 2021, Lear announced that it entered into an agreement to acquire the Interior Comfort Systems business unit of Kongsberg Automotive ASA, which is a key competitor of the Company’s climate comfort products, including CCS and seat heaters.

The loss of these customers would likely have a material adverse impact on our business, results of operations and cash flows. However, as noted above, in many cases automotive OEMs direct their suppliers such as Lear and Adient to work with us for our climate comfort solutions, battery performance solutions and cable technology products. It is, therefore, relevant to understand how our revenues are divided among the OEMs, as shown below.

Our total product revenues for each of the past three years were divided among the OEMs as follows:

 

 

 

2021

 

 

2020

 

 

2019

 

General Motors

 

 

14

%

 

 

14

%

 

 

14

%

Hyundai

 

 

13

%

 

 

12

%

 

 

9

%

Volkswagen

 

 

10

%

 

 

9

%

 

 

8

%

Ford Motor Company

 

 

8

%

 

 

9

%

 

 

11

%

Stellantis(a)

 

 

8

%

 

 

9

%

 

 

10

%

BMW

 

 

6

%

 

 

6

%

 

 

6

%

Honda

 

 

5

%

 

 

6

%

 

 

7

%

Daimler

 

 

5

%

 

 

6

%

 

 

6

%

Mazda

 

 

3

%

 

 

3

%

 

 

4

%

Toyota Motor Corporation

 

 

3

%

 

 

3

%

 

 

4

%

Renault/Nissan

 

 

3

%

 

 

2

%

 

 

3

%

Jaguar/Land Rover

 

 

2

%

 

 

3

%

 

 

3

%

Other (including Medical)

 

 

20

%

 

 

18

%

 

 

15

%

Total

 

 

100

%

 

 

100

%

 

 

100

%

a)

Reflective of the 2021 merger of Peugeot S.A. and Fiat Chrysler Automobiles N.V.

Market Trends

We believe increased consumer demand for personalized thermal comfort in a vehicle is driving increased adoption of our comfort products.  In recent years, we are seeing a trend of equipping second, and in some cases, third row seats with thermal management solutions. This trend is accelerating in all major markets where Gentherm is present, including North America, Europe, Japan, Korea and China.

The Gentherm product portfolio aligns well with long-term technological trends:

 

▪

Increased efficiency and electric range – Our solutions, including the ClimateSense system which we continue to develop, help reduce overall energy consumption of a vehicle, resulting in improved fuel consumption for vehicles with an internal combustion engine, and increased range for electric vehicles. Our Battery Performance Solutions products help improve life and efficiency of batteries, contributing to increased adoption of powertrain electrification.

 

▪

Increased demand for comfort products – We are continuously striving to bring to market products and technologies that improve the wellbeing of vehicle occupants.  From improved performance of our seat heating and cooling devices, to our introduction of the neck climate control system and heated surface products – our focus is to make vehicle comfort an integral part of vehicle occupants experience.

 

▪

Growth of connected/smart devices – One of the most important objectives in achieving comfort is to create a system that is able to sense the needs of vehicle occupants and make performance adjustments based on personalized needs.  We utilize machine learning to create and optimize state of the art algorithms to make our products smarter and more advanced with each generation.

 

▪

Focus on health and wellness – Consumers have an increased focus on personal health and wellness. Our technologies are at the nexus of health, wellness and comfort, where our solutions adjust to enable vehicle occupants to address their health and wellness needs.

11

 

▪

Emergence of shared mobility – As the world transitions from vehicle ownership to mobility as a service model, focus on individual personalized comfort becomes even more important.  Our focus is to create microclimate solutions, when each vehicle occupant can create a personalized thermal experience tailored to their individual needs.

Production and Suppliers

Our global manufacturing and distribution facilities are located close to our key customers. In Automotive, we operate two manufacturing sites in Europe located within North Macedonia and Ukraine and one distribution center located in Hungary. In North America, we operate two manufacturing sites in Mexico. In Asia, we operate two manufacturing sites in China and one in Vietnam, and one distribution center in South Korea.  

For Medical, we operate one manufacturing site within Germany and one manufacturing site and distribution center within the United States.

In September 2019, we committed to a restructuring plan (the “Plan”) to improve our manufacturing productivity and rationalize our footprint. Under this Plan, we planned to relocate and consolidate certain existing automotive manufacturing facilities and, as a result, reduce the number of our manufacturing facilities by two. In March 2020, we announced the initial phase of this Plan, which included the consolidation of all North American electronics manufacturing to Celaya, Mexico. This resulted in the closure of the Burlington, Canada facility, and the transfer of electronics manufacturing to Celaya, Mexico during 2021.  In December 2020, we announced the consolidation of our electronics manufacturing in Asia to Bantian, Shenzhen, China, which resulted in the closure of our Longgang, Shenzhen, China facility during 2021. See Note 5, "Restructuring," to the consolidated financial statements included in this Annual Report for additional information.

The automotive industry is highly reliant on semiconductors and, beginning in the fourth quarter 2020, throughout 2021 and continuing into 2022, is facing a significant supply shortage of semiconductors. See further discussion of the risks relating to the supply shortage of semiconductors and related risks above in “—Impact of COVID-19, Supply Chain Disruptions and Other Matters”, in Item 1A, “Risk Factors” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report.

Proprietary Rights and Patents

The development of new or improved technologies is critical to the execution of our business strategy. Currently owned patents and patents obtained for new or improved technologies form an important basis for the success of the Company and underpin the success of our research and development efforts. We have adopted a policy of obtaining, where practical, the exclusive rights to use technology related to our products through patents or licenses for proprietary technologies or processes. We adapt and commercialize such technologies in products for mass production. We also have developed technologies or furthered the development of acquired technologies through internal research and development efforts.  

As of December 31, 2021, Gentherm held 439 issued patents, of which 238 were U.S. patents and 201 were non-U.S. patents.  Gentherm held 309 patents directed to climate control products (including 2 patents directed to ClimateSense TM) and thermoelectric technologies, 41 patents directed to heating elements and technologies, 33 patents directed to battery cell connecting and cable technologies, 26 patents directed to medical technologies, 15 patents directed to air moving devices, and 15 patents directed to occupant sensing technologies.  The Company continued to evaluate its patents during 2021 and made strategic decisions to reduce low-value patents and patents unrelated to current or planned business strategies.

Competition

See further discussion of the risks relating to competition in Item 1A, “Risk Factors” in this Annual Report.

Gentherm faces competition from other automotive suppliers and, with respect to certain products, from the OEMs and Tier 1s who manufacture or have the capability to manufacture certain products that Gentherm manufactures and supplies. The automotive supply industry competes on the basis of technology, quality, reliability of supply and price. Design, engineering capability and competitive pricing are increasingly important factors.

The competitive landscape for Gentherm’s climate comfort solutions and battery sub-systems includes component specialists, thermal management system suppliers, the Tier 1s and the OEMs with their own integrated solutions.  Independent suppliers that represent the principal competitors of Gentherm include I.G. Bauerhin GmbH and Kongsberg Automotive ASA. In October 2021,

12

Lear announced that it entered into an agreement to acquire the Interior Comfort Systems business unit of Kongsberg Automotive ASA.  The competitive landscape for patient temperature management systems includes patient thermal management medical device manufactures.  The principal manufacturers of products similar to those of Gentherm’s products include 3M Company, Stryker Corporation and Becton, Dickinson and Company.

We believe our expertise in core thermal management technologies and vehicle occupant thermal comfort, as well as our capability in applying specific component design, global footprint and broad product offerings make us well positioned to compete against the traditional thermal management systems suppliers, global Tier 1s and component specialists.

Seasonality

Our principal operations are directly related to the automotive industry. Consequently, we have historically experienced seasonal fluctuations to the extent automotive vehicle production slows, such as in the summer months when many customer plants close for model year changeovers and in December when many customer plants close for the holidays.

Human Capital Management

Employees

At Gentherm, our mission is to “create and deliver extraordinary thermal solutions that make meaningful differences in everyday life, by improving health, wellness, comfort and energy efficiency.” Our people are the foundation for making our mission come to life every day.

Our winning culture behaviors helps shape our core Human Resource programs and our culture, the behaviors are Customer Focus, Global Mindset, Performance & Accountability and Engagement & Inclusion.

Our human capital strategy is to attract, develop and retain results-driven, high-performance talent while providing each employee with a compelling and personal employee experience. We also strive to promote a safe work environment and a culture the values fairness, diversity, equity, inclusion and belonging.  

Our global workforce creates a competitive advantage and operates in over 12 countries in 23 locations.  As of December 31, 2021, and 2020, Gentherm’s employment levels worldwide were as follows:

 

 

2021

 

 

2020

 

Mexico

 

 

3,293

 

 

 

3,938

 

Ukraine

 

 

1,906

 

 

 

1,722

 

Macedonia

 

 

1,845

 

 

 

2,131

 

China

 

 

1,456

 

 

 

1,605

 

Vietnam

 

 

858

 

 

 

916

 

United States and Canada

 

 

488

 

 

 

618

 

Hungary

 

 

285

 

 

 

253

 

Germany

 

 

264

 

 

 

263

 

Korea

 

 

45

 

 

 

36

 

Japan

 

 

21

 

 

 

20

 

Malta

 

 

9

 

 

 

12

 

United Kingdom

 

 

4

 

 

 

5

 

Total

 

 

10,474

 

 

 

11,519

 

 

Notable statistics as of December 31, 2021:

 

▪

36% of our workforce resides in North America; 41% of our workforce resides in Europe; 23% of our workforce resides in Asia.

 

▪

We have cooperative relationships in our facilities where we operate with unions and workers councils. Approximately 23% of the Company's workforce are members of industrial trade unions and are employed under the terms various labor agreements.

13

 

▪

Three of nine Board members are female, and one is diverse. Four of ten executive committee members are female and two are diverse.

 

▪

Over 58% of our global workforce is Female.

 

▪

Within the United States, over 36% of our employees self-disclose as racially or ethnically diverse. Over the last year we increased our diversity representation at the leadership level (Directors and Vice Presidents) by three percentage points

 

Racially and Ethnically Diverse (Self-reported)

 

2021

 

 

2020

 

All Employees

 

 

36

%

 

 

34

%

Leadership

 

 

23

%

 

 

20

%

 

Key Highlights of our Human Capital Strategy

Gentherm’s Human Capital goals have evolved to a more flexible, personal, employee value proposition since the onset of the pandemic to ensure we are aiding our employees in navigating through the blurred demands of work and life. We introduced a new flexible working guideline called “Locate for Your Day”.

In November 2021, we completed our first global engagement survey with a best-in-class response rate of 97%. The results of the survey in addition to several new listening tools help our managers continue to adapt and meet the needs of our workforce.

Health and Safety

At Gentherm, health and safety are an essential part of our culture and values. The “Safety Culture” of a workplace is a key issue for implementing and proceeding with the Vision Zero strategy.  This initiative outlines a global approach and mindset that strives to eliminate all work accidents and injuries by aligning the Company culture with the Seven Golden Rules:

 

1.

Leadership Commitment with a Top-Down Approach

 

2.

Identify All Hazards and Risks

 

3.

Set Safety and Health Targets

 

4.

Ensure a Safety System/ Standards

 

5.

Use Safe and Healthy Technology

 

6.

Improve Qualification

 

7.

Involve People

The global operating health and safety team is not only committed to the Seven Golden Rules to eliminate work accidents and injuries. These rules also are focused on identifying hazards and unsafe behaviors before they happen by “near miss reporting”.

Our teams have continued to benchmark across Gentherm sites which has fostered significant optimization and continuous improvement. By implementing consistent routine components in the daily work across all sites, the overall safety culture improves for all Gentherm operations.

14

Diversity, Equity and Inclusion

Our DE+I mission “Embracing Diversity Inspires Innovation” cascades from our corporate mission. We are building a culture of belonging where we value our differences to positively impact the lives of our employees, customers and communities.  Our Diversity, Equity and Inclusion Council, has built strong momentum in 2021. The DE+I council conducted engagement activities and enrichment programming each month to promote awareness and celebrate various ethnic and underrepresented employees within Gentherm. We took another step forward on our DE+I journey with launching inclusion trainings to all global people leaders with the purpose of building local and global awareness of DE+I at Gentherm, ensuring all team members are educated on consistent standards, identifying feedback mechanisms to solve for conflict, and creating a culture that unites us all.

Total Rewards

Gentherm’s compensation and benefits programs are designed to attract and retain our employees in the locations where we compete for talent using a mix of elements that allow us to achieve our Company’s short and long-term goals.

 

▪

We provide employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location.

 

▪

We align our executives’ and eligible employees’ annual bonus opportunity and long-term equity compensation with our shareholders’ interests by linking realizable pay with company financial and stock performance.

 

▪

We are refreshing our overall compensation structure to ensure we are providing contemporary and equitable total rewards across our business.

Total Talent Development

At Gentherm, we provide foundational leadership development programs to ensure our current and future people leaders are well equipped to engage and lead in today’s complex business environment. Additionally, Gentherm’s performance management process is based on a contemporary coaching model where employees align yearly objectives with their leaders, supported with timely quarterly “check-ins” for progress updates and feedback. We have offered additional training programs to provide on-demand, flexible learning solutions for our global workforce. We introduced the Accelerator program for high potential employee development in 2021.

Environmental, Social, and Governance

In 2021, we issued our second Sustainability report and incorporated ESG into our everyday business operations and future strategies. Our sustainability efforts are based on three pillars: People, Planet, and Places.

 

▪

People: At Gentherm, our leaders treat employees with respect and provide a safe working environment. We provide career opportunities, development, support and more. People create our success.

 

▪

Planet: We strive to minimize our environmental impact. We believe our product lineup reduces the environmental impact of automobiles through our innovative products and technologies, and we continue to improve our operations through more efficient use of resources and reduced emissions.

 

▪

Places: As a global company, we strive to be a positive force in the communities where we do business. Our teams support an array of causes, including STEM education and training, financial support for local charities and donations and support for COVID-19 efforts. Types of community involvement and support vary across our sites, based on local needs, requirements, and culture.

These actions indicate the strength of our commitment to sustainability across Gentherm.

Environmental and Regulatory Compliance

Applicable laws and regulations, and significant changes to such laws and regulations, will potentially lead to increases in costs and complexity, and failure to comply with global and specific country regulations could subject us to civil penalties, production

15

disruptions, or limitations on the sale of affected products. We believe we are materially in compliance with substantially all these requirements or expect to be materially in compliance by the required dates.

Chemical Regulation

There are numerous global laws and regulations that prohibit or restrict the selection and use of certain chemicals for product development and manufacturing and potentially impact an automobile manufacturer’s responsibility for vehicle components at the end of a vehicle’s life. New chemical regulations continue to be introduced and passed, such as the new European requirements that require suppliers of parts and vehicles to the European market to disclose certain substances of concern in parts. Further, increases in the use of circuit boards and other electronics may require additional assessment under the directives related to certain hazardous substances and waste from electrical and electronic equipment.

Vehicle Safety

In the U.S., the National Traffic and Motor Vehicle Safety Act of 1966 (the “Safety Act”) regulates motor vehicle equipment that we manufacture and sell as well as vehicles. The Safety Act prohibits the sale in the United States of any new vehicle or equipment that does not conform to applicable federal motor vehicle safety standards established by the National Highway Traffic Safety Administration (“NHTSA”). The Safety Act further requires that if a vehicle manufacturer or NHTSA determine a vehicle or an item of vehicle equipment does not comply with a safety standard, or that vehicle or equipment contains a defect that poses an unreasonable safety risk, the vehicle manufacturer must conduct a safety recall to remedy that condition in the affected vehicles. Should a vehicle manufacturer or NHTSA determine a safety defect or noncompliance issue exists with respect to any of our products, the cost of such recall campaigns could be substantial.  Further, many other countries have established vehicle and vehicle equipment safety standards and regulations.  Meeting or exceeding the many safety standards is costly as global compliance and non-governmental assessment requirements continue to evolve and grow more complex, and lack harmonization globally.

 

16

 

ITEM 1A.

RISK FACTORS

You should carefully consider each of the risks, assumptions, uncertainties and other factors described below and elsewhere in this Annual Report, as well as any amendments or updates reflected in subsequent filings or furnishings with the SEC.  We believe these risks, assumptions, uncertainties and other factors, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results and could materially and adversely affect our business operations, results of operations, financial condition and liquidity.  

Industry and Operational Risks

The COVID-19 pandemic and measures taken to contain it have significantly adversely affected, and are likely to continue to significantly adversely affect, our business, results of operations, financial condition, cash flows, liquidity and result in stock price volatility.

The COVID-19 pandemic has caused, and continues to cause, a significant adverse effect on the level of economic activity around the world. In response to the COVID-19 pandemic, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions. The actions taken by governments, businesses and individuals in response to the pandemic have resulted in, and are expected to continue to result in, a curtailment of business activities (including changes in demand for a broad variety of goods and services), labor shortages, disruptions in supply, manufacturing and logistics, economic uncertainty and weakness, and volatility in the financial markets, both in the United States and abroad.

The COVID-19 pandemic poses the risk that Gentherm or its suppliers, customers and others may be restricted or prevented from conducting business activities for indefinite or intermittent periods of time, including as a result of employee health and safety concerns, shutdowns, shelter in place orders, travel restrictions and other actions and restrictions that may be requested or mandated by governmental authorities. At various times in the first half of 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. During 2021, the Company continued to see periodic, temporary mandates by governmental authorities that impacted our employees’ ability to travel to and from our manufacturing facilities, following the resurgence of COVID-19 in certain geographic areas. Restrictions on the Company’s access to its facilities and similar limitations for the Company’s customers, OEMs, suppliers and distributors, have had a material adverse impact on the business, financial condition and results of operations and could continue to have an impact in the future.

Gentherm has implemented numerous measures attempting to manage and mitigate the effects of the virus, however, there can be no assurance that these measures will be successful now or in the future. Gentherm has modified its business practices and it may take further actions as may be required by government authorities, for the continued health and safety of the employees, or that the Company otherwise determines are in the best interests of the employees, customers, partners, and suppliers. The Company's management of the impact of COVID-19 has and will continue to require significant investment of time from its management and employees. The focus on managing and mitigating the impacts of COVID-19 on the business may cause the Company to divert or delay the application of its resources toward other or new initiatives or investments, which may cause a material adverse impact on the results of operations.

If the COVID-19 pandemic becomes more pronounced in the markets in which the Company or its customers operate, or there is a continued resurgence in the virus in markets currently recovering from the spread of COVID-19, as we experienced with the emergence of the Delta and Omicron variants during 2021 and continuing into 2022, then the Company's operations in areas impacted by such events could experience further materially adverse financial impacts.  The extent to which the COVID-19 pandemic continues to impact the Company's operations and financial condition will depend on future developments that are highly uncertain and cannot be predicted, including new government actions or restrictions, new information that may emerge concerning the severity of COVID-19, the longevity of COVID-19 and its variants and the impact of COVID-19 on economic activity. The COVID-19 pandemic has impacted the global economy creating certain macroeconomic conditions that make this a particularly challenging business environment for us and the automotive industry, including global supply chain instability, inflationary cost increases and labor shortages, as described in other risk factors in this Annual Report. To the extent the COVID-19 pandemic materially adversely affects the Company's business and financial results, it may also have the effect of significantly heightening many of the other risks associated with the Company's business, results of operations, financial condition, cash flows, liquidity and stock price, including in ways that we cannot predict.

17

The inability of our supply chain, and the supply chain of the OEMs and Tier 1s that we supply, to deliver key components, such as semiconductors, has adversely affected, and could continue to adversely affect our business, profitability and results of operations.

Our products contain a significant number of components that we source globally from suppliers who, in turn, source components from their global suppliers. If our supply chain fails to deliver products to us in sufficient quality and quantity on a timely basis, we will be challenged to meet our production schedules, fulfilling our orders, sales and profits could decline, and our commercial reputation and customer relationships could be damaged. Similarly, OEMs and Tier 1s to whom we supply our products are dependent on an ever-greater number of global suppliers to manufacture and sell their products to consumers, which drives sales of our products. We and our customers are currently operating in a supply-constrained environment and are facing, and we expect to continue to face for at least the first half of 2022 and potentially longer, component shortages, manufacturing disruptions, logistics challenges and inflationary pressures, each of which is described below.  

 

•

Component shortages. The automotive industry is highly reliant on semiconductors and is facing a significant shortage of semiconductors. The semiconductor supply chain is complex, with capacity constraints occurring throughout. We, the OEMs and Tier 1s must compete among the automotive supply chain and with other industries to satisfy current and near-term requirements for semiconductors, and such allocation is not within our control even though we have attempted and will continue to attempt various mitigating actions. Certain semiconductors we utilize are sourced from a very limited number of suppliers, which further exacerbates the risks to our operations. The shortage of semiconductors and other key components (historically, such as TEDs), has disrupted our production schedule and has caused us to procure components on the open market, from time to time, at prices significantly above the contractual pricing we have with our current long-term suppliers. OEM and Tier 1 production has also been impacted by the shortage, which has resulted in reduced sales of our products. Sudden changes in the production schedules of OEMs and Tier 1s also has resulted and may continue to result in operating inefficiencies which could adversely affect our profitability and results of operations. The component shortages have had and may continue to have materially adverse effect on our business, profitability and results of operations.

 

•

Raw materials and component pricing.  In addition to the component shortages we are currently experiencing, we have experienced and we may continue to experience risks associated with pricing of components and certain other raw materials. Some of our products contain certain components, such as semiconductor chips, tellurium, a raw material used in TEDs, and other key raw materials including copper, silver and petroleum-based engineered plastics and raw materials that generally cannot be substituted. The prices for these components and raw materials fluctuate depending on market conditions. If the market prices for these components and raw materials significantly increase, as they have in the past and during the COVID-19 pandemic, our gross profit has and may continue to be adversely impacted to the extent our suppliers pass those price increases on to us.  

 

•

Labor shortages and work stoppages. Labor shortages and work stoppages, including ours and those at our suppliers or customers, and similar events could significantly disrupt our business. Because the automotive industry relies heavily on “just-in-time” delivery of components, labor shortages or work stoppages at one or more of Gentherm's production facilities or those of our suppliers could have adverse effects on the business. Similarly, if one or more of our direct customers or an OEM were to experience labor shortages or work stoppages, such as what occurred during the General Motors labor strike occurring in the Fall of 2019 or the prolonged work stoppages that occurred in the first half of 2020 as a result of the COVID-19 pandemic, our customer would likely halt or limit purchases of our products, which could result in the temporary shutdown of the related Gentherm production facilities or other restructuring initiatives.

 

•

Inflationary pressures. The automotive industry has experienced a period of sustained price increases for various material components and shipping costs. These price increases are expected to continue into the foreseeable future as supply remains constrained and demand remains elevated. Although the Company has developed and implemented strategies to mitigate the impact of higher material component costs and shipping costs, these strategies, together with commercial negotiations with Gentherm's customers and suppliers, have not historically and may not in the future fully offset our price increases which may result in adverse impacts to the Company’s profitability and results of operations.

 

•

Logistics challenges and excess supply. In order to secure components for our products, we have and may continue to strategically purchase components in advance of demand to take advantage of favorable pricing or to address concerns about future availability. If we fail to anticipate customer demand properly, a temporary oversupply could result in excess or obsolete components, which could adversely affect our business and financial performance. In addition, our ongoing efforts to optimize the efficiency of our supply chain could cause supply disruptions and be more expensive, time-consuming and

18

 

resource-intensive than expected. Furthermore, certain of our suppliers may decide to discontinue business with us or limit the allocation of products to us, which could result in our inability to fill our supply needs, jeopardizing our ability to fulfill our contractual obligations, which could in turn, result in a decrease in revenues and profitability, contract penalties or terminations, and damage to customer relationships.

Our supply chain has been and may in the future be adversely impacted by other events outside of our and their control, including other macroeconomic events, trade restrictions, economic recessions, political crises, labor relations issues, liquidity constraints, natural disasters and extreme weather events, which may become more frequent due to climate change.

The automotive industry, our primary market, is cyclical and a decline in the production levels of our major customers, particularly with respect to models for which we supply significant amounts of product, could adversely affect our business, results of operations and financial condition.

Our Automotive segment represents 96%, 95% and 95% of our product revenues for the years ended December 31, 2021, 2020 and 2019, respectively.  Demand for our automotive products is directly related to automotive vehicle production, which is ultimately dependent on consumer demand for automotive vehicles, our content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. Automotive sales and production are cyclical and have been, and we expect will continue to be, materially affected by general economic and industry conditions, labor relations issues, fuel prices, regulatory requirements, government initiatives, trade agreements, the availability and cost of credit for us, customers and consumers and other factors.  

We operate in a highly competitive industry and efforts by our competitors, as well as new non-traditional entrants to the industry could adversely affect our business, results of operations and financial condition.

The automotive component supply industry is subject to intense competition. Business is typically awarded to the supplier offering the most favorable combination of cost, quality, timely delivery, technological innovation and service. There can be no assurance that we will be able to compete successfully with the products of our competitors. Further, our competitors’ efforts to grow market share could exert downward pressure on our product pricing and margins. Many of our competitors are substantially larger in size and have substantially greater financial, marketing and other resources than we do, and therefore may be more effective in adapting to customer requirements while being more profitable. In addition, our customers may increase levels of production insourcing for a variety of reasons, such as shifts in customers’ business strategies or the emergence of low-cost production opportunities in other countries, which may adversely affect our sales as well as the profit margins on our products.

If we do not respond appropriately, the evolution of the automotive industry towards electric vehicles, autonomous vehicles and mobility on demand services could adversely affect our business.

The global automotive industry is experiencing a period of significant technological change. Future automotive vehicle production may be affected by additional industry or consumer behaviors, including the development and use of autonomous and electric vehicles and increasing use of car and ridesharing and on-demand transportation as a service, as well as related regulations. The rapidly evolving nature of the markets in which we compete has attracted, and may continue to attract, new entrants, including new entrants from outside the traditional automotive supply industry. Further, in comparison to us, our competitors may foresee the course of market developments more accurately, develop superior products, produce similar products at a lower cost, or adapt quicker to new technologies. If we do not accurately predict, prepare for and respond to new kinds of technological innovations, market developments and changing customer needs, our sales, profitability and long-term competitiveness may be harmed.

We manage our business based on projected future sales volume, which is highly dependent on information received from customers and general market data, and any inaccuracies or changes in such information could adversely affect our business, results of operations and financial condition.

We manage our business based upon projected future sales volumes, which are based upon many factors, including awarded business and assumptions of conversion rates thereof, customers’ forecasts and general market data. Our product revenues are generally based upon purchase orders issued by our customers, with updated production schedules for volume adjustments, and our customers generally do not guarantee sales volumes. As such, we typically do not have a backlog of firm orders at any point in time. In addition, awarded business may include business under arrangements that our customers have the right to terminate without penalty at any time. Further, our customers’ forecasts are subject to numerous assumptions, and such forecasts often are/may be changed

19

rapidly with limited notice. Therefore, our actual sales volumes, and thus the ultimate amount of revenue that we derive from such sales, are not committed. We also must incur costs and make commitments well in advance of the receipt of orders and resulting revenues from customers.  If actual production orders from our customers are not consistent with our projected future sales volumes, we could realize substantially less revenue and incur greater expenses over the life of vehicle programs.

The receipt of orders and resulting revenues from customers is significantly affected by global automotive production levels and the general business conditions in the automotive industry. Impacts of the COVID-19 pandemic, including changes in demand for a broad variety of goods and services, labor shortages, inflationary pressures and a challenging and dynamic supply chain environment, has caused additional variability in customer purchase orders and caused customers to cancel their purchase orders, which has made it particularly challenging for us to project future sales volumes and manage our business in the current economic climate.

The loss or insolvency of any of our principal customers would adversely affect our future results.

For the year ended December 31, 2021, our top two customers were Adient and Lear which each comprised 15% of our product revenues. Combined, approximately 71% of product revenues to these customers was sourced directly by the Company’s OEM customers. The continued growth, viability and financial stability of our principal customers, as well as the OEMS to which our products are supplied, are critical to our success. The loss of any significant portion of our sales to any of our customers would have a material adverse effect on our results of operations and financial condition. We sometimes experience, and we expect to continue to experience, a delay in our collection of accounts receivable balances from our customers, which may be significant and would be at risk in the event of their bankruptcy or other restructuring.

On October 28, 2021, Lear announced that it entered into an agreement to acquire the Interior Comfort Systems business unit of Kongsberg Automotive ASA, which is a key competitor of our climate comfort products, including CCS and seat heaters. The effects of this acquisition are not yet known; however, a decrease in product revenues to Lear could adversely impact our financial condition, results of operations and cash flows, and the impact of any reduced relationship with Lear on the rest of our business is uncertain.

Our inability to achieve product cost reductions which offset customer-imposed price reductions could adversely affect our financial performance.

Downward pricing pressure is customarily applied by automotive manufacturers to the automotive supply chain. Our customer contracts generally provide for annual price reductions over the production life of the vehicle, while requiring us to assume significant responsibility for the design, development and engineering of our products, as well as the costs incurred through our supply chain. Prices may also be adjusted on an ongoing basis to reflect changes in product content/costs and other commercial factors. Our inability to achieve product cost reductions that offset customer-imposed price reductions could adversely affect our financial condition, results of operations and cash flows.

Our inability to effectively manage the development, timing, quality and costs of new product launches could adversely affect our financial performance.

Gentherm is developing and launching new products and related technologies for its battery performance solutions and electronics systems businesses and intends to launch other new products in the future. The launch of products employing new technologies is a complex process, the success of which depends on a wide range of factors, including the robustness of our product and manufacturing process development, success in sourcing new components and commodities with suitable suppliers, readiness of our and our suppliers' manufacturing facilities and manufacturing processes, as well as factors related to tooling, equipment, employees, initial product quality and other factors. Given the complexity of new product launches, we may experience difficulties managing product quality, timeliness and associated costs.

In addition, new program launches require a significant ramp up of costs up to a few years prior to sales of such products. However, our sales related to these new programs generally are dependent upon the timing and success of our customers’ introduction of new vehicles. Our inability to effectively manage the timing, quality and costs of these new program launches could have a materially adverse effect on our business, results of operations and financial condition.

To the extent we are not able to successfully launch new business, vehicle production at our customers could be significantly delayed or shut down. Such operating failures could result in significant financial penalties to us or a diversion of personnel and financial resources to improving launches rather than investment in continuous process improvement or other growth initiatives, and

20

could result in our customers shifting work away from us to a competitor. Any of the foregoing matters could result in a significant loss of revenue and market shares and could have an adverse effect on our profitability and cash flows.

We use important intellectual property in our business. If we are unable to protect our intellectual property or if a third party makes assertions against us or our customers relating to intellectual property rights, our business could be adversely affected.

We own important intellectual property, including patents, trademarks, copyrights and trade secrets. Our intellectual property plays an important role in maintaining our competitive position in many of the markets that we serve.

We cannot guarantee, however, that we will be able to secure all desired protection, nor that the steps we have taken to protect our intellectual property will be adequate, to prevent infringement of our rights or misappropriation or theft of our technology, trade secrets or know-how. For example, effective patent, trademark, copyright and trade secret protection may be unavailable or limited in some of the countries in which we operate. In addition, while we generally enter into confidentiality agreements with our employees and third parties to protect our trade secrets, know-how, business strategy and other proprietary information, such confidentiality agreements could be breached or otherwise may not provide meaningful protection for our trade secrets and know-how related to the design, manufacture or operation of our products. If it became necessary for us to resort to litigation to protect our intellectual property rights, any proceedings could be burdensome and costly, and we may not prevail. Further, adequate remedies may not be available in the event of an unauthorized use or disclosure of our trade secrets and manufacturing expertise. Finally, for those products in our portfolio that rely on patent protection, once a patent has expired, the product is generally open to competition. Products under patent protection usually generate higher revenues and profitability than those not protected by patents. If we fail to successfully enforce our intellectual property rights, our competitive position could suffer, which could harm our business, financial condition, results of operations and cash flows.

In addition, our competitors may develop technologies that are similar or superior to our proprietary technologies or design around the patents we own or license. Further, as we expand our operations in jurisdictions where the protection of intellectual property rights is less robust, the risk of others duplicating our proprietary technologies increases, despite efforts we undertake to protect them. Foreign governments may adopt regulations, and foreign governments or courts may render decisions, requiring compulsory licensing of intellectual property rights, or foreign governments may require products to meet standards that serve to favor local companies or provide reduced protection relative to other countries.

Our ability to market our products successfully depends on acceptance of our products by existing and potential customers and consumers, as well as the success of our customers.

We have been, and will continue to be, required to educate potential customers and demonstrate that the merits of our existing products justify the costs associated with them. Similar efforts will be required with existing and potential customers for additional products we develop using technologies we develop or license. Customers will only include our products if there appears to be consumer demand. For our automotive products, we rely on OEMs and applicable dealer networks to market our products to consumers, and we do not have any control over the marketing budget or messaging nor the training of employees and agents regarding our products. Further, OEMs and dealer networks may market products offered by our competitors, including products manufactured by such OEMs. If customers or consumers conclude that temperature control seats or our other automotive products are unnecessary or too expensive or that our competitors offer more favorable sales terms or better products, OEMs and other manufacturers may reduce availability or decline to include our products in their vehicles.

Security breaches and other disruptions to our information technology networks and systems, including a disruption related to cybersecurity, could interfere with our operations and could compromise the confidentiality of our proprietary information or personal information.

We rely on our information technology systems and networks in connection with many of our business activities. Some of these networks and systems are managed by third-party service providers and are not under our direct control. Our operations routinely involve receiving, storing, processing and transmitting sensitive information pertaining to our business, customers, suppliers, employees and other sensitive matters. We rely upon the capacity, reliability and security of our IT and data security infrastructure, as well as our ability to expand and continually update this infrastructure in response to the changing needs of our business. If we experience a problem with the functioning of an important IT system or a security breach of our IT systems, due to failure to timely upgrade systems or during system upgrades and/or new system implementations, or resulting from failures of our third-party service providers, the resulting disruptions could have an adverse effect on our business.

21

As with most companies, we have experienced cyber-attacks, attempts to breach our systems and other similar incidents, none of which were material in 2021. Any future cyber incidents could, however, materially disrupt operational systems; result in loss of trade secrets or other proprietary or competitively sensitive information; compromise personally identifiable information regarding customers or employees; delay our ability to deliver products to customers; and jeopardize the security of our facilities. A cyber incident could be caused by malicious outsiders (including state-sponsored espionage or cyberwarfare) or insiders using sophisticated methods to circumvent firewalls, encryption and other security defenses. Because techniques used to obtain unauthorized access or to sabotage systems change frequently and generally are not recognized until they are launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. Information technology security threats, including security breaches, computer malware, “ransomware” and other cyber-attacks, are increasing in both frequency and sophistication and could create financial liability, subject us to legal or regulatory sanctions or damage our reputation with customers, dealers, suppliers and other stakeholders. Many victims of ransomware are forced to pay significant ransoms to regain access to their critical business data, and we may not be permitted under various regulations and laws to make such payments.  With some of our employees working from home during the COVID-19 pandemic, there may be increased opportunities for unauthorized access and cyber-attacks. Security breaches could also result in a violation of U.S. and international privacy and other laws and subject the Company to various litigations, investigations and proceedings. We continuously seek to maintain a robust program of information security and controls, but the impact of a material information technology event could have a material adverse effect on our competitive position, reputation, results of operations, financial condition and cash flows.

Despite our implementation of security measures, our IT systems, like those of other companies, are vulnerable to damages from computer viruses, natural disasters (which may become more frequent due to climate change), unauthorized access, cyber-attack and other similar disruptions. No IT system can be fully secure and impervious to all threats or failures. Any system failure, accident or security breach could result in disruptions to our operations. A material network breach in the security of our IT systems could include the theft of our intellectual property, trade secrets, customer information, human resources information or other confidential information. To the extent that any disruptions or security breach results in a loss or damage to our data, or an inappropriate disclosure of confidential, proprietary or customer information, it could cause significant damage to our reputation, affect our relationships with its customers, lead to claims against us, fines and other penalties assessed upon us by governmental authorities, and ultimately harm our business. In addition, we may be required to incur significant costs to remediate and protect against damage caused by these disruptions or security breaches in the future.

Our business is subject to risks associated with manufacturing processes.

If certain of our existing production facilities become incapable of manufacturing products or production capacity is limited for any reason, such as terror attacks, war, or other civil disturbances, natural disasters (which may be more frequent due to climate change), other catastrophic events, public health crises, labor shortages, work stoppages, or other events that cause facility closures or production disruptions, we may be unable to meet production requirements, sales and profits could decline, and our commercial reputation could be damaged. For example, we experienced extended work stoppages in the first half of 2020 as the pandemic spread and governmental authorities initiated “lock-down” orders for all non-essential activities. Without operation of certain existing production facilities, we may be limited in our ability to deliver products until we restore the manufacturing capability at the particular facility, find an alternative manufacturing facility or arrange an alternative source of supply.

We maintain property damage insurance that we believe to be adequate to provide for reconstruction of facilities and equipment, as well as business interruption insurance to mitigate losses resulting from any production interruption or shutdown caused by an insured loss. However, any recovery under our insurance policies may not offset the lost sales, harm to our business reputation or increased costs that may be experienced during the disruption of operations. Further, any such proceeds may be received and accounted for in a different reporting period, which could materially and adversely affect our business, financial condition, results of operations and cash flow generally or for a specific reporting period.

If we fail to manage our growth effectively or to integrate successfully any new or future business ventures, acquisitions, investments or strategic alliance into our business, our business could be materially adversely harmed.

We regularly consider opportunities to pursue business ventures, acquisitions, investments and strategic alliances that could leverage our products and capabilities, as well as, enhance our customer base, geographic penetration and scale, to complement our current businesses, some of which could be material. Finding and assessing a potential growth opportunity and completing a transaction involves extensive due diligence, management time and expense; however, the amount of information we can obtain about a potential growth opportunity may be limited. Further, we can give no assurance that new business ventures, acquisitions,

22

investments and strategic alliances will positively affect our financial performance or will perform as planned, including regarding anticipated synergies or other financial or operational benefits. We may not be able to successfully assimilate or integrate companies that we acquire, including personnel, financial systems, distribution, operations, internal controls and general operating procedures. Further, for significant transactions, we would expect to incur additional debt, issue equity and/or increase capital expenditures, which may increase leverage risks, result in dilution or reduce capital available for other investments in ongoing operations. If we fail to assimilate or integrate acquired companies successfully, our business, reputation and results of operations could be materially impacted. Likewise, our failure to integrate and manage acquired companies successfully may lead to future impairment of any associated goodwill and intangible asset balances. Given our limited history in the patient temperature management business, the foregoing risks may be heightened due to our lack of experience in integrating similar businesses.

Our global operations subject us to risks that may harm our operations and financial results.

In 2021, 61% of our product revenue was generated from sales to customers outside the United States. We have significant personnel, property, equipment and operations in a number of countries outside of the United States, including China, Germany, Hungary, North Macedonia, Mexico, South Korea, Ukraine and Vietnam. Our exposure to the risks described below is substantial. We also derive a significant portion of revenues from Europe and Asia and conduct certain investing and financing activities in local currencies.

In addition to the general risks relating to our operations, our international operations are subject to unique risks inherent in doing business abroad, including:

 

•

exposure to local economic, political and labor conditions;

 

•

different and complex local laws and regulations and enforcement thereof, including those relating to governance, taxes, litigation, anti-corruption, employment, employee benefits, environmental, competition, permitting, investment, product regulations, repatriation, and export/import restrictions or requirements;

 

•

increases in duties, tariffs and taxation on our products related to U.S. trade disputes; trade restrictions and potential trade wars, including limitation on imports or exports of components or assembled products, unilaterally or bilaterally;

 

•

exposure to infectious disease and epidemics, including the effects on our business operations, and those of our customers and suppliers, in geographic locations impacted by an outbreak, such as the ongoing COVID-19 pandemic;

 

•

violence and civil unrest (including acts of terrorism, drug-cartel related and other forms of violence and outbreaks of war);

 

•

expropriation, nationalization or other protectionist activities;

 

•

currency exchange rate fluctuations and currency controls; in particular, a significant portion of our revenues and expenses are denominated in currencies other than the U.S. Dollar, including the Euro, the Chinese Renminbi, the Vietnamese Dong, the Hungarian Forint, the North Macedonian Denar, the Ukrainian Hryvnia, the South Korean Won and the Mexican Peso;

 

•

local business and cultural factors that differ from our customary standards and practices, including business practices that we are prohibited from engaging in due to anti-corruption laws and regulations; and

 

•

ineffective legal protection of our intellectual property rights in certain countries.

23

 

Additionally, our primary manufacturing locations are in Mexico, China, Vietnam, North Macedonia and Ukraine, all countries that have historically experienced a heightened degree of political, civil and labor uncertainty. Political conflict and related demonstrations and violence in Ukraine in recent years, for example, highlights the risks to our foreign manufacturing facilities. Although our manufacturing facility in Ukraine is located approximately 700 miles by road from Kiev, and approximately the same distance from the activities along the border of Ukraine and Russia where fighting has occurred, we cannot be certain that similar demonstrations, unrest and international tensions will not affect our facility in the future, including due to electrical outages and periodic battles with separatists closer to our facility. In addition, certain of our employees in Ukraine are routinely conscripted into the military and/or sent to the Russian border to fight in the ongoing conflict. Furthermore, most of our products manufactured in Ukraine are shipped across the border from Ukraine to Hungary for further delivery to our customers. If that border crossing were to be closed or restricted for any reason, we would essentially experience a loss of the use of our Ukrainian facility, which would have a material adverse effect on our business.

Defects or quality issues associated with our automotive and medical products could adversely affect the results of our operations.

Our design, manufacture and marketing of automotive products may subject us to warranty claims and product liability in the event that our products fail to perform as expected and, in the case of product liability, such failure of our products results or is alleged to result in bodily injury or property damage. Any large product liability claims, if made, could exceed our insurance coverage limits and insurance may not continue to be available on commercially acceptable terms, if at all, and we may incur significant costs to defend these claims. If any of our products are or are alleged to be defective, we also may be required to participate in a recall or other corrective action involving such products. Automotive manufacturers are increasingly looking to their suppliers for contribution when faced with recalls and product liability claims, as well as requiring their suppliers to guarantee or warrant their products and bear the costs of repair and replacement of such products under new vehicle warranties.  OEMs historically have recalled vehicles for perceived defects in seat heaters, and we have incurred liabilities in connection with the recalls and other field actions.  In addition, governmental regulatory agencies throughout the world, such as NHTSA in the U.S., have safety standards that require manufacturers to remedy defects related to vehicle safety through safety recall campaigns, and a manufacturer is obligated to recall vehicles if it determines that the vehicles do not comply with a safety standard. A recall claim brought against us that is not insured, or a product liability claim brought against us in excess of our available insurance, could have an adverse impact on our results of operations and reputation or market acceptance of our products.  In certain instances, allegedly defective products may be the result of components supplied by our supply chain, and we may be limited in our ability to obtain recovery from our suppliers of materials or services included within our products that are associated with product liability and warranty claims, particularly if the affected items relate to global platforms or involve defects that are identified years after production.

The design, manufacture and marketing of medical products involve certain inherent risks. Manufacturing or design defects, component failures, unapproved or improper use of our products, or inadequate disclosure of risks or other information relating to the use of our products can lead to regulatory action, injury or other serious adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or as required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of a product from the market. A recall, inadequate disclosure or defect could result in significant costs and lost sales and customers, enforcement actions and/or investigations by state and federal governments or other enforcement bodies, as well as negative publicity and damage to our reputation that could reduce future demand for our products. Personal injuries relating to the use of our products can also result in significant product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in regulatory approval of new products or the imposition of post-market approval requirements, such as further clinical testing.  Such clinical testing is costly and time-consuming and could delay market approval or the meeting of additional post-market requirements.

Legal, Regulatory and Compliance Risks

Changes to trade policy, including tariffs and customs regulations, could have a material and adverse effect on our business.

Existing free trade laws and regulations, such as the United States-Mexico-Canada Agreement, provide certain duties and tariffs for qualifying imports and exports, subject to compliance with the applicable classification and other requirements. Changes in laws or policies governing the terms of foreign trade, and in particular increased trade restrictions, tariffs or taxes on imports from countries where we manufacture products, such as China and Mexico, could have a material adverse effect on our business and financial results. For instance, beginning in 2018, the U.S. and Chinese governments have imposed a series of significant incremental retaliatory tariffs to certain imported products. Most notably with respect to the automotive industry, the U.S. imposed tariffs on imports of certain steel,

24

aluminum and automotive components, and China imposed retaliatory tariffs on imports of U.S. vehicles and certain automotive components. Depending upon their duration and implementation, as well as our ability to mitigate their impact, these tariffs and other regulatory actions could materially affect our business, including in the form of increased cost of goods sold, decreased margins, increased pricing for customers, and reduced sales.

Tax matters, including changes in the corporate tax rates, disagreement with taxing authorities and imposition of new taxes could impact our results of operations and financial condition.

We are subject to income and other taxes in the U.S. and internationally. We are also subject to regular reviews, examinations, and audits by the Internal Revenue Service and other taxing authorities with respect to our taxes. Although we believe our tax estimates are reasonable, if a taxing authority disagrees with the positions we have taken, we could face additional tax liability, including interest and penalties. There can be no assurance that payment of such additional amounts upon final adjudication of any disputes will not have a material impact on our result of operations and financial position.

We also need to comply with new, evolving or revised tax laws and regulations. The enactment of or increases in tariffs, or other changes in the application or interpretation of tax legislation and other initiatives, or on specific products that we sell or with which our products compete, may have an adverse effect on our business or on our results of operations.

The value of our deferred tax assets may not be realized, which could materially and adversely affect our operating results.

As of December 31, 2021, we had approximately $68 million in net deferred tax assets, inclusive of a $16 million valuation allowance. These deferred tax assets include net operating loss carryovers and tax credits that can be used to offset taxable income in future periods and reduce income taxes payable in those future periods. Each quarter, we determine the probability of the realization of deferred tax assets, using significant judgments and estimates with respect to, among other things, historical operating results and expectations of future earnings and tax planning strategies. If we determine in the future that there is not sufficient positive evidence to support the valuation of these assets, due to the risk factors described herein or other factors, we may be required to further adjust the valuation allowance to reduce our deferred tax assets. Such a reduction could result in material non-cash expenses in the period in which the valuation allowance is adjusted and could have a material adverse effect on our financial statements.

Our patient temperature management business is subject to extensive industry regulation and failure to comply with all applicable rules and regulation may adversely impact us.

Our patient temperature management products are subject to extensive, complex, costly and evolving government regulation. In the United States, this is principally administered by the Food and Drug Administration (“FDA”). Various regulatory agencies in foreign countries where our medical products are sold also regulate that business. Under both United States and foreign country regulations, we are subject to periodic inspection of our facilities (including third-party facilities that are performing services for us), procedures and operations and testing of our products. Following such FDA inspections, should any noncompliance with regulations or other quality issues be noted, we may receive observations, notices, citations and/or warning letters that could require us to get FDA approval of a corrective action plan and modify certain activities identified during the inspection, possibly at a significant cost. We are also required to report adverse events associated with our medical products to the FDA and other foreign regulatory authorities where our products have been approved or received market clearance. Unexpected or serious health or safety concerns could result in liability claims, recalls, market withdrawals or other regulatory actions. Changes in laws or regulations could require us to change the way we operate or to utilize resources to maintain compliance, which could increase costs or otherwise disrupt operations. In addition, failure to comply with any applicable laws or regulations could result in fines or revocation of our operating permits and licenses or, in rare circumstances, market withdrawal of the product.

The process for obtaining governmental approval to manufacture and market new medical devices is time-consuming and costly. We are dependent on receiving FDA and other governmental or third-party approvals prior to manufacturing, marketing and shipping any new medical products. We cannot be certain that any new medical products we develop will receive FDA or other necessary approvals. Also receipt of approval in one country does not guarantee approval by the FDA or any other foreign regulatory agency.

Any failure to comply with anti-corruption laws and regulations could have a material and adverse effect on our reputation, business and financial results.

Our operations outside of the United States require us to comply with various anti-bribery and anti-corruption regulations, including but not limited to the U.S. Foreign Corrupt Practices Act, the United Kingdom Bribery Act and the China Anti-Unfair

25

Competition Law. Violations of these laws, which are complex and often difficult to interpret and apply, could result in significant criminal penalties or sanctions that could adversely affect our business, financial condition, results of operations and cash flows.

A significant product liability lawsuit, warranty claim or product recall involving us or one of our major customers, or an investigation regarding vehicle safety generally, could materially and adversely affect our financial performance.

In the event that our products fail to perform as expected, whether allegedly due to our fault or that of one of our suppliers, and such failure results in, or is alleged to result in, bodily injury and/or property damage or other losses, we may be subject to product liability lawsuits and other claims, and we have been in the past and may again be required or requested by our customers or regulators to participate in a recall or other corrective action involving such products. We also are a party to agreements with certain of our customers, whereby these customers may pursue claims against us for contribution of all or a portion of the amounts sought in connection with product liability and warranty claims. We carry insurance for certain product liability claims, and have utilized such insurance periodically.  However, such coverage may be limited for future claims. In addition, we may not be successful in recovering amounts from third parties, including suppliers, in connection with these claims. These types of claims could materially and adversely affect our financial condition, operating results and cash flows.

We are involved from time to time in various legal and regulatory proceedings and claims, which could adversely affect our financial performance.

We are involved in various legal and regulatory proceedings and claims that, from time to time, are significant. These are typically claims that arise in the normal course of business including, without limitation, commercial or contractual disputes, including disputes with our customers, suppliers or competitors, intellectual property matters, personal injury claims, environmental matters, tax matters and employment matters. Such legal and regulatory proceedings could result in an adverse outcome for the Company that would adversely affect our financial condition, results of operations and cash flows.

Our results of operations and financial condition may be adversely impacted from a decrease in or cessation or clawback of government incentives related to investments, workforce or production.

We have received, and may receive economic benefits from national, state and local governments in various regions of the world in the form of incentives designed to encourage manufacturers to establish, maintain or increase investment, workforce or production. These incentives may take various forms, including grants, loan subsidies and tax abatements or credits.  The impact of these incentives can be significant in a particular market during a reporting period.  A decrease in, expiration without renewal of, or other cessation or clawback of government incentives for any of our business units, as a result of administrative decision or otherwise, could have an adverse impact on our results of operations and financial condition, as well as our ability to fund new investments.

We are required to comply with environmental laws and regulations that could cause us to incur significant costs.

Our manufacturing facilities are subject to numerous laws and regulations designed to protect the environment, and we expect that additional requirements with respect to environmental matters will be imposed on us in the future. We may also assume, or be deemed to assume, significant environmental liabilities in acquisitions. Environmental liability may be imposed without regard to fault, and under certain circumstances, can be joint and several, resulting in one party being held responsible for the entire obligation. Material future expenditures may be necessary if compliance standards change or material unknown conditions that require remediation are discovered. No assurance can be given that all environmental liabilities have been identified or that no prior owner or operator of our properties or former properties has created an environmental condition not known to us.  Environmental laws could also restrict our ability to expand our facilities or could require us to acquire costly equipment or to incur other significant expenses in connection with our business. Violations of these requirements could result in fines or sanctions, obligations to investigate or remediate contamination, third party property damage or personal injury claims due to the migration of contaminants off-site, or modification or revocation of our operating permits, which could materially and adversely affect our financial condition, results of operations and cash flows. Additionally, proposed and existing efforts to address climate change by reducing greenhouse gas emissions could directly or indirectly affect our costs of energy, materials, manufacturing, distribution, packaging and other operating costs, which could impact our business and financial results.

 

Our business may be negatively impacted by regulatory and customer-imposed requirements to address climate change and other sustainability issues.

As evidenced by shifting industry and consumer behaviors, including the development and use of electric vehicles, the automotive industry and consumers have a heightened focus on climate change and the environmental impact of product

26

manufacturing and end use. This increased focus on sustainability and the environmental impact of the automotive industry and manufacturing processes has caused our customers to impose additional requirements on us and our suppliers, which often exceed regulatory standards. These customer requirements include increased tracking and reporting of greenhouse gas emissions and other environmental metrics, reduced waste and wastewater from operations, increased use of sustainable materials in our products, and the use of renewable energy sources in our factory operations. We expect to incur increased operating costs and capital expenditures to procure renewable energy and additional equipment or make operational and process changes to comply with customer requirements. To the extent we are unable to meet or exceed customer sustainability requirements, demand for our products and our revenues would be adversely impacted. We also expect that the increased focus on sustainability and climate change will result in new legislation or regulations at the federal, state or local level. Such legislative developments could adversely impact our business by increasing costs and could require us to make changes to our operations and result in substantial additional capital expenditures and operating costs. These additional costs, changes in operations, or loss of revenues could have a material adverse effect on our business, financial condition, and results of operations.

We may face particular privacy, data security and data protection risks.

Legislators and/or regulators in countries in which we operate are increasingly adopting or revising privacy, information security and data protection laws. In particular, the European Union’s General Data Protection Regulation (“GDPR”), which became effective on May 25, 2018, imposes additional obligations and risk upon our business and which increases substantially the penalties to which we could be subject in the event of any non-compliance. The GDPR and other similar laws and regulations, including the new California Consumer Protection Act (“CCPA”) and other similar state laws recently or soon to be enacted, as well as any associated inquiries or investigations or any other government actions, may be costly to comply with, result in negative publicity, increase our operating costs, require significant management time and attention, and subject us to remedies that may harm our business, including fines or demands or orders that we modify or cease existing business practices.  The CCPA went into effect on January 1, 2020 and many of its requirements have not yet been interpreted by courts, and best practices are still being developed by the industry, all of which increase the risk of compliance failure and related adverse impacts. Furthermore, in November 2020, the California Privacy Rights Act (“CPRA”) was passed as a ballot measure. While many of the CPRA’s substantive modifications will not go into effect until 2023, they will require businesses to dedicate time and resources on compliance efforts, in some cases requiring new or modified practices and operations.

Financial Risks

Our existing indebtedness and the inability to access capital markets could restrict our business activities or our ability to execute our strategic objectives or adversely affect our financial performance.

As of December 31, 2021, our total consolidated indebtedness was $38.8 million, with $440.0 million available for additional borrowings under the Credit Agreement subject to specified conditions that Gentherm currently satisfies. We may also incur additional indebtedness in the future. If our outstanding borrowings increase, including under existing availability or if we incur additional indebtedness, the amount of our outstanding debt could have important, adverse consequences to us and our investors, including:

 

•

requiring a substantial portion of our cash flow from operations to make interest payments;

 

•

making it more difficult to satisfy other obligations;

 

•

increasing our vulnerability to general adverse economic and industry conditions;

 

•

reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our businesses;

 

•

limiting our flexibility in planning for, or reacting to, changes in our businesses and industries; and

 

•

limiting our ability to borrow additional funds as needed or take advantage of business opportunities as they arise;

Our debt agreements contain certain restrictive covenants and customary events of default. These restrictive covenants limit our ability to take certain actions, such as, among other things: incur additional debt, make certain payments or distributions (including for the repurchase or redemption of our shares), engage in mergers or consolidations, make certain dispositions and transfers of assets, enter into transactions with affiliates and guarantee indebtedness. While not unusual for financings of the type that we have, the restrictions in our credit facilities may prevent us from taking actions that we believe would be in the best interest of our business and

27

may make it difficult for us to execute our business plans, take advantage of business opportunities, or react to changing industry conditions.

To the extent that we incur additional indebtedness, the risks described above could increase. In addition, our actual cash requirements in the future may be greater than expected. Our cash flow from operations may not be sufficient to service our outstanding debt or to repay the outstanding debt as it becomes due, and we may not be able to borrow money, sell assets or otherwise raise funds on acceptable terms, or at all, to service or refinance our debt.

If an event of default would occur under our existing debt agreements or any additional indebtedness, our lenders could declare all amounts outstanding to be immediately due and payable, which may cause cross-defaults under our other debt obligations. If our lenders accelerate the maturity of our indebtedness, we may not have sufficient capital available at that time to pay the amounts due to all lenders on a timely basis, and there is no guarantee that we would be able to repay, refinance, or restructure the payments on such debt. Further, under our existing credit facilities, the lenders would have the right to foreclose on certain of our assets, which could have a material adverse effect on our business, results of operations and financial condition.

An adverse change in the interest rates for our borrowings could adversely affect our financial condition.

The publication of the one-week and two-month USD LIBOR maturities and non-USD LIBOR maturities ceased immediately after December 31, 2021, with the remaining USD LIBOR maturities ceasing immediately after June 30, 2023. Our current outstanding variable rate indebtedness uses LIBOR as a benchmark for establishing the interest rate, and as of December 31, 2021, we had $35 million of variable rate debt tied to USD LIBOR under our First Lien Credit Agreement with maximum maturities extending past June 30, 2023. Under the terms of our Credit Agreement, the cessation of LIBOR or the announcement by the administrator of LIBOR or a governmental authority with jurisdiction over the Administrative Agent requires us to renegotiate or amend this agreement to select a replacement benchmark, which may adversely affect interest rates and result in higher borrowing costs. At this time, it is not possible to predict how markets will respond to Secured Overnight Financing Rate, or SOFR, the preferred alternative rate for LIBOR, or other alternative reference rates. We cannot predict the effect of the potential changes to or elimination of LIBOR, the use of SOFR or other alternative rates or benchmarks and the corresponding effects on our cost of capital. This could materially and adversely affect our results of operations, cash flows and liquidity. We cannot predict the effect of the potential changes to or elimination of LIBOR or the establishment and use of alternative rates or benchmarks and the corresponding effects on our cost of capital, but it may result in interest rates and/or payments that result in higher borrowing costs over time as compared to our borrowing costs if the USD LIBOR continued to be available.

We are subject to significant foreign currency risk and foreign exchange exposure related to our global operations.

A significant portion of our global transactions is conducted in currencies other than the U.S. Dollar. While we sometimes employ financial instruments to hedge some of our transactional foreign exchange exposure, developing an effective and economical foreign currency risk strategy is complex and expensive and no strategy can completely insulate us from those exposures. Exchange rates can be volatile and could adversely affect our financial results and comparability of results from period to period.

We may be unable to realize the expected benefits of our restructuring actions, which could adversely affect our profitability and operations.

We have undertaken significant restructuring activities in recent years that remain ongoing, and may take future restructuring actions to realign and resize our production capacity and cost structure, lower our cost base, improve our financial performance and cash flow generation, and create a simplified organization best positioned to deliver on our key financial and operational priorities. Charges related to these actions or any further restructuring actions may have a material adverse effect on our results of operations and financial condition. We cannot ensure that any current or future restructuring will be completed as planned, on a timely basis or at all, will be on budget, or achieve the desired results.

Common Stock Investment Risks

The price of our Common Stock may fluctuate significantly.

The price of our Common Stock on the Nasdaq Global Select Market has experienced substantial price volatility and may continue to do so in the future. Additionally, the Company, the automotive industry and the stock market as a whole have experienced significant stock price and volume fluctuations that have affected stock prices in ways that may have been unrelated to these

28

companies’ operating performance.  Price volatility over a given period may cause the average price at which the Company repurchases its stock to exceed the stock’s price at a given point in time. If the Company fails to meet expectations related to future growth, profitability, share repurchases or other market expectations, its stock price may decline significantly, which could have a material adverse impact on investor confidence and employee retention.

On December 11, 2020, the Board of Directors authorized a new stock repurchase program, pursuant to which the Company is authorized to repurchase up to $150 million of common stock over a three-year period.  Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations.  Any Company stock repurchases under the program may result in stock price and volume fluctuations.  During the year ended December 31, 2021, the Company repurchased approximately $20 million of shares under the 2020 Stock Repurchase Program with an average price paid per share of $83.44. The 2020 Stock Repurchase Program has $130 million of repurchase authorization remaining as of December 31, 2021.

ITEM 1B.

UNRESOLVED STAFF COMMENTS

None.

ITEM 2.

PROPERTIES

As of December 31, 2021, we operate in over 23 locations across 12 countries, which are primarily for manufacturing, assembly, distribution, warehousing, engineering and testing. The majority of our Automotive facilities located outside of the U.S. are principally used in manufacturing and distribution and are located in China, Hungary, Mexico, North Macedonia, South Korea, Ukraine and Vietnam. Our global headquarters is located in Northville, Michigan, our European headquarters is located in Odelzhausen, Germany and our Asia-Pacific headquarters is located in Shanghai, China. Our Medical business is principally comprised of our headquarters and manufacturing site located in Cincinnati, Ohio and our manufacturing site in Germany. We also have sales offices, warehouses and engineering centers, strategically located throughout the world. Nearly all of our manufacturing and distribution sites in Mexico and Asia are leased, while most of our European sites are owned.

ITEM 3.

LEGAL PROCEEDINGS

We are subject to litigation from time to time in the ordinary course of our business, however there is no current material pending litigation to which we are a party and no material legal proceedings were terminated, settled or otherwise resolved during the fourth quarter of the fiscal year ended December 31, 2021.

ITEM 4.

MINE SAFETY DISCLOSURES.

Not applicable.

 

 

 

29

 

PART II

 

ITEM 5.

MARKET FOR THE REGISTRANT’S COMMON STOCK, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our Common Stock trades on the Nasdaq Global Select Market under the symbol “THRM.”

Holders

As of February 14, 2022, our Common Stock was held by 41 shareholders of record. A substantially greater number of holders are beneficial owners whose shares of record are held by banks, brokers and other nominees.

Dividends

We have not paid any Common Stock cash dividends since formation and we do not expect to pay any in the foreseeable future. The payment of future dividends is within the discretion of our Board of Directors and will depend upon business conditions, our earnings and financial condition and other factors.  Currently, our bank credit facilities limit payment of dividends on our Common Stock.

Stock Repurchase Program

In December 2020, the Board of Directors authorized a new stock repurchase program (the “2020 Stock Repurchase Program”). pursuant to which the Company is authorized to repurchase up to $150 million of its issued and outstanding common stock over a three-year period, expiring December 15, 2023.

Repurchases under the 2020 Stock Repurchase Program may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions (including Rule 10b5-1 trading plans), and may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. The 2020 Stock Repurchase Program may be modified, extended or terminated at any time without prior notice.

Issuer Purchases of Equity Securities During Fourth Quarter 2021

Period

 

(a)

Total Number of Shares Purchased

 

 

(b)

Average Price

Paid Per Share

 

 

(c)

Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs

 

 

(d)

Approximate Dollar Value of Shares That May Yet Be Purchased Under the 2020 Stock Repurchase Program

 

October 1, 2021 to October 31, 2021

 

 

—

 

 

$

—

 

 

 

—

 

 

 

150,000,000

 

November 1, 2021 to November 30, 2021

 

 

186,809

 

 

$

83.54

 

 

 

186,809

 

 

 

134,394,481

 

December 1, 2021 to December 31, 2021

 

 

52,889

 

 

$

83.09

 

 

 

239,698

 

 

 

130,000,105

 

 

 

ITEM 6.

RESERVED

 

 

30

 

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated financial statements (and notes related thereto) and other more detailed financial information appearing elsewhere in this Annual Report. Further, you should read the following discussion and analysis of our financial condition and results of operations together with the “Risk Factors” included elsewhere in this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. See also “Forward-Looking Statements” in Part I of this Annual Report.

Overview

Gentherm Incorporated is a global developer, manufacturer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications in the automotive and medical industries. Within the automotive industry, our products provide solutions for passenger climate comfort and convenience, battery thermal management and cell connecting systems. Within the medical industry our products provide patient temperature management solutions. Our automotive products can be found on vehicles manufactured by nearly all the major OEMs operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that are expected to enable improvements to existing products and to create new product applications for existing and new markets.

Our sales are driven by the number of vehicles produced by the OEMs, which is ultimately dependent on consumer demand for automotive vehicles, our product content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers.  Historically, new vehicle demand and product content (i.e. vehicle features) have been driven by macro-economic and other factors, such as interest rates, automotive manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Vehicle content has also been driven by trends in consumer preferences, such as preferences for smart devices and features, personalized user experience, and comfort, health and wellness. Economic volatility or weakness, as well as geopolitical factors, in North America, Europe or Asia, have had and could result in a significant reduction in automotive sales and production by our customers, which would have an adverse effect on our business, results of operations and financial condition.  In 2020 and 2021, and continuing into 2022, the automotive industry has experienced fluctuating demand and production disruptions related to supply chain challenges, facility closures, labor shortages, work stoppages and inflationary pressures, as a result of the COVID-19 pandemic and associated macroeconomic conditions, as described below. We believe our diversified OEM customer base and geographic revenue base, along with our flexible cost structure, have well positioned us to withstand the impact of industry downturns, including the ongoing impact of the COVID-19 pandemic and associated economic conditions, and benefit from industry upturns in the ordinary course.  However, shifts in the mix of global automotive production to higher cost regions or to vehicles with less of our product content as well as continuing production challenges and inflationary pressures could adversely impact our profitability.  In addition, we may be adversely impacted by volatility, weakness or accelerated growth in markets for hybrid or electric vehicles specifically. We believe our products offer certain advantages for hybrid and electric vehicles, including improved energy efficiency, and position us well to withstand changes in the volume mix between vehicles driven by internal combustion engines and hybrid and other electric vehicles. We also believe that products we are developing, such as ClimateSense®, position us well to address trends in consumer preferences such as personalized user experience, comfort, health and wellness.

Recent Trends

General Economic Condition

The COVID-19 pandemic that began around December 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the global automotive industry in the first half of 2020, with various direct and indirect adverse impacts continuing throughout 2021 and into 2022.

Beginning in February 2020 and continuing into June 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the second quarter of 2020, the Company had reopened all of its manufacturing facilities, in line with industry demand, and in accordance with local government requirements.

31

Although global automotive industry production has improved relative to the first half of 2020, production remains below recent historic levels.

The lingering impacts of COVID-19 into 2021 have impeded global supply chains, resulted in longer lead times and delays in procuring component parts and raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. These broad-based inflationary impacts have negatively impacted the Company’s financial condition, results of operations and cash flows throughout 2021. We expect these inflationary impacts to continue for the foreseeable future.

Supply shortages of semiconductor chips and other components have resulted in decreases in global automotive vehicle production and significant volatility in customer vehicle production schedules. The Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, have been unable to fully meet the vehicle production demands of the OEMs due to events which are outside the Company's control, including but not limited to, the COVID-19 pandemic, the global semiconductor shortage, fires at suppliers’ facilities, significant weather events impacting semiconductor supplier facilities in the southern United States, and other extraordinary events. The Company was able to mitigate the impacts of supply chain disruptions in order to satisfy customer orders during the first three quarters of 2021, however, during the fourth quarter of 2021 and continuing into 2022 we have experienced and may continue to experience direct impacts of ongoing shortages of semiconductors. Our ability to meet customer orders without significant delay and/or expense for 2022 and beyond remains subject to significant uncertainty.

In response to the global supply chain instability and inflationary cost increases the Company has taken several actions to minimize any potential and actual adverse impacts by working closely with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. We expect global supply chain instability will continue to have an adverse impact on our business and financial performance for the foreseeable future, and such adverse impact may be material. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy continue to evolve. Accordingly, the significance of the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing.

Light Vehicle Production Volumes

Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. According to the forecasting firm IHS Markit (February 2022 release), global light vehicle production in 2021 in the Company’s key markets of North America, Europe, China, Japan and Korea, as compared to 2020, are shown below (in millions of units):

 

 

 

2021

 

 

2020

 

 

% Change

 

North America

 

 

13.0

 

 

 

13.0

 

 

 

0.0

%

Europe

 

 

15.9

 

 

 

16.6

 

 

 

(4.2

)%

Greater China

 

 

24.8

 

 

 

23.6

 

 

 

5.1

%

Japan / South Korea

 

 

10.9

 

 

 

11.2

 

 

 

(2.7

)%

Total light vehicle production volume in key markets

 

 

64.6

 

 

 

64.4

 

 

 

0.3

%

 

The IHS Markit (February 2022 release) forecasted light vehicle production volume in the Company’s key markets for full year 2022 to increase to 70.8 million units, an 9.6% increase from full year 2021 light vehicle production volumes. Forecasted light vehicle production volumes are a component of the data we use in forecasting future business. However, these forecasts generally are updated monthly, and future forecasts may be significantly different from period to period due to changes in macroeconomic conditions or matters specific to the automotive industry, such as the fluctuations that occurred since 2020 and remain ongoing due to the COVID-19 pandemic.  Further, due to differences in regional product mix at our manufacturing facilities, as well as material production schedules from our customers for our products on specific vehicle programs, our future forecasted results do not directly correlate with the global and/or regional light vehicle production forecasts of IHS Markit or other third-party sources.

New Business Awards

We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During 2021, we secured an estimated $1,613 million of automotive new business awards, which is at the high end of the

32

range of new business awards in recent years. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by our customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that new business awards are an indicator of future revenue. New business awards are not projections of revenue or future business as of December 31, 2021, the date of this Annual Report or any other date. Customer projections regularly change over time and we do not update our calculation of any new business award after the date initially communicated. Automotive new business awards in 2021 also do not reflect, in particular, the impact of the COVID-19 pandemic and related macroeconomic challenges on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties as described in Item 1 under “Forward-Looking Statements” of this Annual Report.

Restructuring

Manufacturing Footprint Rationalization

In September 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company is relocating and consolidating certain automotive electronics manufacturing plants in North America and China.

During 2021, the Company completed the closures and relocation of its automotive electronics manufacturing operations from Burlington, Canada to Celaya, Mexico and from Longgang, Shenzhen, China to Bantian, Shenzhen, China. As of December 31, 2021, the electronics manufacturing in Acuña, Mexico continues to transition to Celaya, Mexico.

During the year ended December 31, 2021, the Company recognized restructuring expense of $1.3 million for employee separation costs and $1.7 million for other costs, primarily related to equipment move and set up costs. During the year ended December 31, 2020, the Company recognized restructuring expense of $(0.8) million primarily related to a reduction in the estimates of previously recognized employee separation costs and $1.0 million for other costs, primarily related to accelerated depreciation and equipment move and set up costs. During the year ended December 31, 2019, the Company recognized restructuring expense of $4.9 million for employee separation costs, and $2.1 million of other costs, primarily related to accelerated depreciation and fixed asset impairment.

The Company has recorded approximately $10.1 million of restructuring expenses since the inception of this program and as of December 31, 2021, $0.9 remains accrued. Actions under the Plan are expected to be substantially completed by the first half of 2022 and future expenses are expected to be less than $1 million.           

Other Restructuring Activities

As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $0.9 million, $5.4 million and $3.2 million of employee separation costs, respectively, and $0.0 million, $0.2 million and $2.8 million of other related costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs.

See Note 5, “Restructuring,” to the consolidated financial statements included in this Annual Report for information about our restructuring activities.

Divestitures

Divestiture of GPT

On October 1, 2019, the Company completed the sale of its remote power generation systems business, Gentherm Global Power Technologies (“GPT”) for a nominal amount and recognized a $5.9 million loss on sale for the year ended December 31, 2019, which is classified as Net loss on divestitures within the consolidated statements of income. During 2019, the Company also recognized impairment losses of $21.2 million for its GPT assets held for sale. These impairment charges are classified as Impairment loss within the consolidated statements of income.

33

Divestiture of CSZ-IC

On February 1, 2019, the Company completed the sale of its environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) and former Cincinnati Sub-Zero headquarters facility for total cash proceeds of $47.5 million. The Company recognized a $4.3 million pre-tax gain on the sale of CSZ-IC for the year ended December 31, 2019 which is classified as Net loss on divestitures within the consolidated statements of income.

Acquisitions

Acquisition of Beckmann & Egle Industrieelektronik GmbH

On July 1, 2021, the Company acquired the medical business unit of Beckmann & Egle Industrieelektronik GmbH (“B&E”), a developer and manufacturer of electronic control units, for a purchase price of $2.8 million. The acquisition was accounted for as a business combination with the purchase price assigned to inventory, property and equipment and other intangible assets based on their estimated fair values as of the acquisition date. The pro-forma effect of the B&E acquisition does not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented. The results of operations of B&E are reported within the Company’s Medical segment from the date of acquisition.

Acquisition of Stihler Electronic GmbH

On April 1, 2019, the Company acquired Stihler Electronic GmbH (“Stihler”), a leading developer and manufacturer of patient and blood temperature management systems, for a purchase price of $15.5 million, net of cash acquired and including $0.7 million of contingent consideration that was paid upon achievement of a milestone during the year ended December 31, 2020. The results of operations of Stihler are reported within the Company’s Medical segment from the date of acquisition.

Investments in non-consolidated affiliates

During 2021, the Company’s Automotive segment invested $5.2 million for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets.

During 2021, the Company’s Automotive segment invested $2.4 million for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets.

In December 2021, the Company committed to make a $5 million investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has not made any contributions to the Autotech Fund III, LP as of December 31, 2021. This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy.

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Medical.  The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems.

The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry.

See Note 19, “Segment Reporting,” to the consolidated financial statements included in this Annual Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating income.  

34

Results of Operations Year Ended December 31, 2021 Compared to Year Ended December 31, 2020

This section discusses our consolidated results of operations for the year ended December 31, 2021 compared to the year ended December 31, 2020. For a detailed discussion of our consolidated results of operations for the years ended December 31, 2020 compared to the year ended December 31, 2019, see Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operation” under “Results of Operations Year Ended December 31, 2020 Compared to Year Ended December 31, 2019” in our annual report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 1, 2021.

The results of operations for the years ended December 31, 2021 and 2020, in thousands, were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Product revenues

 

$

1,046,150

 

 

$

913,098

 

 

$

133,052

 

Cost of sales

 

 

742,519

 

 

 

644,994

 

 

 

(97,525

)

Gross margin

 

 

303,631

 

 

 

268,104

 

 

 

35,527

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

91,807

 

 

 

81,968

 

 

 

(9,839

)

Reimbursed research and development expenses

 

 

(16,593

)

 

 

(13,928

)

 

 

2,665

 

Net research and development expenses

 

 

75,214

 

 

 

68,040

 

 

 

(7,174

)

Selling, general and administrative expenses

 

 

109,554

 

 

 

105,044

 

 

 

(4,510

)

Restructuring expenses

 

 

3,857

 

 

 

5,803

 

 

 

1,946

 

Total operating expenses

 

 

188,625

 

 

 

178,887

 

 

 

(9,738

)

Operating income

 

 

115,006

 

 

 

89,217

 

 

 

25,789

 

Interest expense, net

 

 

(2,758

)

 

 

(4,559

)

 

 

1,801

 

Foreign currency gain (loss)

 

 

1,487

 

 

 

(5,439

)

 

 

6,926

 

Other income

 

 

117

 

 

 

2,337

 

 

 

(2,220

)

Earnings before income tax

 

 

113,852

 

 

 

81,556

 

 

 

32,296

 

Income tax expense

 

 

20,418

 

 

 

21,866

 

 

 

1,448

 

Net income

 

$

93,434

 

 

$

59,690

 

 

$

33,744

 

 

Product revenues by product category, in thousands, for the years ended December 31, 2021 and 2020 were as follows:

 

 

 

Year Ended December 31

 

 

 

2021

 

 

2020

 

 

% Change

 

Climate Control Seat

 

$

393,816

 

 

$

342,550

 

 

 

15.0

%

Seat Heaters

 

 

270,054

 

 

 

249,665

 

 

 

8.2

%

Steering Wheel Heaters

 

 

102,496

 

 

 

76,272

 

 

 

34.4

%

Automotive Cables

 

 

84,114

 

 

 

73,997

 

 

 

13.7

%

Battery Performance Solutions

 

 

69,594

 

 

 

50,901

 

 

 

36.7

%

Electronics

 

 

51,648

 

 

 

53,238

 

 

 

(3.0

)%

Other Automotive

 

 

32,911

 

 

 

23,375

 

 

 

40.8

%

Subtotal Automotive segment

 

 

1,004,633

 

 

 

869,998

 

 

 

15.5

%

Medical Segment

 

 

41,517

 

 

 

43,100

 

 

 

(3.7

)%

Total Company

 

$

1,046,150

 

 

$

913,098

 

 

 

14.6

%

`

Product Revenues

Below is a summary of our Product revenues, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

Variance Due To:

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

 

 

Automotive Volume

 

 

FX

 

 

Pricing/Other

 

 

Total

 

Product revenues

 

$

1,046,150

 

 

$

913,098

 

 

$

133,052

 

 

 

$

127,044

 

 

$

21,846

 

 

$

(15,838

)

 

$

133,052

 

 

35

 

Product revenues for the year ended December 31, 2021 increased 14.6% as compared to the year ended December 31, 2020. Revenue increased in all product categories except Electronics. The increase in product revenues is due to favorable volumes in our Automotive segment and favorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi and Korean Won. The decrease in product revenues included in Variance Due To Pricing/Other above is primarily attributable to decreases in automotive customer pricing and product revenue in our Medical segment.

Cost of Sales

Below is a summary of our Cost of sales and Gross margin, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

Variance Due To:

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

 

 

Automotive Volume

 

 

Operational

Performance

 

 

FX

 

 

Other

 

 

Total

 

Cost of sales

 

$

742,519

 

 

$

644,994

 

 

$

(97,525

)

 

 

$

(76,750

)

 

$

3,877

 

 

$

(14,294

)

 

$

(10,358

)

 

$

(97,525

)

Gross margin

 

 

303,631

 

 

 

268,104

 

 

 

35,527

 

 

 

$

50,294

 

 

$

3,877

 

 

$

7,552

 

 

$

(26,196

)

 

$

35,527

 

Gross margin - Percentage of product revenues

 

 

29.0

%

 

 

29.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales for the year ended December 31, 2021 increased by 15.1% as compared to the year ended December 31, 2020. The increase in cost of sales is primarily related to increased volumes in our Automotive segment and unfavorable foreign currency impacts primarily attributable to the Euro and Chinese Renminbi.  The offsetting Variance Due To Operational Performance is primarily attributable to an increase in manufacturing productivity, partially offset by higher material and freight costs. The increase in cost of sales is also due to the following items included in Variance Due To Other above:

 

▪

$3.7 million increase due to higher factory costs

 

▪

$3.5 million increase due to wage inflation

 

▪

$1.2 million increase due to the absence of COVID-19 government subsidy programs

 

▪

$1.1 million increase due to pre-production costs

 

▪

$0.9 million increase due to exercises and mark-to-market adjustments in cash settled stock appreciation rights

 

▪

$0.8 million increase due to higher incentive compensation expense

 

▪

$0.9 million decrease due to lower volumes in Medical segment

Net Research and Development Expenses

Below is a summary of our Net research and development expenses, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Research and development expenses

 

$

91,807

 

 

$

81,968

 

 

$

(9,839

)

Reimbursed research and development expenses

 

 

(16,593

)

 

 

(13,928

)

 

 

2,665

 

Net research and development expenses

 

$

75,214

 

 

$

68,040

 

 

$

(7,174

)

Percentage of product revenues

 

 

7.2

%

 

 

7.5

%

 

 

 

 

 

Net research and development expenses for the year ended December 31, 2021 increased 10.5% as compared to the year ended December 31, 2020. The increase in net research and development expenses is primarily related to increased project-related spending, including increased investments in ClimateSense and battery performance solutions and higher incentive compensation expense, partially offset by higher reimbursements for costs to design, develop and purchase tooling pursuant to customer contracts.

36

Selling, General and Administrative Expenses

Below is a summary of our Selling, general and administrative expenses, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Selling, general and administrative expenses

 

$

109,554

 

 

$

105,044

 

 

$

(4,510

)

Percentage of product revenues

 

 

10.5

%

 

 

11.5

%

 

 

 

 

 

Selling, general and administrative expenses for the year ended December 31, 2021 increased 4.3% as compared to the year ended December 31, 2020. The increase in selling, general and administrative expenses is primarily related to higher incentive compensation expense, as well as the absence of COVID-19 cost reduction initiatives that were taken by the Company in the second quarter of 2020 to manage its liquidity position in light of the significant economic uncertainty and the financial impact of the COVID-19 pandemic, partially offset by higher stock compensation expense in 2020 due to the exercises and mark-to-market adjustments of cash settled stock appreciation rights.

Restructuring Expenses

Below is a summary of our Restructuring expenses, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Restructuring expenses

 

$

3,857

 

 

$

5,803

 

 

$

1,946

 

 

Restructuring expenses primarily relate to the Manufacturing Footprint Rationalization restructuring program and other discrete restructuring activities focused on optimizing our manufacturing and engineering footprint and the reduction of global overhead expenses. During the year ended December 31, 2021, the Company recognized expenses of $2.2 million for employee separation costs charges and $1.7 million of other costs, primarily related to equipment move and set up costs. During the year ended December 31, 2020, the Company recognized expenses of $4.6 million for employee separation costs and $1.2 million of other related costs.

See Note 5, "Restructuring," in notes to the consolidated financial statements included in this Annual Report for additional information.

Interest Expense

Below is a summary of our Interest expense, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Interest expense, net

 

$

(2,758

)

 

$

(4,559

)

 

$

1,801

 

 

The decrease in interest expense during the year ended December 31, 2021 compared to 2020 reflects the $169.5 million increased borrowings under the Credit Facility in the first quarter of 2020, primarily to provide additional liquidity and financial flexibility in response to the initial impacts from the onset of the COVID-19 pandemic. A portion of these increased borrowings were repaid by the end of December 31, 2020, and the remainder was repaid in the first quarter of 2021. No amounts were drawn on the

37

Credit Facility during the year ended December 31, 2021.  Amounts outstanding on the Revolving Credit Facility as of the year ended December 31, 2021 and 2020 were $35.0 million and $186.2 million, respectively.

See Note 9, "Debt," to the consolidated financial statements included in this Annual Report for additional information.

Foreign Currency Gain (Loss)

Below is a summary of our Foreign currency gain (loss), in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Foreign currency gain (loss)

 

$

1,487

 

 

$

(5,439

)

 

$

6,926

 

 

Foreign currency gain for the year ended December 31, 2021, included net realized foreign currency loss of $1.6 million and unrealized net foreign currency gain of $3.1 million.

Foreign currency loss for the year ended December 31, 2020, included net realized foreign currency gain of $2.2 million and unrealized net foreign currency loss of $7.6 million.

Other Income

Below is a summary of our Other income, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Other income

 

$

117

 

 

$

2,337

 

 

$

(2,220

)

 

The decrease in other income is primarily due to the 2020 non-recurring gain on sale of certain patents from a non-core business.  See Note 7, “Goodwill and Other Intangibles,” to the consolidated financial statements included in this Annual Report for additional information.

Income Tax Expense

Below is a summary of our Income tax expense, in thousands, for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

Favorable /

(Unfavorable)

 

Income tax expense

 

$

20,418

 

 

$

21,866

 

 

$

1,448

 

 

Income tax expense was $20.4 million for the year ended December 31, 2021, on earnings before income tax of $113.9 million, representing an effective tax rate of 17.9%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to certain favorable tax effects on equity vesting, intercompany transactions during the year and the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, offset by the unfavorable impact of the global intangible low-tax income (“GILTI”), withholding taxes, other non-deductible expenses and uncertain tax positions.

Income tax expense was $21.9 million for the year ended December 31, 2020, on earnings before income tax of $81.6 million, representing an effective tax rate of 26.8%. The tax amount included the effect of the settlement and closure of multi-year international tax audits of $3.4 million. Adjusted for the audit impacts, the effective tax rate was 22.6%.  The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the international provisions of the U.S. tax reform, such as GILTI.

38

Liquidity and Capital Resources

Overview

Our primary sources of liquidity and capital resources are cash flows from operations and borrowings available under our Credit Agreement. Our cash requirements consist principally of working capital, capital expenditures, research and development, operating lease payments, income tax payments and general corporate purposes. We generally reinvest available cash flows from operations into our business, while opportunistically utilizing our authorized stock repurchase program. Further, we continuously evaluate acquisition and investment opportunities that will enhance our business strategies.

As of December 31, 2021, the Company had $190.6 million of cash and cash equivalents, $440 million of availability under our Credit Agreement and $26.5 million of availability under our North America receivables factoring arrangement. We also continue to maintain access to the capital markets and may issue debt or equity securities, which may provide an additional source of liquidity.

We continue to expect to be able to move funds between different countries to manage our global liquidity needs without material adverse tax implications, subject to current monetary policies and the terms of the Credit Agreement. We utilize a combination of strategies, including dividends, cash pooling arrangements, intercompany loan repayments and other distributions and advances to provide the funds necessary to meet our global liquidity needs. There are no significant restrictions on the ability of our subsidiaries to pay dividends or make other distributions to Gentherm Incorporated. As of December 31, 2021, the Company’s cash and cash equivalents held by our non-U.S. subsidiaries totaled approximately $161.5 million. If additional non-U.S. cash was needed for our U.S. operations, we may be required to accrue and pay withholding if we were to distribute such funds from non-U.S. subsidiaries to the U.S.; however, based on our current liquidity needs and strategies, we do not anticipate a need to accrue and pay such additional amounts.

We currently believe that our cash and cash equivalents and borrowings available under our Credit Agreement and the North America receivables factoring arrangement will be adequate to meet anticipated cash requirements for at least the next twelve months and the foreseeable future.

Cash and Cash Flows

The table below summarizes our cash activity for each of the last two fiscal years (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Cash, cash equivalents and restricted cash at beginning of period

 

$

268,345

 

 

$

52,948

 

Net cash provided by operating activities

 

 

143,076

 

 

 

110,695

 

Net cash used in investing activities

 

 

(48,830

)

 

 

(18,220

)

Net cash (used in) provided by financing activities

 

 

(169,141

)

 

 

115,480

 

Foreign currency effect on cash and cash equivalents

 

 

(2,844

)

 

 

7,442

 

Cash, cash equivalents and restricted cash at end of period

 

$

190,606

 

 

$

268,345

 

Cash Flows From Operating Activities

Net cash provided by operating activities totaled $143.1 million and $110.7 million for the years ended December 31, 2021 and 2020, respectively. Cash flow provided by operating activities for the year ended December 31, 2021 consisted primarily of net income of $93.4 million, increased by $54.3 million for non-cash charges for depreciation, amortization, non-cash stock based compensation, and loss on disposition of property and equipment, partially offset by non-cash charges of $0.5 million for deferred income taxes and other, and $4.2 million related to changes in assets and liabilities. Cash flows provided by operating activities for the year ended December 31, 2020 consisted primarily of net income of $59.7 million, increased by $51.5 million for non-cash charges for depreciation, amortization, non-cash stock based compensation, deferred income taxes and loss on disposition of property and equipment, and $2.3 million related to changes in operating assets and liabilities, partially offset by $2.7 million net gain on sale of property and equipment and other.

39

Cash Flows From Investing Activities

Net cash used in investing activities totaled $48.8 million and $18.2 million for the years ended December 31, 2021 and 2020, respectively. The increase in usage is primarily attributable to increased capital expenditures of $21.2 million during the year ended December 31, 2021 as compared to the year ended December 31, 2020. Additionally, during the year ended December 31, 2021, usage included $10.4 million paid for business acquisitions and technology investments. During the year ended December 31, 2020, usage included $3.1 million paid for acquisition of intangible assets, partially offset by $2.1 million proceeds for the sale of patents, property and equipment.

Cash Flows From Financing Activities

Net cash used in financing activities totaled $169.1 million for the year ended December 31, 2021 and net cash provided by financing activities totaled $115.5 million for the year ended December 31, 2020. Cash flows used in financing activities for the year ended December 31, 2021 primarily included $153.2 million of debt repayments, $20.0 million paid to repurchase common stock and $4.1 million paid for employee taxes related to the net settlement of restricted stock units that vested during the year, partially offset by $8.3 million of proceeds from the exercise of common stock options. Cash flows provided by financing activities for the year ended December 31, 2020 primarily included proceeds of $201.1 million received from the increased borrowings under our Credit Agreement, $16.6 million of proceeds from the exercise of common stock options, partially offset by $91.4 million of debt repayments, $9.1 million paid to repurchase common stock and $1.1 million paid for employee taxes related to the net settlement of restricted stock units that vested during the year.

Debt

The following table summarizes the Company’s debt at December 31, 2021 and 2020 (dollars in thousands).

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

Interest

Rate

 

 

Principal

Balance

 

 

Interest

Rate

 

 

Principal

Balance

 

Amended Credit Agreement:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Revolving Note (U.S. Dollar denominations)

 

 

1.35

%

 

$

35,000

 

 

 

1.65

%

 

$

171,500

 

U.S. Revolving Note (Euro denominations)

 

 

—

 

 

 

—

 

 

 

1.50

%

 

 

14,684

 

DEG Vietnam Loan

 

 

5.21

%

 

 

3,750

 

 

 

5.21

%

 

 

6,250

 

Total debt

 

 

 

 

 

 

38,750

 

 

 

 

 

 

 

192,434

 

Current maturities

 

 

 

 

 

 

(2,500

)

 

 

 

 

 

 

(2,500

)

Long-term debt, less current maturities

 

 

 

 

 

$

36,250

 

 

 

 

 

 

$

189,934

 

 

Credit Agreement

Gentherm, together with certain of its subsidiaries, maintain a revolving credit note (“U.S. Revolving Note”) under its Amended and Restated Credit Agreement (the “Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Credit Agreement has a maximum borrowing capacity of $475 million and matures on June 27, 2024. The Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets, merge with other companies or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio (based on consolidated EBITDA for the applicable trailing 12-month period as defined in the  Credit Agreement) as of the end of any fiscal quarter.

DEG Vietnam Loan

The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank.  The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began November, 2017 and will end May, 2023.  

40

See Note 9, “Debt,” to the consolidated financial statements included in this Annual Report for additional information.

Other Sources of Liquidity

In June, 2021, we entered into a receivable factoring agreement with HSBC Bank USA, National Association. Under the receivable factoring agreement, we can sell receivables for certain of our North America account debtors up to $41.3 million, on a revolving basis, subject to outstanding balances and concentration limits. As of December 31, 2021, there were no outstanding receivables transferred under the receivable factoring agreement and our availability under the receivables factoring agreement was $26.5 million.

Material Cash Requirements

The following table summarizes current and long-term material cash requirements as of December 31, 2021, which we expect to fund primarily with operating cash flows.

 

 

 

Payments Due by Period

 

Material Cash Requirements (in thousands)

 

Total

 

 

Less than 1 year

 

 

1 to 3 years

 

 

3 to 5 years

 

 

More than 5 years

 

Long-term debt obligations (1)

 

$

38,750

 

 

$

2,500

 

 

$

36,250

 

 

$

—

 

 

$

—

 

Operating lease obligations (2)

 

 

29,671

 

 

 

6,541

 

 

 

8,864

 

 

 

6,728

 

 

 

7,538

 

Purchase obligations (3)

 

 

24,457

 

 

 

19,832

 

 

 

4,625

 

 

 

—

 

 

 

—

 

Capital commitments (4)

 

 

5,388

 

 

 

5,388

 

 

 

—

 

 

 

—

 

 

 

—

 

Other

 

 

250

 

 

 

50

 

 

 

100

 

 

 

100

 

 

 

—

 

Total

 

$

98,516

 

 

$

34,311

 

 

$

49,839

 

 

$

6,828

 

 

$

7,538

 

 

 

(1)

Long-term debt obligations do not include an amount payable for interest. See Note 9, “Debt,” to the consolidated financial statements included in this Annual Report for additional information.

 

(2)

See Note 8, “Leases,” to the consolidated financial statements included in this Annual Report for additional information.

 

(3)

Purchase obligations are comprised of commitments to secure the supply of certain semiconductor chips. We have entered into agreements with various suppliers to reserve the rights to certain semiconductor chips over the next 12 to 24 months, with volume commitments determined based on our anticipated production requirements. Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. We have not included amounts for other material and component purchase obligations related to standard recurring purchases of materials for use in our manufacturing operations as these amounts are generally consistent from year to year, closely reflect our levels of production, and are not long-term in nature.

 

(4)

Capital commitments is comprised of commitments for capital expenditures. Such commitments are typically less than one year.  

Other Commitments

In December 2021, the Company committed to make a $5 million investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten year life of the fund. The Company has not made any contributions to the Autotech Fund III, LP as of December 31, 2021. Timing of the capital contributions is unknown and therefore amounts have been excluded from the Material Cash Requirements table above.

Capital Expenditures

We anticipate capital expenditures in fiscal year 2022 of approximately $50 million to $60 million. We will continue support organic growth through capacity expansion in our facilities and make capital improvements as necessary. We believe cash on hand, cash generated from operations, and the borrowing capacity available under our Credit Agreement will be sufficient to support our capital expenditures.

41

Stock Repurchase Program

On December 11, 2020, the Board of Directors authorized the 2020 Stock Repurchase Program, pursuant to which the Company is authorized to repurchase up to $150 million of its issued and outstanding common stock over a three-year period, expiring December 15, 2023. During the year ended December 31, 2021, the Company repurchased approximately $20 million of shares under the 2020 Stock Repurchase Program with an average price paid per share of $83.44.  The 2020 Stock Repurchase Program has $130 million of repurchase authorization remaining as of December 31, 2021.

Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources.

For further information related to our stock repurchase program, see Note 15, "Equity" in notes to the consolidated financial statements included in this Annual Report.

Effects of Inflation

The automotive component supply industry has historically been subject to inflationary pressures with respect to materials and labor. In 2021 and continuing in 2022, macroeconomic effects of the COVID-19 pandemic have resulted in inflationary cost increases in certain materials, labor and transportation. These inflationary cost increases are expected to continue into the foreseeable future as demand remains elevated and supply remains constrained. Although the Company has developed and implemented strategies to mitigate the impact of higher material component costs and transportation costs, these strategies, together with commercial negotiations with Gentherm's customers and suppliers may not fully offset our future cost increases. Such inflationary cost increase may increase the cash required to fund our operations by a material amount.

Critical Accounting Estimates

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material to our financial statements.

We have identified the following estimates as our most critical accounting estimates, which are those that are most important to aid in fully understanding and evaluating the Company’s financial condition and results of operations, and that require management’s most subjective and complex judgments. Information regarding our other significant accounting estimates and policies are disclosed in Note 2, Summary of Significant Accounting Policies, of the notes to the consolidated financial statements.

Impairments of Goodwill

Critical estimates: Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized.

42

The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis. The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. To further support the fair value estimate determined by the income approach, the Company utilizes a market valuation approach to estimate the fair value of a reporting unit. The market approach considers historical and/or anticipated financial metrics of a reporting unit and applies valuation multiples based on recent observed transactions involving companies similar enough to the reporting units from which to draw meaningful conclusions.

Judgments and uncertainties: These fair value calculations contain uncertainties as they require management to make assumptions about future cash flows and appropriate discount rates to reflect the risk inherent in the future cash flows and to derive a reasonable enterprise value and related premium. Our ability to realize the future cash flows used in our fair value calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. The estimated future cash flows reflect management's latest assumptions of the financial projections based on current and anticipated competitive landscape, including estimates of revenue based on production volumes over the foreseeable future and long-term growth rates, and operating margins based on historical trends and future cost containment activities.

Also, the market valuation approach is highly subjective as it requires the selection of comparable companies and valuation multiples.

Impact if actual results differ from assumptions: As of December 31, 2021, our goodwill balance included $37.3 million related to our Automotive segment and $28.7 million related to our Medical segment. These balances could be fully or partially impaired if management does not achieve the expected cash flows assumed in the fair value estimates or if assumptions and cash flow estimates change in future periods.

Income Taxes

Critical estimates: The Company is subject to income taxes in the United States and numerous international jurisdictions. In calculating our effective income tax rate, we make judgments regarding certain tax positions, including the timing and amount of deductions and allocations of income among various tax jurisdictions. When determining whether we will be able to realize deferred tax assets, judgment is used to evaluate the positive and negative evidence, including forecasting taxable income using historical and future operating results. The provision for income taxes includes current income taxes as well as deferred income taxes. Deferred tax assets and liabilities are measured based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates.

Judgments and uncertainties: We have various tax filing positions with regard to the timing and amount of deductions and credits and the allocation of income among various tax jurisdictions, based on our interpretation of local tax laws, supported by external advisor review for material positions.

Valuation allowances are established when necessary on a jurisdictional basis to reduce deferred tax assets to the amounts expected to be realized when management considers it more likely than not that some portion or all of a deferred tax asset will not be realized. The determination as to whether a deferred tax asset will be realized is based on the evaluation of positive and negative evidence, which includes historical profitability, future market growth, future taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies. The Company assesses deferred taxes and the adequacy or need for a valuation allowance on a quarterly basis.

43

The Company is subject to ongoing tax examinations and assessments in various jurisdictions. At any time, multiple tax years are subject to audit by the various tax authorities and a number of years may elapse before a particular matter, for which a liability has been established, is audited and fully resolved or clarified. In evaluating the exposures associated with various tax filing positions, the Company may record liabilities for such exposures. The Company generally adjusts its liabilities for unrecognized tax benefits and related indemnification obligations through earnings in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or when more information becomes available. Although management believes that the judgments and estimates discussed herein are reasonable, actual results could differ, and may materially increase or decrease the effective tax rate, as well as impact the Company’s operating results.

Impact if actual results differ from assumptions: Some or all of management’s judgments are subject to review by the taxing authorities. If one or more of the taxing authorities were to successfully challenge our right to realize some or all of the tax benefit we have recorded, and we were unable to realize this benefit, it could have a material adverse effect on our financial results and cash flows. Further, if the Company is unable to generate sufficient future taxable income, there is a material change in the actual effective tax rates, a change to the time period within which the underlying temporary differences become taxable or deductible, or if the tax laws change unfavorably, then the Company could be required to increase the valuation allowance against deferred tax assets, resulting in an increase in income tax expense and the effective tax rate.

For the year ended December 31, 2021, each change of the effective tax rate by one percentage point would impact income tax expense by $1.1 million.

Recent Accounting Pronouncements

For a complete description of recent accounting standards which we have not yet been required to implement which may be applicable to our operations, as well as significant accounting standards that have been adopted during the year ended December 31, 2021, see Note 3, “New Accounting Pronouncements,” to the consolidated financial statements included in this Annual Report.

 

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK  

Our exposure to market risk for changes in interest rates relates primarily to our debt obligations and foreign currency contracts. We have in the past, and may in the future, place our investments in bank certificates of deposits, debt instruments of the U. S. government, and in high-quality corporate issuers.

We are exposed to market risk from changes in foreign currency exchange rates, short-term interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to our debt obligations under our Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which the Company hedges its exposure to foreign currency exchange risks and price fluctuations in material commodities is fifteen months. We had foreign currency derivative contracts with a notional value of $14.0 million and $13.3 million outstanding at December 31, 2021 and 2020 and copper commodity swap contracts with a notional value of $0.3 million and $0 million outstanding as of December 31, 2021 and 2020, respectively. The potential loss in fair value for foreign currency derivative contracts from a hypothetical 10% adverse change in quoted currency exchange rates would be approximately $1.3 million and $1.3 million as of December 31, 2021 and 2020, respectively. The potential gain in fair value from a hypothetical 10% change in quoted currency exchange rates would be approximately $1.6 million and $1.6 million as of December 31, 2021 and 2020, respectively. The impact of a 10% change in rates on fair value differs from a 10% change in the net fair value asset due to the existence of hedges. The model assumes a parallel shift in currency exchange rates; however, currency exchange rates rarely move in the same direction. The assumption that currency exchange rates change in a parallel fashion may overstate the impact of changing currency exchange rates on assets and liabilities denominated in currencies other than the U.S. dollar.

44

The potential loss in fair value for copper commodity swap contracts from a hypothetical 10% adverse change in quoted copper commodity prices would be $0.1 million and $0 million as of December 31, 2021 and 2020, respectively. The potential gain in fair value from a hypothetical 10% positive change in quoted copper commodity prices would be $0.1 million and $0 million as of December 31, 2021 and 2020, respectively.

We do not enter into derivative financial instruments for speculative or trading purposes. Our hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated balance sheet.  When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk.  We record the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales in the consolidated statements of income. Though we continuously monitor the hedging program, derivative positions and hedging strategies, foreign currency forward exchange agreements have not always been designated as hedging instruments for accounting purposes.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

 Interest Rate Sensitivity

The table presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency. The instruments actual cash flows are denominated in the currency indicated in parentheses.

 

 

Expected Maturity Date

 

 

 

2022

 

 

2023

 

 

2024

 

 

Total

 

 

Fair Value

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-Term Debt:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Variable rate ($USD)

 

$

—

 

 

$

—

 

 

$

35,000

 

 

$

35,000

 

 

$

35,000

 

Variable interest rate as of December 31, 2021

 

 

 

 

 

 

 

 

 

 

1.35

%

 

 

1.35

%

 

 

 

 

Fixed rate ($USD)

 

$

2,500

 

 

$

1,250

 

 

$

—

 

 

$

3,750

 

 

$

3,778

 

Fixed interest rate

 

 

5.21

%

 

 

5.21

%

 

 

 

 

 

 

5.21

%

 

 

 

 

 

Based on the amounts outstanding as of December 31, 2021, a hypothetical 100 basis point change (increase or decrease) in interest rates would impact annual interest expense by $0.4 million.

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates.  The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.

 

 

Expected Maturity or Transaction Date

 

 

Anticipated Transactions and Related Derivatives

 

2022

 

 

Total

 

 

Fair Value

 

 

USD Functional Currency

 

 

 

 

 

 

 

 

 

 

 

 

 

Forward Exchange Agreements:

 

 

 

 

 

 

 

 

 

 

 

 

 

(Receive $MXN / Pay $USD)

 

 

 

 

 

 

 

 

 

 

 

 

 

Total contract amount

 

$

13,974

 

 

$

13,974

 

 

$

294

 

 

Average contract rate

 

 

21.47

 

 

 

21.47

 

 

 

 

 

 

 

 

 

45

 

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The audited consolidated financial statements and related financial information required to be filed hereunder are indexed on page F-1 of this Annual Report and are incorporated herein by reference.

 

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management of the Company, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of December 31, 2021. As defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (as amended, the “Exchange Act”), disclosure controls and procedures are controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported on a timely basis, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2021.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f), for the Company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2021 based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control-Integrated Framework (2013).” Based on that evaluation, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2021.

The attestation report of the Company’s independent registered public accounting firm, regarding the effectiveness of the Company’s internal control over financial reporting, is set forth in Item 15, "Exhibits and Financial Statement Schedules," included under the caption "Report of Independent Registered Public Accounting Firm".

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting, that occurred during the quarter ended December 31, 2021, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

 

ITEM 9B.

OTHER INFORMATION

None.

 

 

46

 

ITEM 9C.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

 

 

47

 

PART III

 

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item is set forth under the following captions in our proxy statement to be filed with respect to the 2022 annual meeting of shareholders (the “Proxy Statement”), all of which is incorporated herein by reference: “Proposal No. 1 – Election of Directors”, “Board Matters – The Board of Directors”, “Board Matters – Significant Refreshment of Standing Committees of the Board”, “Board Matters – Corporate Governance”,  “Executive Officers”, “Additional  Information – Delinquent Section 16(a) Reports” and “Additional Information – Requirements for Submission of Shareholder Proposals and Nominations for 2023 Annual Meeting.”

 

ITEM 11.

EXECUTIVE COMPENSATION.

The information required by this item set forth under the following captions in our Proxy Statement, all of which is incorporated herein by reference: “Compensation Discussion and Analysis”, “Named Executive Officer Compensation Tables”, “Board Matters – Director Compensation” and “Compensation Committee Report.”

 

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The information required by this item is set forth under the following captions in our Proxy Statement, all of which is incorporated herein by reference: “Additional Information – Equity Compensation Plans” and “Security Ownership of Certain Beneficial Owners and Management.”

 

ITEM 13.

The information required by this item is set forth under the following captions in our Proxy Statement, all of which is incorporated herein by reference: “Related Person Transactions” and “Proposal No. 1 – A Board Substantially Consisting of Independent Directors.”

 

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES.

The information required by this item is set forth under the following captions in our Proxy Statement, all of which is incorporated herein by reference: “Audit Committee Matters.”

 

 

 

48

 

PART IV

 

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

The following documents are filed as part of this Annual Report:

 

1.

Financial Statements.

The following financial statements of the Company and reports of independent accountants are included in Item 15 of this Annual Report:

 

 

  

Page

 

Reports of Ernst & Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42)

 

F-2

 

Report of Grant Thornton LLP, Independent Registered Public Accounting Firm (PCAOB ID: 248)

 

F-5

 

Consolidated Balance Sheets

 

F-6

 

Consolidated Statements of Income

  

F-7

 

Consolidated Statements of Comprehensive Income

  

F-8

 

Consolidated Statements of Changes in Shareholders’ Equity

  

F-9

 

Consolidated Statements of Cash Flows

  

F-10

 

Notes to the Consolidated Financial Statements

  

F-11

 

 

2.

Financial Statement Schedule.

The following Schedule to Financial Statements is included herein:

Schedule II — Valuation and Qualifying Accounts.

49

 

3.

Exhibits.

The exhibits to this Annual Report are as follows:

 

 

 

 

 

 

  

Incorporated by Reference

Exhibit
Number

 

Exhibit Description

 

Filed/Furnished Herewith

  

Form

 

Period Ending

 

Exhibit / Appendix Number

 

Filing Date

  3.1

  

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

 

 

 

8-K

 

 

 

3.2

 

3/5/18

  3.2

  

Amended and Restated Bylaws of Gentherm Incorporated

 

 

 

8-K

 

 

 

3.1

 

5/26/16

  4

  

Description of Securities

 

 

 

10-K

 

12/31/19

 

4

 

2/20/20

10.1**

  

Summary of Non-Employee Director Compensation (effective starting with the 2021 annual meeting of shareholders)

 

 

 

10-Q 

 

6/30/21 

 

10.3 

 

7/30/21 

10.2**

 

Second Amended and Restated Gentherm Incorporated Senior Level Performance Bonus Plan

 

 

 

8-K 

 

 

 

10.1 

 

3/15/21 

10.3**

 

Gentherm Incorporated Second Half 2020 Senior Level Performance Bonus Plan

 

 

 

8-K

 

 

 

10.1

 

10/6/20

10.4.1**

 

2013 Equity Incentive Plan

 

 

 

Schedule 14A

 

 

 

A

 

4/22/13

10.4.2**

 

Amendment to the Gentherm Incorporated 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.2

 

5/19/17

10.4.3**

 

Second Amendment to the Gentherm Incorporated 2013 Equity Incentive Plan, effective as of May 21, 2020

 

 

 

8-K

 

 

 

10.1

 

5/26/20

10.4.4**

 

Form of Stock Option Award Agreement under the 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.1

 

6/27/13

10.4.5**

 

Form of Stock Appreciation Right Award Agreement under the 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.2

 

6/27/13

10.4.6**

 

Form of Restricted Stock Award Agreement under the 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.3

 

6/27/13

10.4.7**

 

Form of Restricted Stock Award Agreement (Retention Award) under the 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.1

 

10/4/17

10.4.8**

 

Form of Restricted Stock Unit Award Agreement (Performance-Based) under the 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.1

 

6/13/18

10.4.9**

 

Form of Restricted Stock Unit Award Agreement (Time-Based) under the 2013 Equity Incentive Plan

 

 

 

8-K

 

 

 

10.2

 

6/13/18

10.4.10**

 

Form of Restricted Stock Unit Award Agreement (Performance-Based) under the 2013 Equity Incentive Plan – Anversa

 

 

 

8-K

 

 

 

10.2

 

12/12/18

10.4.11**

 

Form of Restricted Stock Unit Award Agreement (Time-Based) under the 2013 Equity Incentive Plan – Anversa

 

 

 

8-K

 

 

 

10.3

 

12/12/18

10.4.12**

 

Form of Restricted Stock Unit Award Agreement (Performance-Based) under the 2013 Equity Incentive Plan (effective as of 2020 grants)

 

 

 

10-Q

 

3/31/20

 

10.1

 

5/7/20

10.4.13**

 

Form of Restricted Stock Unit Award Agreement (Time-Based) under the 2013 Equity Incentive Plan (effective as of 2020 grants)

 

 

 

10-Q

 

3/31/20

 

10.2

 

5/7/20

10.4.14**

 

Form of Restricted Stock Award Agreement (Director) under the Gentherm Incorporated 2013 Equity Incentive Plan  

 

 

 

10-Q 

 

 6/30/20

 

10.7 

 

8/4/20

10.4.15**

 

Form of Restricted Stock Award Agreement (Director) (effective as of 2021 grants)

 

 

 

10-Q

 

6/30/21

 

10.2

 

7/30/21

10.4.16**

 

Form of Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan (effective as of 2021 grants)

 

 

 

8-K

 

 

 

10.2

 

3/15/21

50

 

 

 

 

 

  

Incorporated by Reference

Exhibit
Number

 

Exhibit Description

 

Filed/Furnished Herewith

  

Form

 

Period Ending

 

Exhibit / Appendix Number

 

Filing Date

10.4.17**

 

Form of Performance Stock Unit Award Agreement under the 2013 Equity Incentive Plan (effective as of 2021 grants)

 

 

 

8-K

 

 

 

10.3

 

3/15/21

10.5.1

 

Amended and Restated Credit Agreement, dated as of June 27, 2019, by and among Gentherm Incorporated, Gentherm (Texas), Inc., Gentherm Licensing, Limited Partnership, Gentherm Medical, LLC, Gentherm GmbH, Gentherm Enterprises GmbH, Gentherm Licensing GmbH, Gentherm Global Power Technologies Inc. and Gentherm Canada ULC, the lenders party thereto, and Bank of America, N.A., as administrative agent, swing line lender and L/C issuer.

 

 

 

8-K

 

 

 

10.1

 

6/28/19

10.5.2

 

Amended and Restated Pledge and Security Agreement, dated as of June 27, 2019, by and among Gentherm Incorporated, Gentherm Licensing, Limited Partnership, Gentherm (Texas), Inc., Gentherm Medical, LLC, Gentherm Properties I, LLC, Gentherm Properties II, LLC and Bank of America, N.A.

 

 

 

8-K

 

 

 

10.2

 

6/28/19

10.5.3

 

First Amendment to Amended and Restated Credit Agreement, dated as of October 7, 2019 and effective as of October 1, 2019, by and among Gentherm Incorporated, Gentherm Licensing, Limited Partnership, Gentherm (Texas), Inc., Gentherm Medical, LLC, Gentherm Properties I, LLC, Gentherm Properties II, LLC and Bank of America, N.A.

 

 

 

10-K 

 

12/31/19 

 

10.6.3 

 

2/20/20 

10.6.1**

 

Employment Contract between Gentherm Incorporated and Phillip Eyler, dated as of September 18, 2017

 

 

 

8-K

 

 

 

10.1

 

10/3/17

10.6.2**

 

Amendment to Employment Terms between Gentherm Incorporated and Phillip Eyler, dated as of December 7, 2018

 

 

 

8-K

 

 

 

10.1

 

12/7/18

10.6.3**

 

Second Amendment to Employment Terms between Gentherm Incorporated and Phillip Eyler dated as of April 21, 2020

 

 

 

10-Q 

 

6/30/20

 

10.4

 

8/4/20

10.7.1**

 

Offer Letter between Gentherm Incorporated and Matteo Anversa, dated as of October 22, 2018

 

 

 

8-K

 

 

 

10.1

 

12/12/18

10.7.2**

 

First Amendment to Offer Letter Agreement between Gentherm Incorporated and Matteo Anversa dated as of April 21, 2020

 

 

 

10-Q 

 

6/30/20

 

10.5

 

8/4/20

10.7.3**

 

Second Amendment to Offer Letter Agreement between Gentherm Incorporated and Matteo Anversa, dated as of March 12, 2021

 

 

 

8-K

 

 

 

10.5

 

3/15/21

10.8.1**

 

Employment Contract between Gentherm GmbH and Thomas Stocker, effective September 1, 2019

 

 

 

10-Q

 

9/30/19 

 

10.1

 

10/29/19

10.8.2**

 

First Amendment to the Employment Agreement between Gentherm Enterprises GmbH and Thomas Stocker, effective June 28, 2021

 

 

 

10-Q

 

6/30/21

 

10.1

 

7/30/21

10.9**

 

Offer Letter between Gentherm Incorporated and Hui (Helen) Xu, effective November 4, 2019

 

 

 

10-K 

 

12/31/19 

 

10.11 

 

2/20/20

10.10**

 

Offer Letter between Gentherm Incorporated and Yijing Brentano, effective February 23, 2018

 

 

 

10-K 

 

12/31/19 

 

10.12 

 

2/20/20

10.11**

 

Offer Letter between Gentherm Incorporated and Matt Fisch dated January 29, 2020

 

X

 

 

 

 

 

 

 

 

10.12.1**

 

Executive Relocation and Employment Agreement between Gentherm Incorporated and Paul Giberson dated June 6, 2019

 

 

 

10-Q 

 

6/30/20

 

10.2

 

8/4/20

51

 

 

 

 

 

  

Incorporated by Reference

Exhibit
Number

 

Exhibit Description

 

Filed/Furnished Herewith

  

Form

 

Period Ending

 

Exhibit / Appendix Number

 

Filing Date

10.12.2**

 

First Amendment to Executive Relocation and Employment Agreement between Gentherm Incorporated and Paul Giberson dated as of April 21, 2020

 

 

 

10-Q 

 

6/30/20

 

10.3

 

8/4/20

10.12.3**

 

Second Amendment to Executive Relocation and Employment Agreement between Gentherm Incorporated and Paul Giberson, dated as of March 12, 2021

 

 

 

8-K

 

 

 

10.6

 

3/15/21

10.12.4**

 

Letter Agreement with Paul Giberson, dated as of September 22, 2021

 

 

 

10-Q

 

9/30/21

 

10.1

 

10/29/21

10.13**

 

Severance Pay Plan for Eligible Employees of Gentherm Incorporated

 

 

 

8-K

 

 

 

10.4

 

3/15/21

10.14**

 

Form of First Amendment to Executive Offer Letter

 

 

 

8-K

 

 

 

10.7

 

3/15/21

10.15.1**

 

Amended and Restated Gentherm Incorporated Deferred Compensation Plan, dated May 20, 2019 (and effective January 1, 2019)

 

 

 

10-Q

 

6/30/19

 

10.4

 

7/26/19

10.15.2**

 

Deferred Compensation Agreement, between Gentherm Incorporated and Phillip Eyler, dated as of December 31, 2018.

 

 

 

8-K

 

 

 

10.2

 

1/4/19

16.1

 

Letter from Grant Thornton LLP

 

 

 

8-K

 

 

 

16

 

1/31/20

16.2

 

Letter from Grant Thornton LLP

 

 

 

8-K/A

 

 

 

16

 

2/26/20

21

  

List of Subsidiaries (Direct and Indirect) of the Company

 

X

 

 

 

 

 

 

 

 

23.1

  

Consent of Ernst & Young LLP

 

X

 

 

 

 

 

 

 

 

23.2

 

Consent of Grant Thornton LLP

 

X

 

 

 

 

 

 

 

 

24

 

Power of Attorney

 

X

 

 

 

 

 

 

 

 

31.1

  

Section 302 Certification - CEO

 

X

 

 

 

 

 

 

 

 

31.2

  

Section 302 Certification – CFO

 

X

 

 

 

 

 

 

 

 

32.1

  

Section 906 Certification – CEO

 

X

 

 

 

 

 

 

 

 

32.2

  

Section 906 Certification - CFO

 

X

 

 

 

 

 

 

 

 

101.INS

  

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

X

 

 

 

 

 

 

 

 

101.SCH

  

Inline XBRL Taxonomy Extension Schema Document.

 

X

 

 

 

 

 

 

 

 

101.CAL

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

X

 

 

 

 

 

 

 

 

101.DEF

  

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

X

 

 

 

 

 

 

 

 

101.LAB

  

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

X

 

 

 

 

 

 

 

 

101.PRE

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

X

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Date File – the cover page XBRL tags are embedded within the Inline XBRL document

 

X

 

 

 

 

 

 

 

 

 

*

Gentherm Incorporated agrees to furnish any omitted schedules or exhibits upon the request of the Securities and Exchange Commission.

**

Indicates management contract or compensatory plan or arrangement.

 

 

ITEM 16.

Form 10-K Summary

None.

 

 

52

 

INDEX TO FINANCIAL STATEMENTS

 

 

  

Page

 

Reports of Ernst & Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42)

  

F-2

 

Report of Grant Thornton LLP, Independent Registered Public Accounting Firm (PCAOB ID: 248)

  

F-5

 

Consolidated Balance Sheets as of December 31, 2021 and 2020

  

F-6

 

Consolidated Statements of Income for the years ended December 31, 2021, 2020 and 2019

  

F-7

 

Consolidated Statements of Comprehensive Income for the years ended December 31, 2021, 2020 and 2019

  

F-8

 

Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2021, 2020 and 2019

  

F-9

 

Consolidated Statements of Cash Flows for the years ended December 31, 2021, 2020 and 2019

  

F-10

 

Notes to the Consolidated Financial Statements

  

F-11

 

 

 

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Gentherm Incorporated

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Gentherm Incorporated (the Company) as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, shareholders' equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes and financial statement schedule listed in the Index at Item 15 (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 17, 2022 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical audit matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.

 

Valuation of Goodwill – Medical

Description of the Matter

As of December 31, 2021, the Company’s goodwill related to the medical reporting unit (segment) was $28.7 million. As discussed in Note 2 to the consolidated financial statements, goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that it is more likely than not that a reporting unit’s fair value is less than it’s carrying amount.

Auditing management’s annual goodwill impairment assessment for the medical reporting unit was complex and highly judgmental due to the significant estimation required to determine the fair value of the reporting unit. In particular, the fair value estimates used in the valuation of the medical reporting unit were sensitive to significant assumptions, such as changes in the discount rate, revenue growth rates, including the terminal growth rate and operating margins, which are affected by expectations about future market or economic conditions.

How We Addressed the Matter in our Audit

We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s annual goodwill assessment, and annual forecasting process whereby the Company develops significant assumptions that are used in its analyses.  This included controls over management's review of the valuation model and the significant assumptions used in the fair value measurements discussed above.  

To test the estimated fair value of the Company’s medical reporting unit, we performed audit procedures that included, among others, assessing the methodologies used and directly testing the significant assumptions and the underlying data used by the Company in its analysis, including assessing the completeness and accuracy of such underlying data. We utilized internal valuation specialists to assist in the evaluation of the assumptions and other relevant information that are most significant to the fair value estimate of the reporting unit, such as assessing the fair value methodologies applied and evaluating the reasonableness of the discount rate selected by management. We compared the significant assumptions used by management to current industry and economic trends, historical performance, guideline public companies in the same industry and strategic plans. We performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions. Furthermore, we assessed the appropriateness of the disclosures in the consolidated financial statements.

F-2

 

 

/s/ ERNST & YOUNG LLP

We have served as the Company’s auditor since 2020.

Detroit, Michigan

February 17, 2022

 

 

F-3

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Gentherm Incorporated

Opinion on Internal Control Over Financial Reporting

We have audited Gentherm Incorporated’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Gentherm Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, shareholders' equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes and financial statement schedule listed in the Index at Item 15 and our report dated February 17, 2022 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ ERNST & YOUNG LLP

Detroit, Michigan

February 17, 2022

F-4

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Shareholders

Gentherm Incorporated

Opinion on the financial statements

We have audited the consolidated balance sheet of Gentherm Incorporated (a Michigan corporation) and subsidiaries (the “Company”) as of December 31, 2019 (not presented herein), and the related consolidated statements of income, comprehensive income, changes in shareholders’ equity, and cash flows for the year then ended, and the related notes and financial statement schedule included under Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ GRANT THORNTON LLP

We served as the Company’s auditor from 2007 to 2020.

Southfield, Michigan

February 20, 2020 (except for the section of Note 2 entitled Revision of Prior Period Financial Statements in the previously filed 2020 financial statements, which is not presented herein, and Note 18 and Note 19 as to which the date is March 1, 2021)

 

 

 

F-5

 

 

GENTHERM INCORPORATED

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

190,606

 

 

$

268,345

 

Accounts receivable, net

 

 

182,987

 

 

 

211,672

 

Inventory, net

 

 

159,477

 

 

 

122,401

 

Other current assets

 

 

32,775

 

 

 

41,188

 

Total current assets

 

 

565,845

 

 

 

643,606

 

Property and equipment, net

 

 

155,270

 

 

 

152,581

 

Goodwill

 

 

66,033

 

 

 

68,024

 

Other intangible assets, net

 

 

37,554

 

 

 

46,421

 

Operating lease right-of-use assets

 

 

24,387

 

 

 

30,642

 

Deferred income tax assets

 

 

69,630

 

 

 

73,912

 

Other non-current assets

 

 

16,624

 

 

 

7,653

 

Total assets

 

$

935,343

 

 

$

1,022,839

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

122,727

 

 

$

116,043

 

Current lease liabilities

 

 

5,669

 

 

 

6,032

 

Current maturities of long-term debt

 

 

2,500

 

 

 

2,500

 

Other current liabilities

 

 

82,193

 

 

 

81,409

 

Total current liabilities

 

 

213,089

 

 

 

205,984

 

Long-term debt, less current maturities

 

 

36,250

 

 

 

189,934

 

Non-current lease liabilities

 

 

19,789

 

 

 

24,233

 

Pension benefit obligation

 

 

6,832

 

 

 

8,163

 

Other non-current liabilities

 

 

5,577

 

 

 

8,194

 

Total liabilities

 

$

281,537

 

 

$

436,508

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

Common Stock:

 

 

 

 

 

 

 

 

No par value; 55,000,000 shares authorized 33,008,185 and 32,921,341 issued and outstanding at December 31, 2021 and December 31, 2020, respectively

 

 

118,646

 

 

 

121,073

 

Paid-in capital

 

 

5,866

 

 

 

7,458

 

Accumulated other comprehensive loss

 

 

(36,922

)

 

 

(14,982

)

Accumulated earnings

 

 

566,216

 

 

 

472,782

 

Total shareholders’ equity

 

 

653,806

 

 

 

586,331

 

Total liabilities and shareholders’ equity

 

$

935,343

 

 

$

1,022,839

 

The accompanying notes are an integral part of these consolidated financial statements

 

 

F-6

 

 

GENTHERM INCORPORATED

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Product revenues

 

$

1,046,150

 

 

$

913,098

 

 

$

971,684

 

Cost of sales

 

 

742,519

 

 

 

644,994

 

 

 

683,349

 

Gross margin

 

 

303,631

 

 

 

268,104

 

 

 

288,335

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

91,807

 

 

 

81,968

 

 

 

91,033

 

Reimbursed research and development expenses

 

 

(16,593

)

 

 

(13,928

)

 

 

(18,557

)

Net research and development expenses

 

 

75,214

 

 

 

68,040

 

 

 

72,476

 

Selling, general and administrative expenses

 

 

109,554

 

 

 

105,044

 

 

 

118,680

 

Restructuring expenses

 

 

3,857

 

 

 

5,803

 

 

 

12,919

 

Total operating expenses

 

 

188,625

 

 

 

178,887

 

 

 

204,075

 

Operating income

 

 

115,006

 

 

 

89,217

 

 

 

84,260

 

Interest expense, net

 

 

(2,758

)

 

 

(4,559

)

 

 

(4,763

)

Foreign currency gain (loss)

 

 

1,487

 

 

 

(5,439

)

 

 

2,326

 

Impairment loss

 

 

—

 

 

 

—

 

 

 

(21,206

)

Net loss on divestitures

 

 

—

 

 

 

—

 

 

 

(1,587

)

Other income

 

 

117

 

 

 

2,337

 

 

 

121

 

Earnings before income tax

 

 

113,852

 

 

 

81,556

 

 

 

59,151

 

Income tax expense

 

 

20,418

 

 

 

21,866

 

 

 

10,285

 

Net income

 

$

93,434

 

 

$

59,690

 

 

$

48,866

 

Basic earnings per share

 

$

2.82

 

 

$

1.83

 

 

$

1.48

 

Diluted earnings per share

 

$

2.79

 

 

$

1.81

 

 

$

1.47

 

Weighted average number of shares – basic

 

 

33,086

 

 

 

32,666

 

 

 

33,120

 

Weighted average number of shares – diluted

 

 

33,510

 

 

 

33,028

 

 

 

33,298

 

The accompanying notes are an integral part of these consolidated financial statements

 

 

 

 

 

 

F-7

 

 

GENTHERM INCORPORATED

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net income

 

$

93,434

 

 

$

59,690

 

 

$

48,866

 

Other comprehensive (loss) income:

 

 

 

 

 

 

 

 

 

 

 

 

Pension benefit obligations

 

 

558

 

 

 

(80

)

 

 

(1,032

)

Foreign currency translation adjustments

 

 

(21,551

)

 

 

27,242

 

 

 

(2,722

)

Unrealized (loss) gain on foreign currency derivative securities, net of tax

 

 

(952

)

 

 

211

 

 

 

899

 

Unrealized gain on commodity derivative securities, net of tax

 

 

5

 

 

 

—

 

 

 

—

 

Other comprehensive (loss) income, net of tax

 

 

(21,940

)

 

 

27,373

 

 

 

(2,855

)

Comprehensive income

 

$

71,494

 

 

$

87,063

 

 

$

46,011

 

The accompanying notes are an integral part of these consolidated financial statements

 

 

F-8

 

 

 

GENTHERM INCORPORATED

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Earnings

 

 

Total

 

Balance at December 31, 2018

 

 

33,857

 

 

$

140,300

 

 

$

14,934

 

 

$

(39,500

)

 

$

363,965

 

 

$

479,699

 

Cumulative effect of accounting change due to adoption of ASU 2016-02

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

261

 

 

 

261

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

48,866

 

 

 

48,866

 

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,855

)

 

 

—

 

 

 

(2,855

)

Stock compensation, net

 

 

412

 

 

 

25,490

 

 

 

(4,082

)

 

 

—

 

 

 

—

 

 

 

21,408

 

Stock repurchase

 

 

(1,595

)

 

 

(63,283

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(63,283

)

Balance at December 31, 2019

 

 

32,674

 

 

$

102,507

 

 

$

10,852

 

 

$

(42,355

)

 

$

413,092

 

 

$

484,096

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

59,690

 

 

 

59,690

 

Other comprehensive income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

27,373

 

 

 

—

 

 

 

27,373

 

Stock compensation, net

 

 

493

 

 

 

27,658

 

 

 

(3,394

)

 

 

—

 

 

 

—

 

 

 

24,264

 

Stock repurchase

 

 

(246

)

 

 

(9,092

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(9,092

)

Balance at December 31, 2020

 

 

32,921

 

 

$

121,073

 

 

$

7,458

 

 

$

(14,982

)

 

$

472,782

 

 

$

586,331

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

93,434

 

 

 

93,434

 

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(21,940

)

 

 

—

 

 

 

(21,940

)

Stock compensation, net

 

 

327

 

 

 

17,573

 

 

 

(1,592

)

 

 

—

 

 

 

—

 

 

 

15,981

 

Stock repurchase

 

 

(240

)

 

 

(20,000

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(20,000

)

Balance at December 31, 2021

 

 

33,008

 

 

$

118,646

 

 

$

5,866

 

 

$

(36,922

)

 

$

566,216

 

 

$

653,806

 

The accompanying notes are an integral part of these consolidated financial statements

 


 

F-9

 

 

 

GENTHERM INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating Activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

93,434

 

 

$

59,690

 

 

$

48,866

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

38,780

 

 

 

41,114

 

 

 

44,246

 

Deferred income taxes

 

 

(150

)

 

 

849

 

 

 

(7,743

)

Non-cash stock based compensation

 

 

14,530

 

 

 

8,829

 

 

 

6,253

 

Loss on disposition of property and equipment

 

 

973

 

 

 

683

 

 

 

462

 

Gain on sale of patents

 

 

—

 

 

 

(1,978

)

 

 

—

 

Impairment loss

 

 

—

 

 

 

—

 

 

 

21,206

 

Net loss on divestitures

 

 

—

 

 

 

—

 

 

 

1,587

 

Other

 

 

(271

)

 

 

(748

)

 

 

1,042

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

25,099

 

 

 

(46,742

)

 

 

7,154

 

Inventory

 

 

(39,873

)

 

 

(814

)

 

 

(3,859

)

Other assets

 

 

10,307

 

 

 

(11,997

)

 

 

13,363

 

Accounts payable

 

 

8,166

 

 

 

29,960

 

 

 

(10,253

)

Other liabilities

 

 

(7,919

)

 

 

31,849

 

 

 

(3,521

)

Net cash provided by operating activities

 

 

143,076

 

 

 

110,695

 

 

 

118,803

 

Investing Activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(38,468

)

 

 

(17,219

)

 

 

(23,729

)

Cost of technology investments

 

 

(7,557

)

 

 

—

 

 

 

—

 

Proceeds from the sale of patents and property and equipment

 

 

22

 

 

 

2,140

 

 

 

219

 

Acquisition of business

 

 

(2,827

)

 

 

—

 

 

 

(14,823

)

Acquisition of intangible assets

 

 

—

 

 

 

(3,141

)

 

 

—

 

Proceeds from divestiture of businesses, net

 

 

 

 

 

 

—

 

 

 

44,173

 

Net cash (used in) provided by investing activities

 

 

(48,830

)

 

 

(18,220

)

 

 

5,840

 

Financing Activities:

 

 

 

 

 

 

 

 

 

 

 

 

Borrowing of debt

 

 

—

 

 

 

201,194

 

 

 

37,812

 

Repayments of debt

 

 

(153,243

)

 

 

(91,439

)

 

 

(96,999

)

Cash paid for the repurchase of Common Stock

 

 

(20,000

)

 

 

(9,092

)

 

 

(63,283

)

Proceeds from the exercise of Common Stock options

 

 

8,279

 

 

 

16,552

 

 

 

16,557

 

Cash paid for the cancellation of restricted stock

 

 

(4,108

)

 

 

(1,117

)

 

 

(1,402

)

Acquisition contingent consideration payment

 

 

(69

)

 

 

(618

)

 

 

—

 

Cash paid for financing costs

 

 

—

 

 

 

—

 

 

 

(1,278

)

Net cash (used in) provided by financing activities

 

 

(169,141

)

 

 

115,480

 

 

 

(108,593

)

Foreign currency effect

 

 

(2,844

)

 

 

7,442

 

 

 

(2,722

)

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(77,739

)

 

 

215,397

 

 

 

13,328

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

268,345

 

 

 

52,948

 

 

 

39,620

 

Cash, cash equivalents and restricted cash at end of period

 

$

190,606

 

 

$

268,345

 

 

$

52,948

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for taxes

 

$

14,857

 

 

$

5,013

 

 

$

11,008

 

Cash paid for interest

 

$

2,378

 

 

$

4,204

 

 

$

4,462

 

The accompanying notes are an integral part of these consolidated financial statements

 

 

F-10

 

 

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1 — Overview

Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is a global developer, manufacturer and marketer of innovative thermal management technologies for a broad range of heating, cooling and temperature control applications, primarily in the automotive and medical industries. Within the automotive industry, our products provide solutions for passenger climate comfort and convenience, battery thermal management and cell connecting systems. Within the medical industry our products provide patient temperature management solutions. Our automotive products can be found on vehicles manufactured by nearly all the major automotive original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that are expected to enable improvements to existing products and to create new product applications for existing and new markets.

Impact of COVID-19, Supply Chain Disruptions and Other Matters

  The COVID-19 pandemic that began around December 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the global automotive industry in the first half of 2020, with various direct and indirect adverse impacts continuing throughout 2021.

Beginning in February 2020 and continuing into June 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the second quarter of 2020, the Company had reopened all of its manufacturing facilities, in line with industry demand, and in accordance with local government requirements. Although global automotive industry production has improved relative to the first half of 2020, production remains below recent historic levels.

The lingering impacts of COVID-19 into 2021 has impeded global supply chains, resulted in longer lead times and delays in procuring component parts and raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. These broad-based inflationary impacts have negatively impacted the Company’s financial condition, results of operations and cash flows for the fiscal year ended December 31, 2021.

Supply shortages of semiconductor chips and other components have resulted in decreases in global automotive vehicle production and significant volatility in customer vehicle production schedules. The Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, have been unable to fully meet the vehicle production demands of the OEMs due to events which are outside the Company's control, including but not limited to, the COVID-19 pandemic, the global semiconductor shortage, fires at suppliers’ facilities, significant weather events impacting semiconductor supplier facilities in the southern United States, and other extraordinary events.

In response to the global supply chain instability and inflationary cost increases the Company has taken several actions to minimize any potential and actual adverse impacts by working with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. The consequences of the pandemic and adverse impact to the global economy continue to evolve. Accordingly, the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing.

 

F-11

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 2 — Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

On February 1, 2019, the Company completed the divestiture of its environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) and on October 1, 2019, the Company completed the divestiture of its remote power generation systems business, Gentherm Global Power Technologies (“GPT”). The Company’s consolidated financial statements herein include the results of CSZ-IC and GPT through their respective dates of divestiture, and are included in the Medical segment. CSZ-IC and GPT are not subject to discontinued operations classification.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

Intercompany transactions and balances between consolidated businesses have been eliminated.

Use of Estimates

In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

Segment Reporting

The Company has two reportable segments: Automotive and Medical.

The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems.

The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health.

Revenue Recognition

Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-

F-12

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales.

Automotive Revenues

The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, an LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts.

Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program.

The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts.

Medical Revenues

Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer.

Assets Recognized from the Costs to Obtain a Contract with a Customer

The Company has no material contract assets or contract liabilities as of December 31, 2021.

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $1,946 and $1,805 as of December 31, 2021 and 2020, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2021 and 2020, $174 and $263, respectively, was amortized into Product revenues.

F-13

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

Cash and Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation.  The Company had Cash and cash equivalents of $161,496 and $106,598 held in foreign jurisdictions as of December 31, 2021 and 2020, respectively. Restricted cash includes cash that is legally restricted as to use or withdrawal.

Disclosures About Fair Value of Financial Instruments

The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s revolving credit note under the June 27, 2019 amended and restated credit agreement (“Credit Agreement”) approximates its fair value because interest charged on the loan balance is variable.  See Note 14, “Fair Value Measurement,” for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments.

Concentration of Credit Risk

Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2021, the Company’s Automotive customers, Adient and Lear both individually represented 22% and 18%, respectively, of the Company’s accounts receivable balance.  As of December 31, 2020, Adient and Lear both individually represented 18% of the Company’s accounts receivable balance.  

Accounts Receivable

Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. The Company’s accounts receivables are continually assessed for collectability and any allowance is recorded based upon the age of outstanding receivables, historical payment experience and customer creditworthiness. We write-off accounts receivable when they become uncollectible. The allowance for doubtful accounts was $1,399 and $1,161 as of December 31, 2021 and 2020, respectively.  

Primarily in the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash.

Inventory

The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve.

F-14

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Property and Equipment

Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense.

Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows:

 

Asset Category

 

Useful Life

Buildings and improvements

 

1 to 30 years

Plant and equipment

 

10 years

Production tooling

 

2 to 10 years

Leasehold improvements

 

Term of lease

Information technology

 

1 to 5 years

 

The Company recognized depreciation expense of $29,622, $31,037 and $33,639 for the years ended December 31, 2021, 2020 and 2019, respectively.

Tooling

The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2021 and 2020, the Company had $3,778 and $4,831, respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years. Management periodically evaluates the recoverability of tooling costs, based on estimated future cash flows, and makes provisions, where appropriate, for tooling costs that will not be recovered.

Goodwill and Other Intangible Assets

Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition.

Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows:

Asset Category

 

Useful Life

Customer relationships

 

8 to 15 years

Technology

 

5 to 10 years

Product development costs

 

5 to 10 years

Trade names

 

Indefinite

Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. Our policy is to expense all costs associated with the

F-15

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

development and issuance of new patents as incurred. Such costs are classified as research and development expenses in the accompanying consolidated statements of income.  

Impairments of Other Intangible Assets and Goodwill

Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized.

The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit.

The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.

Investments in non-consolidated affiliates

During 2021, the Company’s Automotive segment invested $5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets.

During 2021, the Company’s Automotive segment invested $2,357 for an ownership interest in Forciot Oy (“Forciot”), a technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets.

In December 2021, the Company committed to make a $5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten year life of the fund. The Company has not made any contributions to the Autotech Fund III, LP as of December 31, 2021. This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy.

Research and Development Expenses

Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in research and development.  

F-16

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

Leases

The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 10 years and may include options to extend the lease.  Land leases have remaining lease terms that range from 39 to 41 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties.

The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Gentherm is not currently party to any leases that qualify as financing leases.

Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgement is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate.

Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company.  

For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income.

Income Taxes

The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2021 and 2020, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized.  If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization.

F-17

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense.

Derivative Financial Instruments – Hedge Accounting

The Company accounts for its derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets.  When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk.  Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Foreign currency gain (loss) for foreign currency derivatives, and cost of goods sold for commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting.

Earnings per Share

Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of common stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of common stock equivalents.

Stock Based Compensation

Share based payments that involve the issuance of common stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant.  

Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.

Note 3 — New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". This ASU simplifies the accounting for income taxes by removing certain exceptions previously included in the guidance. In addition, the ASU amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021 and there was no significant impact on its financial statements and related disclosures as a result.

F-18

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

Reference Rate Reform

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. In January 2021, the FASB subsequently issued ASU 2021-01, “Reference Rate Reform (Topic 848): Scope” to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. ASU 2020-04 and ASU 2021-01 are effective as of March 12, 2020 through December 31, 2022 and may be applied retrospectively to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. Upon adoption of this standard, the Company does not expect it to have a material impact to the Company’s financial statements.

Note 4 – Acquisitions and Divestitures

Acquisition of Beckmann & Egle Industrieelektronik GmbH

On July 1, 2021, the Company acquired the medical business unit of Beckmann & Egle Industrieelektronik GmbH (“B&E”), a developer and manufacturer of electronic control units, for a purchase price of $2,827. The acquisition was accounted for as a business combination with the purchase price assigned to inventory, property and equipment and other intangible assets based on their estimated fair values as of the acquisition date. The pro forma effect of the B&E acquisition does not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented. The results of operations of B&E are reported within the Company’s Medical segment from the date of acquisition.

Divestiture of GPT

On October 1, 2019, the Company completed the sale of GPT for a nominal amount and recognized a $5,885 loss on sale for the year ended December 31, 2019, which is classified as Net loss on divestitures within the consolidated statements of income. During 2019, the Company also recognized impairment losses of $21,206 for its GPT assets held for sale. These impairment charges are classified as Impairment loss within the consolidated statements of income.

Acquisition of Stihler Electronic GmbH

On April 1, 2019, the Company acquired Stihler Electronic GmbH (“Stihler”), a leading developer and manufacturer of patient and blood temperature management systems, for a purchase price of $15,476, net of cash acquired and including $653 of contingent consideration that was paid upon achievement of a milestone during the year ended December 31, 2020. The results of operations of Stihler are reported within the Company’s Medical segment from the date of acquisition.

Divestiture of CSZ-IC

On February 1, 2019, the Company completed the sale of its environmental test equipment business, CSZ-IC and former Cincinnati Sub-Zero headquarters facility for total cash proceeds of $47,500. The Company recognized a $4,298 pre-tax gain on the sale of CSZ-IC for the year ended December 31, 2019 which is classified as Net loss on divestitures within the consolidated statements of income.

F-19

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

Note 5 — Restructuring

Manufacturing Footprint Rationalization

In September 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company is relocating and consolidating certain automotive electronics manufacturing plants in North America and China.

During 2021, the Company completed the closures and relocation of its automotive electronics manufacturing operations from Burlington, Canada to Celaya, Mexico and from Longgang, Shenzhen, China to Bantian, Shenzhen, China. As of December 31, 2021, the electronics manufacturing in Acuña, Mexico continues to transition to Celaya, Mexico.

During the year ended December 31, 2021, the Company recognized restructuring expense of $1,303 for employee separation costs and $1,665 for other costs, primarily related to equipment move and set up costs.  

During the year ended December 31, 2020, the Company recognized restructuring expense of $(832) for employee separation costs and $1,019 for other costs, primarily related to accelerated depreciation and equipment move and set up costs. The net activity for the year ended December 31, 2020 was primarily related to a reduction in the estimates of previously recognized employee separation costs.      

During the year ended December 31, 2019, the Company recognized restructuring expense of $4,863 for employee separation costs, and $2,087 of other costs, primarily related to accelerated depreciation and fixed asset impairment.

The Company has recorded approximately $10,105 of restructuring expenses since the inception of this program and as of December 31, 2021, $943 remains accrued. Actions under the Plan are expected to be substantially completed by the first half of 2022 and future expenses are expected to be less than $1,000.           

Other Restructuring Activities

As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $889, $5,382 and $3,193 of employee separation costs, respectively, and $0, $234 and $2,776 of other related costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs.

Restructuring Expenses By Reporting Segment

Restructuring expense by reporting segment for the years ended December 31, 2021, 2020 and 2019 was as follows:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Automotive

 

$

2,793

 

 

$

5,075

 

 

$

9,353

 

Medical

 

 

—

 

 

 

112

 

 

 

1,838

 

Corporate

 

 

1,064

 

 

 

616

 

 

 

1,728

 

Total

 

$

3,857

 

 

$

5,803

 

 

$

12,919

 

 

F-20

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Restructuring Liability

The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2021 and 2020:

 

 

Employee Separation Costs

 

 

Other Related Costs

 

 

Total

 

 

 

Balance at December 31, 2019

 

$

5,994

 

 

$

71

 

 

$

6,065

 

 

 

Additions, charged to restructuring expenses

 

 

6,932

 

 

 

1,271

 

 

 

8,203

 

 

 

Change in estimate

 

 

(2,382

)

 

 

(18

)

 

 

(2,400

)

 

 

Cash payments

 

 

(5,052

)

 

 

(757

)

 

 

(5,809

)

 

 

Non-cash utilization

 

 

—

 

 

 

(687

)

 

 

(687

)

 

 

Currency translation and other

 

 

135

 

 

 

120

 

 

 

255

 

 

 

Balance at December 31, 2020

 

$

5,627

 

 

$

—

 

 

$

5,627

 

 

 

Additions, charged to restructuring expenses

 

 

2,406

 

 

 

1,927

 

 

 

4,333

 

 

 

Change in estimate

 

 

(214

)

 

 

(262

)

 

 

(476

)

 

 

Cash payments

 

 

(6,129

)

 

 

(1,709

)

 

 

(7,838

)

 

 

Non-cash utilization

 

 

—

 

 

 

(218

)

 

 

(218

)

 

 

Currency translation and other

 

 

(196

)

 

 

262

 

 

 

66

 

 

 

Balance at December 31, 2021

 

$

1,494

 

 

$

—

 

 

$

1,494

 

 

 

 

 

F-21

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 6 — Details of Certain Financial Statement Components

 

 

December 31,

 

 

 

2021

 

 

2020

 

Inventory:

 

 

 

 

 

 

 

 

Raw materials, net of reserve

 

$

96,426

 

 

$

68,362

 

Work in process, net of reserve

 

 

9,495

 

 

 

8,247

 

Finished goods, net of reserve

 

 

53,556

 

 

 

45,792

 

Total inventory, net

 

$

159,477

 

 

$

122,401

 

Other current assets:

 

 

 

 

 

 

 

 

Notes receivable

 

$

13,033

 

 

$

19,200

 

Income tax and other tax receivable

 

 

10,681

 

 

 

10,514

 

Billable tooling

 

 

3,778

 

 

 

4,831

 

Prepaid expenses

 

 

3,407

 

 

 

3,930

 

Other

 

 

1,876

 

 

 

2,713

 

Total other current assets

 

$

32,775

 

 

$

41,188

 

Property and equipment:

 

 

 

 

 

 

 

 

Machinery and equipment

 

$

155,463

 

 

$

142,833

 

Buildings and improvements

 

 

100,788

 

 

 

99,011

 

Information technology

 

 

33,060

 

 

 

30,338

 

Production tooling

 

 

25,180

 

 

 

22,783

 

Leasehold improvements

 

 

11,445

 

 

 

11,762

 

Construction in progress

 

 

14,506

 

 

 

8,968

 

Total property and equipment

 

 

340,442

 

 

 

315,695

 

Less: accumulated depreciation

 

 

(185,172

)

 

 

(163,114

)

Total property and equipment, net

 

$

155,270

 

 

$

152,581

 

Other current liabilities:

 

 

 

 

 

 

 

 

Accrued employee liabilities

 

$

28,818

 

 

$

26,612

 

Liabilities from discounts and rebates

 

 

27,343

 

 

 

22,910

 

Income tax and other taxes payable

 

 

17,068

 

 

 

14,714

 

Restructuring

 

 

1,494

 

 

 

5,627

 

Accrued warranty

 

 

1,916

 

 

 

2,391

 

Other

 

 

5,554

 

 

 

9,155

 

Total other current liabilities

 

$

82,193

 

 

$

81,409

 

 

Note 7 — Goodwill and Other Intangibles

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2021 and 2020 were as follows:

 

 

Automotive

 

 

Medical

 

 

Total

 

December 31, 2019

 

$

36,938

 

 

$

27,634

 

 

$

64,572

 

Exchange rate impact

 

 

2,557

 

 

 

895

 

 

 

3,452

 

Balance as of December 31, 2020

 

$

39,495

 

 

$

28,529

 

 

$

68,024

 

Acquisition of B&E

 

 

—

 

 

 

976

 

 

 

976

 

Exchange rate impact

 

 

(2,166

)

 

 

(801

)

 

 

(2,967

)

Balance as of December 31, 2021

 

$

37,329

 

 

$

28,704

 

 

$

66,033

 

 

F-22

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Other Intangible Assets

Other intangible assets and accumulated amortization balances as of December 31, 2021 and 2020 were as follows:

 

 

Gross

Carrying Value

 

 

Accumulated

Amortization

 

 

Net Carrying

Value

 

Definite-lived:

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationships

 

$

90,448

 

 

$

(64,105

)

 

$

26,343

 

Technology

 

 

29,464

 

 

 

(24,487

)

 

 

4,977

 

Product development costs

 

 

20,329

 

 

 

(19,772

)

 

 

557

 

Software development

 

 

1,007

 

 

 

—

 

 

 

1,007

 

Indefinite-lived:

 

 

 

 

 

 

 

 

 

 

 

 

Tradenames

 

 

4,670

 

 

 

—

 

 

 

4,670

 

Balance as of December 31, 2021

 

$

145,918

 

 

$

(108,364

)

 

$

37,554

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross

Carrying Value

 

 

Accumulated

Amortization

 

 

Net Carrying

Value

 

Definite-lived:

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationships

 

$

97,815

 

 

$

(63,432

)

 

$

34,383

 

Technology

 

 

30,615

 

 

 

(24,075

)

 

 

6,540

 

Product development costs

 

 

22,164

 

 

 

(21,336

)

 

 

828

 

Indefinite-lived:

 

 

 

 

 

 

 

 

 

 

 

 

Tradenames

 

 

4,670

 

 

 

—

 

 

 

4,670

 

Balance as of December 31, 2020

 

$

155,264

 

 

$

(108,843

)

 

$

46,421

 

 

In connection with the acquisition of B&E, the Company recorded technology of $976. These definite-lived assets are being amortized using the straight-line method over their estimated useful lives of approximately seven years.

On February 28, 2020, Gentherm acquired the automotive patents and technology of a development-stage technology company for $3,141. The investment was accounted for as an asset acquisition of defensive intangible assets and will be amortized over six years.

On June 19, 2020, Gentherm sold patents from a non-core business for $2,055.  The gain on sale of $1,978 was recorded in Other income in the consolidated statements of income.

A total of $8,821, $9,226 and $10,068 in other intangible assets were amortized in 2021, 2020 and 2019, respectively.

An estimate of other intangible asset amortization by year, is as follows:

2022

 

$

7,929

 

2023

 

$

4,752

 

2024

 

$

3,692

 

2025

 

$

3,678

 

2026

 

$

3,261

 

   

F-23

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 8 — Leases

Components of lease expense for the years ended December 31, 2021, 2020 and 2019 were as follows:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Lease cost:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease cost

 

$

8,227

 

 

$

6,773

 

 

$

5,899

 

Short-term lease cost

 

 

1,941

 

 

 

1,834

 

 

 

3,444

 

Sublease income

 

 

(163

)

 

 

(158

)

 

 

(128

)

Total lease cost

 

$

10,005

 

 

$

8,449

 

 

$

9,215

 

 

Other information related to leases is as follows:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

 

 

Operating cash flows for operating leases

 

$

7,685

 

 

$

6,817

 

Right-of-use lease assets obtained in exchange for lease obligations:

 

 

 

 

 

 

 

 

Operating leases

 

$

2,379

 

 

$

25,161

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

 

December 31, 2020

 

Weighted average remaining lease term:

 

 

 

 

 

 

 

 

Operating leases

 

6.9 years

 

 

5.4 years

 

Weighted average discount rate:

 

 

 

 

 

 

 

 

Operating leases

 

 

4.53

%

 

 

4.65

%

 

A summary of operating leases as of December 31, 2021, under all non-cancellable operating leases with terms exceeding one year is as follows:

.

2022

 

$

6,541

 

2023

 

 

4,664

 

2024

 

 

4,200

 

2025

 

 

3,783

 

2026

 

 

2,945

 

2027 or later

 

 

7,538

 

Total future minimum lease payments

 

 

29,671

 

Less imputed interest

 

 

(4,213

)

Total

 

$

25,458

 

 

F-24

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 9 — Debt  

The following table summarizes the Company’s debt as of December 31, 2021 and 2020:

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

Interest

Rate

 

 

Principal

Balance

 

 

Interest

Rate

 

 

Principal

Balance

 

Amended Credit Agreement:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Revolving Note (U.S. Dollar denominations)

 

 

1.35

%

 

$

35,000

 

 

 

1.65

%

 

$

171,500

 

U.S. Revolving Note (Euro denominations)

 

 

—

 

 

 

—

 

 

 

1.50

%

 

 

14,684

 

DEG Vietnam Loan

 

 

5.21

%

 

 

3,750

 

 

 

5.21

%

 

 

6,250

 

Total debt

 

 

 

 

 

 

38,750

 

 

 

 

 

 

 

192,434

 

Current maturities

 

 

 

 

 

 

(2,500

)

 

 

 

 

 

 

(2,500

)

Long-term debt, less current maturities

 

 

 

 

 

$

36,250

 

 

 

 

 

 

$

189,934

 

Credit Agreement

 On June 27, 2019, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent, which includes a revolving credit note (“U.S. Revolving Note”). The Credit Agreement has maximum borrowing capacity of $475,000 and matures on June 27, 2024. The Credit Agreement also provides $15,000 availability for the issuance of letters of credit and a maximum of $40,000 for swing line borrowing. Any amount of the facility utilized for letters of credit or swing line loans outstanding will reduce the amount available under the Credit Agreement. The Company had no outstanding letters of credit issued under the Credit Agreement as of December 31, 2021 and December 31, 2020.

       The U.S. borrowers and guarantors participating in the Credit Agreement also entered into a related amended and restated pledge and security agreement.  The amended and restated pledge and security agreement grants a security interest to the lenders in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Credit Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Credit Agreement are unconditionally guaranteed by certain of the Company’s subsidiaries. The Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders.

The Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets, merge with other companies or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio (based on consolidated EBITDA for the applicable trailing 12-month period as defined in the Credit Agreement) as of the end of any fiscal quarter. The Credit Agreement also contains customary events of default. As of December 31, 2021, the Company was in compliance with the terms of the Credit Agreement.

Under the Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Eurocurrency rate (“Eurocurrency Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate (0.07% at December 31, 2021) plus 0.50%, Bank of America’s prime rate (3.25% at December 31, 2021), or the Eurocurrency rate plus 1.00%. The rate for Eurocurrency Rate Loans denominated in U.S. Dollars is equal to the London Interbank Offered Rate (0.10% at December 31, 2021). All loans denominated in a currency other than the U.S. Dollar must be Eurocurrency Rate Loans. Interest is payable at least quarterly.

The Applicable Rate varies based on the Consolidated Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Amended Credit Agreement, the lowest and highest possible Applicable Rate is 1.25% and 2.25%, respectively, for Eurocurrency Rate Loans and 0.25% and 1.25%, respectively, for Base Rate Loans.

F-25

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

In March 2020, the Company increased its borrowings under the Credit Agreement by $169,546 as a safeguard to increase its cash position and provide additional financial flexibility due to the COVID-19 pandemic. The proceeds were used for working capital and for other general corporate purposes permitted by the Credit Agreement. As of the end of the first quarter of 2021, the Company repaid the full drawdown of $169,546 from March 2020 under the Credit Agreement. As of December 31, 2021, $35,000 was outstanding under the Credit Agreement. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing twelve months calculated for purposes of the Consolidated Leverage Ratio, $440,000 remained available as of December 31, 2021 for additional borrowings under the Credit Agreement subject to specified conditions that Gentherm currently satisfies.    

 DEG Vietnam Loan

The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank.  The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”).  The DEG Vietnam Loan is subject to semi-annual principal payments that began November, 2017 and will end May, 2023.  Under the terms of the DEG Vietnam Loan, the Company must maintain a minimum Enhanced Equity Ratio, as defined by the DEG Vietnam Loan agreement, based on the financial statements of Gentherm’s wholly owned subsidiary, Gentherm Vietnam Co. Ltd.  As of December 31, 2021, the Company was in compliance with all terms as outlined in the DEG Vietnam Loan.

The scheduled principal maturities of our debt as of December 31, 2021 were as follows:

 

 

 

DEG

Vietnam

Note

 

 

U.S.

Revolving

Note

 

 

Total

 

2022

 

$

2,500

 

 

$

—

 

 

$

2,500

 

2023

 

 

1,250

 

 

 

—

 

 

 

1,250

 

2024

 

 

—

 

 

 

35,000

 

 

 

35,000

 

Total

 

$

3,750

 

 

$

35,000

 

 

$

38,750

 

 

Note 10 — Pension and Other Post Retirement Benefit Plans

The Company maintains a U.S. defined benefit pension plan covering its former Chief Executive Officer (“U.S. Plan”) and a German defined benefit pension plan covering certain retired executive employees of the Company’s wholly owned subsidiary, Gentherm GmbH (“German Plan”).

The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2021, 2020 and 2019 were as follows:

 

 

U.S. Plan

 

 

German Plan

 

 

 

Year Ended December 31,

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

 

2019

 

Net periodic benefit cost:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Service cost

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Interest cost

 

 

42

 

 

 

85

 

 

 

127

 

 

 

91

 

 

 

88

 

 

 

147

 

Expected return on plan assets

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(120

)

 

 

(121

)

 

 

(126

)

Amortization of prior service cost and actuarial loss

 

 

26

 

 

 

7

 

 

 

—

 

 

 

133

 

 

 

124

 

 

 

72

 

Net periodic benefit cost

 

$

68

 

 

$

92

 

 

$

127

 

 

$

104

 

 

$

91

 

 

$

93

 

Assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Discount rate

 

 

1.20

%

 

 

2.40

%

 

 

3.65

%

 

 

1.08

%

 

 

1.06

%

 

 

1.06

%

Long-term return on assets

 

N/A

 

 

N/A

 

 

N/A

 

 

 

2.90

%

 

 

3.10

%

 

 

3.10

%

 

F-26

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2021 and 2020 is as follows:

 

 

U.S. Plan

 

 

German Plan

 

 

 

As of December 31,

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Change in projected benefit obligation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at beginning of year

 

$

3,847

 

 

$

3,871

 

 

$

8,934

 

 

$

8,353

 

Interest cost

 

 

42

 

 

 

85

 

 

 

91

 

 

 

88

 

Paid pension distributions

 

 

(342

)

 

 

(342

)

 

 

(310

)

 

 

(294

)

Actuarial (gain) loss

 

 

(101

)

 

 

233

 

 

 

9

 

 

 

40

 

Exchange rate impact

 

 

—

 

 

 

—

 

 

 

(622

)

 

 

747

 

Balance at end of year

 

$

3,446

 

 

$

3,847

 

 

$

8,102

 

 

$

8,934

 

Change in plan assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at beginning of year

 

 

—

 

 

 

—

 

 

 

4,276

 

 

 

3,825

 

Actual return on plan assets

 

 

—

 

 

 

—

 

 

 

98

 

 

 

96

 

Contributions

 

 

—

 

 

 

—

 

 

 

310

 

 

 

294

 

Paid pension distributions

 

 

—

 

 

 

—

 

 

 

(310

)

 

 

(294

)

Exchange rate impact

 

 

—

 

 

 

—

 

 

 

(305

)

 

 

355

 

Balance at end of year

 

$

—

 

 

$

—

 

 

$

4,069

 

 

$

4,276

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Underfunded Status

 

$

(3,446

)

 

$

(3,847

)

 

$

(4,033

)

 

$

(4,658

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance sheet classification:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other current liabilities

 

$

(342

)

 

$

(342

)

 

$

(306

)

 

$

—

 

Pension benefit obligation

 

 

(3,104

)

 

 

(3,505

)

 

 

(3,727

)

 

 

(4,658

)

Accumulated other comprehensive loss (pre-tax):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Actuarial losses

 

 

575

 

 

 

701

 

 

 

3,288

 

 

 

3,644

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Discount rate

 

 

1.80

%

 

 

1.20

%

 

 

1.25

%

 

 

1.08

%

Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2022 are as follows:

 

 

U.S Plan

 

 

German Plan

 

Actuarial losses

 

$

21

 

 

$

124

 

 

The accumulated benefit obligations were as follows:

 

 

U.S. Plan

 

 

German Plan

 

 

 

As of December 31,

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Accumulated benefit obligation

 

$

3,446

 

 

$

3,847

 

 

$

8,102

 

 

$

8,934

 

 

Interest costs are recognized in Selling, general and administrative expenses in the consolidated statements of income and actuarial gains and losses are included the consolidated balance sheet as part of Accumulated other comprehensive loss within shareholders’ equity. Actuarial gains or losses are amortized to Selling, general and administrative expense in the consolidated statements of income based on the average future life of the Plan using the corridor method. Prior service cost is included in Selling, general and administrative expenses in the consolidated statements of income.

 

F-27

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Plan assets – German Plan

Plan assets are comprised of Gentherm GmbH’s pension insurance policies and are pledged to the beneficiaries of the German Plan. A market valuation technique, based on observable underlying insurance charges, is used to determine the fair value of the pension plan assets (Level 2).

The expected return on plan assets assumption used to calculate Gentherm GmbH’s pension benefit obligation was determined using actual returns realized on plan assets in the prior year.

Contributions

We do not expect contributions to be paid to the U.S. Plan or the German Plan during the next fiscal year.

The schedule of future expected pension payments is as follows:

 

 

Projected Pension

Benefit Payments

 

Year

 

U.S Plan

 

 

German Plan

 

2022

 

$

342

 

 

$

306

 

2023

 

 

342

 

 

 

316

 

2024

 

 

342

 

 

 

309

 

2025

 

 

342

 

 

 

301

 

2026

 

 

342

 

 

 

292

 

2027-2031

 

 

1,710

 

 

 

2,988

 

Total

 

$

3,420

 

 

$

4,512

 

 

Defined contribution plans

The Company also sponsors defined contribution plans for eligible employees. On a discretionary basis, the Company matches a portion of the employee contributions and or makes additional discretionary contributions. Gentherm recognized costs of $1,724, $1,275 and $1,384 related to contributions to its defined contribution plans during the years ended December 31, 2021, 2020 and 2019, respectively.  

Note 11 — Commitments and Contingencies  

Legal and other contingencies

The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters.  The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves.

Product Liability and Warranty Matters

In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims in the future or that it will not incur significant costs to defend such claims.

F-28

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims.  

The following is a reconciliation of the changes in accrued warranty costs:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Balance at beginning of year

 

$

2,391

 

 

$

4,596

 

Warranty claims paid

 

 

(2,164

)

 

 

(2,598

)

Warranty expense for products shipped during the current period

 

 

1,813

 

 

 

1,223

 

Adjustments to warranty estimates from prior periods

 

 

(73

)

 

 

(893

)

Adjustments due to currency translation

 

 

(51

)

 

 

63

 

Balance at end of year

 

$

1,916

 

 

$

2,391

 

 

Other matters

Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. Commitments for capital expenditures as of December 31, 2021 were $5,388. During the year ended December 31, 2021, the Company entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over the next 24 months, with volume commitments determined based on our anticipated production requirements. As of December 31, 2021, the Company’s total commitments for these semiconductor chip agreements was $24,457. Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of December 31, 2021 were immaterial.

Employees

Approximately 23% of the Company’s workforce are members of industrial trade unions and are employed under the terms of various labor agreements.  None of these agreements expire in 2022.

Note 12 — Earnings Per Share

The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share:  

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net income

 

$

93,434

 

 

$

59,690

 

 

$

48,866

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average shares of Common Stock outstanding

 

 

33,085,732

 

 

 

32,666,025

 

 

 

33,120,076

 

Dilutive effect of stock options, restricted stock awards and restricted stock units

 

 

423,988

 

 

 

362,079

 

 

 

177,513

 

Diluted weighted average shares of Common Stock outstanding

 

 

33,509,720

 

 

 

33,028,104

 

 

 

33,297,589

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$

2.82

 

 

$

1.83

 

 

$

1.48

 

Diluted earnings per share

 

$

2.79

 

 

$

1.81

 

 

$

1.47

 

F-29

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive.

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Anti-dilutive securities share impact

 

 

—

 

 

 

12,000

 

 

 

214,000

 

 

See Note 17 for information about the Company’s different equity incentive plans.

 

Note 13 —Financial Instruments

Derivative Financial Instruments

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which the Company hedges its exposure to foreign currency exchange risks and price fluctuations in material commodities is fifteen months. The Company had foreign currency derivative contracts with a notional value of $13,974 and $13,299 and copper commodity swap contracts with a notional value of $309 and $0 outstanding as of December 31, 2021 and 2020, respectively. The principal currency hedged by the Company was the Mexican Peso.

The Company does not enter into derivative financial instruments for speculative or trading purposes. The Company’s hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to AOCI in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales, in the consolidated statements of income. Cash flows associated with derivatives are reported in net cash provided by operating activities in the Company’s Consolidated Statements of Cash Flows.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2021 is as follows:

 

 

 

 

 

 

 

Asset Derivatives

 

 

Liability Derivatives

 

 

 

 

 

 

 

Hedge

Designation

 

Fair Value

Hierarchy

 

Balance Sheet

Location

 

Fair

Value

 

 

Balance Sheet

Location

 

Fair

Value

 

 

Net Asset/

(Liabilities)

 

Foreign currency derivatives

 

Cash flow hedge

 

Level 2

 

Other current assets

 

$

294

 

 

Other current liabilities

 

$

—

 

 

$

294

 

Commodity hedges

 

Cash flow hedge

 

Level 2

 

Other current assets

 

$

6

 

 

Other current liabilities

 

$

—

 

 

$

6

 

F-30

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

 

Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2020 is as follows:  

 

 

 

 

 

 

 

Asset Derivatives

 

 

Liability Derivatives

 

 

 

 

 

 

 

Hedge

Designation

 

Fair Value

Hierarchy

 

Balance Sheet

Location

 

Fair

Value

 

 

Balance Sheet

Location

 

Fair

Value

 

 

Net Asset/

(Liabilities)

 

Foreign currency derivatives

 

Cash flow hedge

 

Level 2

 

Other current assets

 

$

1,513

 

 

Other current liabilities

 

$

—

 

 

$

1,513

 

Commodity hedges

 

Cash flow hedge

 

Level 2

 

Other current assets

 

$

—

 

 

Other current liabilities

 

$

—

 

 

$

—

 

 

Information related to the effect of derivative instruments in the consolidated statements of income is as follows:  

 

 

 

 

Year Ended December 31,

 

 

 

Location

 

2021

 

 

2020

 

 

2019

 

Foreign currency derivatives

 

Cost of sales

 

$

1,609

 

 

$

(1,629

)

 

$

1,976

 

 

 

Other comprehensive (loss) income

 

 

(1,217

)

 

 

272

 

 

 

1,151

 

 

 

Foreign currency loss

 

 

—

 

 

 

(118

)

 

 

(46

)

Total foreign currency derivatives

 

 

 

$

392

 

 

$

(1,475

)

 

$

3,081

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commodity derivatives

 

Cost of sales

 

$

14

 

 

$

—

 

 

$

—

 

 

 

Other comprehensive (loss) income

 

 

6

 

 

 

—

 

 

 

—

 

Total commodity derivatives

 

 

 

$

20

 

 

$

—

 

 

$

—

 

 

The Company did not incur any hedge ineffectiveness during the years ended December 31, 2021 and 2020.  

Accounts Receivable Factoring

In June 2021, the Company entered into a receivable factoring arrangement that provides for aggregate purchases of up to $41,300 of specified customer accounts in North America. The receivable factoring arrangement results in true sales of the transferred receivables, which are excluded from amounts reported in the consolidated condensed balance sheets when the receivables are transferred in accordance with ASC 860, "Transfers and Servicing”.  As of December 31, 2021, there were no outstanding receivables transferred under the receivable factoring agreement.

 

F-31

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 14 — Fair Value Measurement

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  Fair value measurements are based on one or more of the following three valuation techniques:

Market: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Income: This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations.

Cost: This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Items Measured at Fair Value on a Recurring Basis

Except for derivative financial instruments (see Note 13) and pension plan assets (see Note 10), the Company has no material financial assets and liabilities that are carried at fair value at December 31, 2021 and 2020. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value.

Items Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy.  On July 1, the Company acquired B&E for $2,827. The purchase price was allocated to inventory (Level 2), property and equipment (Level 2) and other intangible assets (Level 3) based on their estimated fair values as of the acquisition date. As of December 31, 2021, and December 31, 2020, there were no other significant assets or liabilities measured at fair value on a non-recurring basis. 

 Items Not Carried at Fair Value

The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs).  As of December 31, 2021, and 2020, the carrying values of the indebtedness under the Company’s Credit Agreement were not materially different than their estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 9). Discount rates used to measure the fair value of Gentherm’s DEG Vietnam Loan are based on quoted swap rates. As of December 31, 2021, the carrying value of the DEG Vietnam Loan was $3,750, as compared to an estimated fair value of $3,778. As of December 31, 2020, the carrying value of the DEG Vietnam Loan was $6,250 as compared to an estimated fair value of $6,360.   

F-32

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

Note 15 — Equity

Common Stock  

The Company is authorized to issue up to 59,991,000 shares, of which 55,000,000 shares shall be common stock, without par value, and 4,991,000 shall be Preferred Stock, without par value.  As of December 31, 2021, an aggregate of 33,008,185 shares of its common stock were issued and outstanding.  As of December 31, 2021, there are no preferred stock shares issued or outstanding. The Company’s common stock is listed on the Nasdaq Global Select Market under the symbol, “THRM”, and has the following rights and privileges:

 

▪

Voting rights. All shares of the Company’s common stock have identical rights and privileges. With limited exceptions, holders of common stock are entitled to one vote for each outstanding share of common stock held of record by each shareholder on all matters properly submitted for the vote of the Company’s shareholders.

 

▪

Dividend rights. Subject to applicable law, any contractual restrictions and the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably such dividends and other distributions that the Company’s Board of Directors, in its discretion, declares from time to time.

 

▪

Liquidation rights. Upon the dissolution, liquidation or winding up of the Company, subject to the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably the assets of the Company available for distribution to the Company’s shareholders in proportion to the number of shares of common stock held by each shareholder.

 

▪

Conversion, Redemption and Preemptive Rights. Holders of common stock have no conversion, redemption, sinking fund, preemptive, subscription or similar rights.

Stock Repurchase Program  

In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023.

Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the year ended December 31, 2021, the Company repurchased approximately $20,000 of shares under the 2020 Stock Repurchase Program with an average price paid per share of $83.44. The 2020 Stock Repurchase Program had $130,000 repurchase authorization remaining as of December 31, 2021.

 

F-33

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 16 – Reclassifications Out of Accumulated Other Comprehensive Income (Loss)

Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2021, 2020 and 2019 are as follows:

 

 

Defined

Benefit

Pension

Plans

 

 

Foreign

Currency

Translation

Adjustments

 

 

Commodity Hedge Derivatives

 

 

Foreign

Currency

Hedge

Derivatives

 

 

Total

 

Balance at December 31, 2020

 

$

(3,451

)

 

$

(12,637

)

 

$

—

 

 

$

1,106

 

 

$

(14,982

)

Other comprehensive income (loss) before reclassifications

 

 

512

 

 

 

(21,274

)

 

 

20

 

 

 

392

 

 

 

(20,350

)

Income tax effect of other comprehensive income (loss) before reclassifications

 

 

(71

)

 

 

(277

)

 

 

(4

)

 

 

(85

)

 

 

(437

)

Amounts reclassified from accumulated other comprehensive loss into net income

 

 

159

 

 

 

—

 

 

 

(14

)

a

 

(1,609

)

a

 

(1,464

)

Income taxes reclassified into net income

 

 

(42

)

 

 

—

 

 

 

3

 

 

 

350

 

 

 

311

 

Net current period other comprehensive income (loss)

 

 

558

 

 

 

(21,551

)

 

 

5

 

 

 

(952

)

 

 

(21,940

)

Balance at December 31, 2021

 

$

(2,893

)

 

$

(34,188

)

 

$

5

 

 

$

154

 

 

$

(36,922

)

 

(a)

The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales.  See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income.

 

 

 

Defined Benefit

Pension Plans

 

 

Foreign Currency

Translation

Adjustments

 

 

Foreign Currency

Hedge

Derivatives

 

 

Total

 

Balance at December 31, 2019

 

$

(3,371

)

 

$

(39,879

)

 

$

895

 

 

$

(42,355

)

Other comprehensive (loss) income before reclassifications

 

 

(328

)

 

 

27,147

 

 

 

(1,751

)

 

 

25,068

 

Income tax effect of other comprehensive (loss) income before reclassifications

 

 

117

 

 

 

95

 

 

 

381

 

 

 

593

 

Amounts reclassified from accumulated other comprehensive loss into net income

 

 

131

 

 

 

—

 

 

 

2,023

 

a

 

2,154

 

Income taxes reclassified into net income

 

 

—

 

 

 

—

 

 

 

(442

)

 

 

(442

)

Net current period other comprehensive (loss) income

 

 

(80

)

 

 

27,242

 

 

 

211

 

 

 

27,373

 

Balance at December 31, 2020

 

$

(3,451

)

 

$

(12,637

)

 

$

1,106

 

 

$

(14,982

)

 

(a)

The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales.  See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income.

 

 

 

Defined Benefit

Pension Plans

 

 

Foreign Currency

Translation

Adjustments

 

 

Foreign Currency

Hedge

Derivatives

 

 

Total

 

Balance at December 31, 2018

 

$

(2,339

)

 

$

(37,157

)

 

$

(4

)

 

$

(39,500

)

Other comprehensive (loss) income before reclassifications

 

 

(1,264

)

 

 

(2,329

)

 

 

2,259

 

 

 

(1,334

)

Income tax effect of other comprehensive (loss) income before reclassifications

 

 

232

 

 

 

(393

)

 

 

(493

)

 

 

(654

)

Amounts reclassified from accumulated other comprehensive loss into net income

 

 

—

 

 

 

—

 

 

 

(1,108

)

a

 

(1,108

)

Income taxes reclassified into net income

 

 

—

 

 

 

—

 

 

 

241

 

 

 

241

 

Net current period other comprehensive (loss) income

 

 

(1,032

)

 

 

(2,722

)

 

 

899

 

 

 

(2,855

)

Balance at December 31, 2019

 

$

(3,371

)

 

$

(39,879

)

 

$

895

 

 

$

(42,355

)

 

(a)

The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales.  See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income.

F-34

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

We expect all of the existing gains and losses related to foreign currency and commodity derivatives reported in Accumulated other comprehensive income (loss) as of December 31, 2021 to be reclassified into earnings during the twelve-month period ending December 31, 2022.

Note 17 — Accounting for Stock Based Compensation

On May 16, 2013, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Plan”), covering 3,500,000 shares of our Common Stock.  The 2013 Plan was amended on May 19, 2017 to increase the number of available shares by 2,000,000 and further amended on May 21, 2020 to increase the number of available shares by 2,450,000. The 2013 Plan permits the granting of various awards including stock options (including both nonqualified options and incentive options), stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”) shares and certain other awards to employees, outside directors and consultants and advisors of the Company.  As of December 31, 2021, the Company had an aggregate of 2,739,534 shares of Common Stock available to issue under the 2013 Plan.  All equity plans are administered by the Compensation Committee of the Board.  

During the three-year period ended December 31, 2021, the Company has outstanding stock options, SARs, restricted stock awards and restricted stock units to employees, directors and consultants.  These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement.  For equity-based awards with a service condition, the requisite service period typically ranges between three to four years for employees and consultants and one year for directors. As of December 31, 2021, there were 319,336 PSUs outstanding. These awards cliff vest after three-years based on the Company’s achievement of either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year a target three year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement, or the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period. In each case, awards will be earned at 50% of the target number of shares for achieving a minimum threshold or up to 200% of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals. All other outstanding, unvested equity-based awards were service based. Equity-based award vesting may be accelerated at the discretion of the Board under conditions specified in the 2013 plan.

Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a Monte Carlo simulation to account for the market condition.  That simulation takes into account the beginning stock price of our common stock, the expected volatilities for the relative TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group.  The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our common stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. Each of ROIC and Adjusted EBITDA is considered a performance condition and the grant-date fair value for ROIC PSUs and Adjusted EBITDA PSUs corresponds with management's expectation of the probable outcome of the performance condition as of the grant date.

F-35

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

The total recognized and unrecognized stock-based compensation expense is as follows:

Stock-Based Compensation Expense

 

2021

 

 

2020

 

 

2019

 

 

Unrecognized Stock-Based Compensation Expense at December 31, 2021

 

Options

 

$

482

 

 

$

836

 

 

$

885

 

 

$

-

 

Restricted Shares

 

 

1,198

 

 

 

1,495

 

 

 

1,600

 

 

 

309

 

Restricted Stock Units

 

 

4,594

 

 

 

3,137

 

 

 

1,751

 

 

 

7,423

 

Performance Based Units

 

 

5,535

 

 

 

3,361

 

 

 

2,017

 

 

 

8,572

 

Stock Appreciation Rights

 

 

2,721

 

 

 

5,494

 

 

 

2,336

 

 

 

-

 

Total Stock-Based Compensation

 

$

14,530

 

 

$

14,323

 

 

$

8,589

 

 

$

16,304

 

The related deferred tax benefit for the years ended December 31, 2021, 2020 and 2019 was $2,725, $3,002, and $1,573, respectively. If Gentherm were to realize expired share-based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below.

Stock Options

The following table summarizes stock option activity during the years ended December 31, 2021, 2020 and 2019:

Options

 

Shares

 

 

Weighted-Average

Exercise Price

 

 

Weighted-Average

Remaining

Contractual Term

 

 

Aggregate

Intrinsic Value

 

Outstanding at December 31, 2018

 

 

1,653,000

 

 

$

38.53

 

 

 

4.28

 

 

$

3,610

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Exercised

 

 

(428,250

)

 

 

38.66

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(355,750

)

 

 

39.99

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

869,000

 

 

$

37.87

 

 

 

3.51

 

 

$

5,172

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Exercised

 

 

(434,250

)

 

 

38.12

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(6,750

)

 

 

38.05

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

428,000

 

 

$

37.61

 

 

 

3.20

 

 

$

11,815

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Exercised

 

 

(215,250

)

 

 

38.46

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(6,000

)

 

 

38.05

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

206,750

 

 

$

36.72

 

 

 

2.60

 

 

$

10,375

 

Exercisable at December 31, 2021

 

 

206,750

 

 

$

36.72

 

 

 

2.60

 

 

$

10,375

 

 

There have been no stock options granted since the year ended December 31, 2017 and all options are currently vested. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $8,269, $5,317 and $1,681, respectively.

F-36

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

Restricted Stock

The following table summarizes restricted stock activity during the years ended December 31, 2021, 2020 and 2019:

Unvested Restricted Shares

 

Shares

 

 

Weighted-Average

Grant Date

Fair Value

 

Outstanding at December 31, 2018

 

 

136,566

 

 

$

37.16

 

Granted

 

 

19,920

 

 

 

40.16

 

Vested

 

 

(91,566

)

 

 

37.09

 

Forfeited

 

 

(30,000

)

 

 

38.05

 

Outstanding at December 31, 2019

 

 

34,920

 

 

$

38.31

 

Granted

 

 

32,406

 

 

 

39.96

 

Vested

 

 

(32,420

)

 

 

38.33

 

Forfeited

 

 

—

 

 

 

—

 

Outstanding at December 31, 2020

 

 

34,906

 

 

$

39.82

 

Granted

 

 

13,742

 

 

 

70.18

 

Vested

 

 

(37,272

)

 

 

41.70

 

Forfeited

 

 

—

 

 

 

—

 

Outstanding at December 31, 2021

 

 

11,376

 

 

$

70.33

 

 

The compensation cost associated with restricted shares is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted shares vested in 2021, 2020 and 2019 was $1,554, $1,499 and $3,697, respectively.

RSUs

The following table summarizes restricted stock unit activity during the years ended December 31, 2021, 2020 and 2019:

Unvested Restricted Stock Units

 

Time Vesting

Shares

 

 

Weighted-Average

Grant Date

Fair Value

 

Outstanding at December 31, 2018

 

 

86,392

 

 

$

42.53

 

Granted

 

 

107,391

 

 

 

40.99

 

Vested

 

 

(23,956

)

 

 

42.62

 

Forfeited

 

 

(28,086

)

 

 

39.88

 

Outstanding at December 31, 2019

 

 

141,741

 

 

$

42.16

 

Granted

 

 

132,864

 

 

 

34.41

 

Vested

 

 

(50,953

)

 

 

42.13

 

Forfeited

 

 

(14,747

)

 

 

39.16

 

Outstanding at December 31, 2020

 

 

208,905

 

 

$

37.26

 

Granted

 

 

93,539

 

 

 

79.79

 

Vested

 

 

(88,296

)

 

 

38.49

 

Forfeited

 

 

(20,522

)

 

 

48.76

 

Outstanding at December 31, 2021

 

 

193,626

 

 

$

56.02

 

 

The total intrinsic value of restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $3,398, $2,214 and $1,000, respectively.

F-37

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

PSUs

The following table summarizes performance stock unit activity during the years ended December 31, 2021, 2020 and 2019:

 

Unvested Performance Stock Units

 

Relative TSR Target

Shares

 

 

Weighted-Average

Grant Date

Fair Value

 

 

ROIC Target

Shares

 

 

Weighted-Average

Grant Date

Fair Value

 

 

Adjusted EBITDA Target Shares

 

 

Weighted-Average

Grant Date

Fair Value

 

 

Total

 

Outstanding at December 31, 2018

 

 

64,785

 

 

$

62.45

 

 

 

64,792

 

 

$

42.53

 

 

 

—

 

 

$

—

 

 

 

129,577

 

Granted

 

 

56,380

 

 

 

57.39

 

 

 

56,375

 

 

 

41.51

 

 

 

—

 

 

 

—

 

 

 

112,755

 

Vested

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(26,124

)

 

 

53.98

 

 

 

(26,128

)

 

 

39.41

 

 

 

—

 

 

 

—

 

 

 

(52,252

)

Outstanding at December 31, 2019

 

 

95,041

 

 

$

61.77

 

 

 

95,039

 

 

$

42.78

 

 

 

—

 

 

$

—

 

 

 

190,080

 

Granted

 

 

77,967

 

 

 

49.25

 

 

 

77,967

 

 

 

33.72

 

 

 

—

 

 

 

—

 

 

 

155,934

 

Vested

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(15,090

)

 

 

56.84

 

 

 

(15,090

)

 

 

39.96

 

 

 

—

 

 

 

—

 

 

 

(30,180

)

Outstanding at December 31, 2020

 

 

157,918

 

 

$

56.06

 

 

 

157,916

 

 

$

38.58

 

 

 

—

 

 

$

—

 

 

 

315,834

 

Granted

 

 

20,626

 

 

 

118.08

 

 

 

40,580

 

 

 

78.98

 

 

 

39,930

 

 

 

79.49

 

 

 

101,136

 

Performance Adjustment

 

 

30,828

 

 

 

69.18

 

 

 

(30,830

)

 

 

44.92

 

 

 

—

 

 

 

—

 

 

 

(2

)

Vested

 

 

(61,656

)

 

 

69.18

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(61,656

)

Forfeited

 

 

(16,148

)

 

 

61.10

 

 

 

(17,374

)

 

 

44.32

 

 

 

(2,454

)

 

 

79.49

 

 

 

(35,976

)

Outstanding at December 31, 2021

 

 

131,568

 

 

$

62.09

 

 

 

150,292

 

 

$

47.52

 

 

 

37,476

 

 

$

79.49

 

 

 

319,336

 

 

The total intrinsic value of performance stock units vested during the years ended December 31, 2021, 2020 and 2019 was $4,265, $0 and $0, respectively.

SARs

The following table summarizes SARs activity during the years ended December 31, 2021, 2020 and 2019:

Stock Appreciation Rights

 

Shares

 

 

Weighted-Average

Exercise Price

 

 

Weighted-Average

Remaining

Contractual Term

 

 

Aggregate

Intrinsic Value

 

Outstanding at December 31, 2018

 

 

988,100

 

 

$

40.61

 

 

 

3.57

 

 

$

2,064

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Exercised

 

 

(179,500

)

 

 

32.84

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(254,350

)

 

 

42.63

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

554,250

 

 

$

39.41

 

 

 

2.84

 

 

$

2,981

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Exercised

 

 

(342,150

)

 

 

38.22

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(40,500

)

 

 

44.39

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

171,600

 

 

$

40.60

 

 

 

2.44

 

 

$

4,224

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Exercised

 

 

(116,000

)

 

 

40.34

 

 

 

 

 

 

 

 

 

Forfeited

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

55,600

 

 

$

41.15

 

 

 

1.28

 

 

$

2,544

 

Exercisable at December 31, 2021

 

 

55,600

 

 

$

41.15

 

 

 

1.28

 

 

$

2,544

 

 

There have been no SARs granted since the year ended December 31, 2017 and all SARs are currently vested. The total intrinsic value of SARs exercised during the years ended December 31, 2021, 2020 and 2019 was $4,301, $4,164 and $1,588, respectively.

 

F-38

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

Note 18 — Income Taxes

The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2021, 2020 and 2019:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Earnings before income tax:

 

 

 

 

 

 

 

 

 

 

 

 

Domestic

 

$

(4,547

)

 

$

(11,374

)

 

$

74,531

 

Foreign

 

 

118,399

 

 

 

92,930

 

 

 

(15,380

)

Earnings before income tax

 

$

113,852

 

 

$

81,556

 

 

$

59,151

 

 

The components of the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 are summarized as follows:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Current income tax expense:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

1,944

 

 

$

784

 

 

$

262

 

State and local

 

 

234

 

 

 

83

 

 

 

94

 

Foreign

 

 

18,390

 

 

 

20,150

 

 

 

17,672

 

Total current income tax expense

 

$

20,568

 

 

 

21,017

 

 

 

18,028

 

Deferred income tax (benefit) expense:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

(4,400

)

 

 

(2,302

)

 

 

(2,490

)

State and local

 

 

(91

)

 

 

32

 

 

 

(1

)

Foreign

 

 

4,341

 

 

 

3,119

 

 

 

(5,252

)

Total deferred (benefit) income tax expense

 

 

(150

)

 

 

849

 

 

 

(7,743

)

Total income tax expense

 

$

20,418

 

 

$

21,866

 

 

$

10,285

 

As of December 31, 2021, deferred U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries since these earnings will not be taxable upon repatriation to the United States. These earnings will be primarily treated as previously taxed income from either the one-time transition tax or global intangible low-taxed income (“GILTI”) provision, or they will be offset with a 100% dividend received deduction.  However, the Company continues to provide a deferred tax liability for foreign income and withholding tax that will be incurred with respect to the undistributed foreign earnings that are not indefinitely reinvested.

F-39

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2021 and 2020:

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating losses

 

$

25,610

 

 

$

22,658

 

Intangible assets

 

 

21,179

 

 

 

29,145

 

Research and development credits

 

 

9,736

 

 

 

10,773

 

Property and equipment

 

 

7,071

 

 

 

7,426

 

Valuation reserves and accrued liabilities

 

 

7,333

 

 

 

7,131

 

Capitalized Research and Development Costs

 

 

9,018

 

 

 

 

 

Stock compensation

 

 

3,832

 

 

 

4,200

 

Defined benefit obligation

 

 

1,466

 

 

 

1,974

 

Inventory

 

 

1,914

 

 

 

1,571

 

Other credits

 

 

10,158

 

 

 

12,068

 

Unrealized foreign currency exchange loss

 

 

—

 

 

 

1,431

 

Other

 

 

146

 

 

 

64

 

Total deferred tax asset

 

 

97,463

 

 

 

98,441

 

Valuation allowance

 

 

(16,090

)

 

 

(17,197

)

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Unrealized foreign currency exchange gains

 

$

(2,488

)

 

$

—

 

Undistributed profits of subsidiary

 

 

(6,676

)

 

 

(5,727

)

Property and equipment

 

 

(2,420

)

 

 

(2,758

)

Other

 

 

(1,428

)

 

 

(572

)

Total deferred tax liability

 

 

(13,012

)

 

 

(9,057

)

Net deferred tax asset

 

$

68,361

 

 

$

72,187

 

Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2021, 2020 and 2019 are as follows:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Statutory Federal income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

Increase (decrease) resulting from:

 

 

 

 

 

 

 

 

 

 

 

 

Change in valuation allowance

 

 

(1.2

)%

 

 

(0.4

)%

 

 

11.5

%

Effect of different tax rates of foreign jurisdictions

 

 

(5.2

)%

 

 

(4.7

)%

 

 

(24.8

)%

US taxes on foreign income, net of taxes paid credit

 

 

2.0

%

 

 

2.5

%

 

 

4.3

%

Tax credits & deductions related to R&D

 

 

(2.3

)%

 

 

(3.8

)%

 

 

(3.6

)%

Non-deductible expenses

 

 

1.7

%

 

 

2.1

%

 

 

3.4

%

Other foreign, state and local taxes

 

 

1.6

%

 

 

1.4

%

 

 

1.7

%

Tax effects of intercompany transfers

 

 

0.6

%

 

 

1.4

%

 

 

1.5

%

Undistributed profit of subsidiaries

 

 

1.0

%

 

 

0.9

%

 

 

1.2

%

Stock Option Compensation

 

 

(2.0

)%

 

 

(0.4

)%

 

 

1.0

%

Audit Settlements and Statute Expirations

 

 

0.0

%

 

 

3.9

%

 

 

0.6

%

Other

 

 

0.7

%

 

 

2.9

%

 

 

(0.4

)%

Effective rate

 

 

17.9

%

 

 

26.8

%

 

 

17.4

%

 

The Company has Net Operating Loss (“NOL”) carryforwards as follows:

Jurisdiction

 

Amount as of

December 31, 2021

 

 

Years of Expiration

U.S. state income tax

 

$

67,795

 

 

2022-2041

Foreign

 

$

199,153

 

 

Never

 

F-40

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

We have NOL carryforwards in various states associated with the benefits of the state dividends received reduction and foreign royalty exclusion.  The state NOL carryforwards generally expire at various dates from 2022 to 2041. We have concluded that there is not sufficient evidence these NOL carryforwards will be utilized, and thus have not recognized the benefit of these NOL carryforwards.

At December 31, 2021, certain non-U.S. subsidiaries had NOL carryforwards totaling $199,153 which have no expiration date.

The Company is subject to taxation in the United States and various state and foreign jurisdictions. As of December 31, 2021, the Company was no longer subject to U.S. Federal examinations by tax authorities for tax years before 2017 and was no longer subject to foreign examinations by tax authorities for tax years before 2014.

The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025.   The amount of corporate income tax savings realized by the Company as a result of the tax holidays during the current and prior years was immaterial as a result of operating losses previously generated.

At December 31, 2021, 2020 and 2019, the Company had total unrecognized tax benefits of $5,665, $4,967 and $3,795, respectively, all of which, if recognized, would affect the effective income tax rates. The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Balance at beginning of year

 

$

4,967

 

 

$

3,795

 

 

$

2,819

 

Additions based on tax position related to current year

 

 

1,105

 

 

 

1,489

 

 

 

661

 

Additions based on tax position related to prior year

 

 

160

 

 

 

179

 

 

 

352

 

Reductions from settlements and statute of limitation expiration

 

 

(312

)

 

 

(650

)

 

 

—

 

Effect of foreign currency translation

 

 

(255

)

 

 

154

 

 

 

(37

)

Balance at end of year

 

$

5,665

 

 

$

4,967

 

 

$

3,795

 

 

The Company classifies income tax-related penalties and net interest as income tax expense.  In the years ended December 31, 2021, 2020 and 2019, income tax related interest and penalties were not material. It is reasonably possible that audit settlements, the conclusions of current examinations or the expiration of the statute of limitations in several jurisdictions could impact the Company’s unrecognized tax benefits.

      

Note 19 — Segment Reporting

Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss.

The Company’s reportable segments are as follows:

 

•

Automotive — this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems.

 

•

Medical — this segment represents the results from our patient temperature management business within the medical industry.

The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment.

F-41

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2021, 2020 and 2019. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level.

 

 

 

Automotive

 

 

Medical

 

 

Corporate

 

 

Total

 

2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenues

 

$

1,004,633

 

 

$

41,517

 

 

$

—

 

 

$

1,046,150

 

Depreciation and amortization

 

 

35,389

 

 

 

2,460

 

 

 

931

 

 

 

38,780

 

Operating income (loss)

 

 

162,994

 

 

 

(1,829

)

 

 

(46,159

)

 

 

115,006

 

2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenues

 

$

869,998

 

 

$

43,100

 

 

$

—

 

 

$

913,098

 

Depreciation and amortization

 

 

37,662

 

 

 

2,366

 

 

 

1,086

 

 

 

41,114

 

Operating income (loss)

 

 

138,410

 

 

 

971

 

 

 

(50,164

)

 

 

89,217

 

2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenues

 

$

920,225

 

 

$

51,459

 

 

$

—

 

 

$

971,684

 

Depreciation and amortization

 

 

40,923

 

 

 

1,621

 

 

 

1,702

 

 

 

44,246

 

Operating income (loss)

 

 

141,206

 

 

 

(5,735

)

 

 

(51,211

)

 

 

84,260

 

 

 

Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2021, 2020 and 2019 are as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Climate Control Seat

 

$

393,816

 

 

$

342,550

 

 

$

359,355

 

Seat Heaters

 

 

270,054

 

 

 

249,665

 

 

 

284,174

 

Steering Wheel Heaters

 

 

102,496

 

 

 

76,272

 

 

 

65,426

 

Automotive Cables

 

 

84,114

 

 

 

73,997

 

 

 

88,031

 

Battery Performance Solutions

 

 

69,594

 

 

 

50,901

 

 

 

41,498

 

Electronics

 

 

51,648

 

 

 

53,238

 

 

 

47,542

 

Other Automotive

 

 

32,911

 

 

 

23,375

 

 

 

34,199

 

Subtotal Automotive segment

 

 

1,004,633

 

 

 

869,998

 

 

 

920,225

 

Medical

 

 

41,517

 

 

 

43,100

 

 

 

36,860

 

GPT

 

 

—

 

 

 

—

 

 

 

11,181

 

CSZ-IC

 

 

—

 

 

 

—

 

 

 

3,418

 

Subtotal Medical segment

 

 

41,517

 

 

 

43,100

 

 

 

51,459

 

Total Company

 

$

1,046,150

 

 

$

913,098

 

 

$

971,684

 

 

F-42

GENTHERM INCORPORATED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(In thousands, except share and per share data)

 

 

 

 

Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2021, 2020 and 2019 is as follows:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

404,466

 

 

$

377,577

 

 

$

440,316

 

China

 

 

142,816

 

 

 

101,039

 

 

 

71,461

 

South Korea

 

 

93,516

 

 

 

88,745

 

 

 

63,339

 

Germany

 

 

66,929

 

 

 

58,536

 

 

 

81,315

 

Japan

 

 

63,527

 

 

 

57,785

 

 

 

76,197

 

Romania

 

 

51,367

 

 

 

33,147

 

 

 

26,213

 

Other

 

 

223,529

 

 

 

196,269

 

 

 

212,843

 

Total Non-U.S.

 

 

641,684

 

 

 

535,521

 

 

 

531,368

 

Total Company

 

$

1,046,150

 

 

$

913,098

 

 

$

971,684

 

 

The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2021, 2020 and 2019:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Lear

 

 

15

%

 

 

15

%

 

 

16

%

Adient

 

 

15

%

 

 

14

%

 

 

15

%

 

Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2021 and 2020 is as follows:

 

 

 

 

December 31,

 

Property and equipment, net

 

2021

 

 

2020

 

North Macedonia

 

$

32,682

 

 

$

36,925

 

China

 

 

25,411

 

 

 

20,375

 

Mexico

 

 

20,296

 

 

 

16,034

 

Vietnam

 

 

19,876

 

 

 

21,080

 

United States

 

 

19,222

 

 

 

19,011

 

Germany

 

 

16,174

 

 

 

15,641

 

Ukraine

 

 

9,539

 

 

 

9,034

 

Hungary

 

 

8,995

 

 

 

10,079

 

Other

 

 

3,075

 

 

 

4,402

 

Total

 

$

155,270

 

 

$

152,581

 

 

 

 

F-43

 

 

 

GENTHERM INCORPORATED

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

For the Years Ended December 31, 2021, 2020 and 2019

(In thousands)

Description

 

Balance at

Beginning

of Period

 

 

Charged to

Costs and

Expenses

 

 

Other Activity

 

 

Deductions

from

Reserves

 

 

Balance at

End of

Period

 

Allowance for Doubtful Accounts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2019

 

$

851

 

 

$

969

 

 

$

(8

)

 

$

(619

)

 

$

1,193

 

Year Ended December 31, 2020

 

 

1,193

 

 

 

1,298

 

 

 

33

 

 

 

(1,363

)

 

 

1,161

 

Year Ended December 31, 2021

 

 

1,161

 

 

 

1,066

 

 

 

(12

)

 

 

(816

)

 

 

1,399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for Deferred Income Tax Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2019

 

$

9,977

 

 

$

7,830

 

 

$

(491

)

 

$

—

 

 

$

17,316

 

Year Ended December 31, 2020

 

 

17,316

 

 

 

—

 

 

 

139

 

 

 

(258

)

 

 

17,197

 

Year Ended December 31, 2021

 

 

17,197

 

 

 

357

 

 

 

(102

)

 

 

(1,362

)

 

 

16,090

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reserve for Inventory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2019

 

$

6,270

 

 

$

1,679

 

 

$

(56

)

 

$

(1,820

)

 

$

6,073

 

Year Ended December 31, 2020

 

 

6,073

 

 

 

1,768

 

 

 

214

 

 

 

(914

)

 

 

7,141

 

Year Ended December 31, 2021

 

 

7,141

 

 

 

2,499

 

 

 

(134

)

 

 

(3,492

)

 

 

6,014

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

GENTHERM INCORPORATED

 

 

 

 

 

 

By:

/S/    Phillip Eyler

 

 

 

Phillip Eyler

 

 

 

Chief Executive Officer

 

 

 

 

 

 

 

Date:  February 17, 2022

 

 Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

 

Signature

 

Capacity

 

Date

 

 

 

 

 

/s/   PHILLIP EYLER 

 

Director, President and Chief

 

February 17, 2022

PHILLIP EYLER

 

Executive Officer (Principal Executive Officer)

 

 

 

 

 

 

 

/s/    MATTEO ANVERSA

 

Executive Vice President, Chief

 

February 17, 2022

MATTEO ANVERSA

 

Financial Officer and Treasurer (Principal Financial Officer)

 

 

 

 

 

 

 

/s/    JENNIFER ZOLDOS

 

Chief Accounting Officer

 

February 17, 2022

JENNIFER ZOLDOS

 

(Principal Accounting Officer)

 

 

 

 

 

 

 

*

 

Director, Chairman of the Board

 

February 17, 2022

RONALD HUNDZINSKI

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

SOPHIE DESORMIERE

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

YVONNE HAO

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

David Heinzmann

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

CHARLES KUMMETH

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

BETSY METER

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

BYRON SHAW

 

 

 

 

 

 

 

 

 

*

 

Director

 

February 17, 2022

JOHN STACEY

 

 

 

 

 

*By:

/s/ Phillip Eyler

 

Phillip Eyler, Attorney-in-Fact

 

 
thrm-ex1011_303.htm

Exhibit 10.11

 

gentherm

 

January 29, 2020

          

Matt Fisch

 

 

Dear Matt:

 

I am very pleased to confirm our job offer to you for the position of Senior Vice President and Chief Technical Officer with Gentherm, Inc. In this position, you will be part of Gentherm’ s Executive Committee and report to Phil Eyler, President and CEO effective April 6, 2020.  Your starting semi-monthly base salary will be $17,291.67 (annually $415,000). As a salaried exempt associate, you will be paid semi-monthly according to the Company’s regular payroll procedures.

Additionally, you will be eligible for Gentherm’s North America annual bonus program targeted at 50% of your salary. Bonus is assessed by individual goals and company performance and is determined by a combination of EBITDA and Revenue, subject to approval by the Compensation Committee of the Gentherm Board of Directors. Bonus is paid annually after a review of each 12-month objectives.

Equity:  Subject to approval by the Compensation Committee of the Board of Directors, you would receive an equity compensation grant commensurate with your position. Typically, equity grants are awarded by the Compensation Committee in approximately March each year.

Sign-On Grant:  On the first date of your employment, equity having a grant date value of $250,000 would be awarded (the “Sign-On Equity Grant”).  This amount, divided by Gentherm’s 10-trading day average stock price ending on such date, will determine the number of restricted stock units (RSUs) that you will receive. These grants vest over 3 years.

Sign-On Bonus: You will be entitled to receive a signing and retention bonus totaling $125,000, to be paid with your first paycheck. This bonus must be repaid if you voluntarily terminate your employment within the first year. You will receive a second bonus totaling $125,000 on the anniversary of your hire date.  This bonus must be repaid if you voluntarily terminate your employment within the second year.

Paid Time Off:  You are eligible to accrue 6.67 hours per semi-monthly pay cycle, which is equivalent to 4 weeks of vacation per year. For your first year, you are eligible for 120.06 accrued hours. Additionally, you are eligible for 5 paid sick days a year.  For your first year, you are eligible for 5 sick days. Please refer to the enclosed benefit guide for details.  

Car Allowance:  $1500 monthly car allowance

Long Term Disability: In addition to our standard Long-Term Disability plan, you are entitled to an individual executive plan, paid for by Gentherm which covers 60% of your base salary, minus the group coverage (60% of base up to $8000/month), up to an additional $6000/month.

 

 

 

Relocation:  A Tier 1 relocation benefit package will be provided to assist you with your move to your new location.  The relocation policy details and repayment agreement are attached for your review and acceptance.

The following are highlights of our benefits and are detailed in the enclosed Employee Benefit Guide:

 

Medical

Dental

Vision

Life & Accident

Insurance

Disability Insurance

Retirement Planning

 

Please note that this offer is contingent upon the following:

 

•Satisfactory completion of the drug screen and background verification.  All of these tests must have a satisfactory result in order to pass the pre-employment process. If any of the above return to us with an unacceptable result, we will rescind our offer of employment. The pre-employment drug test must be taken within five (5) days of accepting our offer.  The necessary paperwork will be sent to you for you to bring with you to the lab.  

 

•Satisfactory completion of I-9 Employment Eligibility/Verification within your first three (3) days of employment by providing the documentation required by law to verify your present eligibility to work in the United States.  Please see the enclosed Form I-9 instructions so that you can bring the correct documents with you. Under federal law, we are not permitted to allow you to work unless and until the documentation required by the I-9 Employment Eligibility/Verification is supplied to us. This offer does not constitute an offer to sponsor you for a visa or for permanent residency.  

 

•Signing the various Company documents which will be sent to you during your onboarding process.

 

Matt, we are looking forward to having you at Gentherm and welcome you to the team!  Please feel free to contact me with any questions.  

 

Sincerely,

 

 

/s/Barbara Runyon

 

Senior Vice President and Chief Human Resources Officer

 

Enclosures

 

 

 

 

To indicate your acceptance of this offer, please sign below and return the signed offer letter, by email to Barbara.runyon@gentherm.com  Please note that this offer expires on January 31, 2020.  

 

Please be advised that this offer does not constitute or imply a contract of employment. Your signature indicates acknowledgement that if employed, your employment is to be “at will” which means that either the Company or you may terminate your employment at any time, with or without cause and/or notice.

 

 

/s/Matt Fisch

 

February 5, 2020

Signature

 

Date

 

 

thrm-ex21_6.htm

Exhibit 21

LIST OF SUBSIDIARIES

 

Name

 

Jurisdiction of Formation

 

 

 

Gentherm Holding (Malta) Ltd.

 

Malta

 

 

 

Gentherm Automotive Systems (Malta) Ltd.

 

Malta

 

 

 

Gentherm Automotive Technologies (Shanghai) Co. Ltd.

 

China

 

 

 

Gentherm Electronics (Shenzhen) Co. Ltd.

 

China

 

 

 

Gentherm Technologies (Shanghai) Co. Ltd.

 

China

 

 

 

Gentherm Automotive Systems (China) Ltd.

 

China

 

 

 

Gentherm International Holdings (Hong Kong) Limited

 

China

 

 

 

Gentherm GmbH

 

Germany

 

 

 

Gentherm Enterprises GmbH

 

Germany

 

 

 

Gentherm Licensing GmbH

 

Germany

 

 

 

Gentherm Vietnam Co. Ltd.

 

Vietnam

 

 

 

Gentherm Japan Inc.

 

Japan

 

 

 

Gentherm Korea Inc.

 

South Korea

 

 

 

Gentherm Properties I, LLC

 

Michigan

 

 

 

Gentherm Properties II, LLC

 

Michigan

 

 

 

Gentherm Equity, LLC

 

Michigan

 

 

 

Gentherm Licensing, L.P.

 

Michigan

 

 

 

Gentherm Medical, LLC

 

Ohio

 

 

 

Gentherm (Texas), Inc.

 

Texas

 

 

 

Gentherm Hungary Kft

 

Hungary

 

 

 

Gentherm Ukraine TOV

 

Ukraine

 

 

 

Gentherm de Mexico S.A. de C.V

 

Mexico

 

 

 

Gentherm Canada ULC

 

Canada

 

 

 

Stihler Electronic GmbH

 

Germany

 

 

 

Gentherm U.K. LTD.

 

United Kingdom

 

 

 

Gentherm Luxembourg II S.a.r.l

 

Luxembourg

 

 

 

Gentherm North Macedonia DOOEL Prilep

 

North Macedonia

 

 

 

 

thrm-ex231_11.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:           

 

(1)

Registration Statement (Form S-8 Nos. 333-139868, as amended, and 333-164990, as amended) pertaining to the Gentherm Incorporated 2006 Equity Incentive Plan,

 

(2)

Registration Statement (Form S-8 Nos. 333-176884, as amended, and 333-181975, as amended) pertaining to the Gentherm Incorporated 2011 Equity Incentive Plan, and

 

(3)

Registration Statement (Form S-8 Nos. 333-189442, 333-218155, and 333-245646) pertaining to the Gentherm Incorporated 2013 Equity Incentive Plan,

 

 

of our reports dated February 17, 2022, with respect to the consolidated financial statements and schedule of Gentherm Incorporated and the effectiveness of internal control over financial reporting of Gentherm Incorporated included in this Annual Report (Form 10-K) of Gentherm Incorporated for the year ended December 31, 2021.

 

 

/s/ ERNST & YOUNG LLP

 

 

 

Detroit, Michigan

 

February 17, 2022

 

 

thrm-ex232_9.htm

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our report dated February 20, 2020 (except for the section of Note 2 entitled Revision of Prior Period Financial Statements in the previously filed 2020 financial statements, which is not presented herein, and Note 18 and Note 19 for which the date is March 1, 2021), with respect to the consolidated financial statements included in the Annual Report of Gentherm Incorporated on Form 10-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statements of Gentherm Incorporated on Forms S-8 (File No. 333-139868, as amended, 333-164990, as amended, 333-176884, as amended, 333-181975, as amended, 333-189442, 333-218155 and 333-245646).

 

/s/ GRANT THORNTON LLP

 

Southfield, Michigan

February 17, 2022

 

thrm-ex24_12.htm

Exhibit 24

POWER OF ATTORNEY

Each of the undersigned, being a Member of the Board of Directors of Gentherm Incorporated (the "Registrant"), hereby severally constitutes and appoints Phillip Eyler, the Registrant's Chief Executive Officer, with full powers of substitution and resubstitution, his true and lawful attorney, with full powers to sign for him, in his name, in the capacity indicated herein, (a) the annual report of the Registrant for the fiscal year ending December 31, 2021 on Form 10-K and (b) any and all amendments to such Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes said attorney might or could do in person, and hereby ratifying and confirming all that said attorney, or his substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.  This power of attorney may be executed in separate original or facsimile counterparts.

IN WITNESS WHEREOF, the undersigned have executed this instrument this 17th day of February, 2022.

 

/s/ Sophie Desormière

Sophie Desormière

 

/s/ Yvonne Hao

Yvonne Hao

 

/s/ David  Heinzmann

David  Heinzmann

 

/s/ Ronald Hundzinski

Ronald Hundzinski

 

/s/ Charles Kummeth

Charles Kummeth

 

/s/ Betsy Meter

Betsy Meter

 

/s/ Byron Shaw

Byron Shaw

 

/s/ John Stacey

John Stacey

 

thrm-ex311_7.htm

Exhibit 31.1

CERTIFICATION

I, Phillip Eyler, certify that:

1.

I have reviewed this annual report on Form 10-K for the period ended December 31, 2021 of Gentherm Incorporated;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

/s/ Phillip Eyler

Phillip Eyler

President & Chief Executive Officer

February 17, 2022

 

thrm-ex312_8.htm

Exhibit 31.2

CERTIFICATION

I, Matteo Anversa, certify that:

1.

I have reviewed this annual report on Form 10-K for the period ended December 31, 2021 of Gentherm Incorporated;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

/s/ Matteo Anversa

Matteo Anversa

Executive Vice President, Chief Financial Officer and Treasurer

February 17, 2022

 

thrm-ex321_10.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K for the period ended December 31, 2021 of Gentherm Incorporated (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Phillip Eyler, President & Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1).

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2).

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Phillip Eyler

Phillip Eyler

President & Chief Executive Officer

February 17, 2022

 

thrm-ex322_13.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K for the period ended December 31, 2021 of Gentherm Incorporated (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matteo Anversa, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1).

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2).

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Matteo Anversa

Matteo Anversa

Executive Vice President, Chief Financial Officer and Treasurer

February 17, 2022